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Abstract 
 
Iron plays important roles in a multitude of biological process, but is toxic when present in 
excess. This excess of iron leads to the medical condition referred to generally as Fe overload 
disorder. Therefore, designing iron chelators to alleviate this toxic effect by complexation with so-
called labile (nonprotein bound) Fe, that can be excreted from the body, has received increasing 
attention. Recently, Fe chelators have also shown much promise as anti-proliferative agents suitable 
for the treatment of cancer. To this end of developing iron chelators for the treatment of either iron 
overload or cancer, the synthesis and characterization of new iron complexes of a series of 
biologically active heterocyclic dithiocarbazate Schiff base ligands was achieved. These ligands 
bear a pyridyl ring in addition to an imine and thiolate functional group and utilize this NNS set of 
donor atoms to form stable tridentate low spin ferric and ferrous complexes similar to heterocyclic 
hydrazone and thiosemicarbazone chelators that have been studied previously. Both Fe
II 
and Fe
III
 
complexes of these dithiocarbazate Schiff base ligands were isolated and structurally, 
spectroscopically and electrochemically characterized. In all cases, totally reversible Fe
III
/Fe
II
 redox 
couples in mixed aqueous solvent were identified at a potential higher than that found in analogous 
thiosemicarbazone iron complexes. Furthermore, the stability of Fe
III
 complexes of these 
dithiocarbazate Schiff bases in mixed aqueous solvent at physiological pH was investigated. The Fe
 
complexes of this series are only stable in the presence of water while in their Fe
II
 form similar to 
the pyridine carbaldehyde isonicotinoyl hydrazone (HPCIH) series. The corresponding Fe
III
 
complexes rapidly oxidise water and so the ferric oxidation state of these complexes has no 
biological role. This is relevant as the complexes are unable to participate in any oxidative 
processes such as the oxidation of oxy-hemoglobin (HbO2) to met-hemoglobin (metHb), which is in 
contrast to thiosemicarbazones Fe complexes to be discussed later. The effectiveness of the 
dithiocarbazate Schiff base chelators to mobilize intracellular iron and to prevent iron uptake from 
transferrin as well as their anti-proliferative activity were examined. All ligands were more effective 
in chelating intracellular iron than the clinically proven chelator desferrioxamine (DFO). The Schiff 
base ligands derived from 2-pyridinecarbaldehyde exhibited no marked antiproliferative activity 
and were not cytotoxic in contrast to those derived from the ketones 2-acetylpyridine and di-2-
pyridylketone which exhibited significant activity against cancer cell proliferation. 
  Recently, there has been a serious concern about such side effects, such as 
methemoglobinia, in some anticancer therapies involving the known Fe chelator 3-amino-2-
pyridinecarbaldehyde thiosemicarbazone (3-AP; Triapine), which significantly increases the levels 
of metHb and hypoxia in patients, limiting its usefulness. However, the mechanism producing such 
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effects has not been investigated. Considering this, the kinetics of methemoglobin formation by 
some members of structurally-related thiosemicarbazone ligands derived from di-2-pyridyl ketone, 
benzoyl pyridine and acetyl pyridine (HDpT, HBpT and HApT respectively) was investigated in 
this thesis. This was performed in vitro with human hemoglobin in reaction with the relevant Fe
III
 
complex and it was found that the reaction proceeds with two distinct time-resolved steps 
corresponding to separate oxidation of the α- and β-chains in the α2β2 tetrameric protein. Different 
reaction rates of Fe
III
 complexes within the same series (sharing the same parent ketone and 
exhibiting a similar Fe
III/II
 redox potential) have been attributed to a combination of steric and H-
bonding effects and are not related to the driving force of the electron transfer reaction.  
Although the design of numerous iron chelators that show activity at inducing Fe 
mobilisation from cells, the intracellular location of these chelators or the mechanism of how these 
chelators can access Fe in the cell  are not well understood. Therefore, the final part of this thesis 
focussed on the synthesis of a range of new fluorescent ligands bearing Fe chelating groups. The 
fluorophores include rhodamine B and difluoroboron dipyrromethene (BODIPY) covalently bound 
to pyridyl hydrazone or hydrazine ligands that have previously shown high activity binding to Fe 
within cells. The rhodamine B derivatives probes are non-fluorescent in their uncomplexed form but 
become fluroescent in complex with Fe while the BODIPY derivatives show the opposite 
behaviour. All free ligands and their 2:1 ligand:Fe complex have been spectroscopically and 
electrochemically characterized. Kinetic analysis of the ring-opening rhodamine B derivatives by 
either protonation or complexation with iron was investigated. 
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Chapter 1   Introduction 
 
 
 
1.1  Iron — an essential element  
1.1.1 The crucial role of iron in the human body 
 
Iron is essential to all life forms and is one of the most abundant transition metals in the 
human body (with copper and zinc). Iron distribution in the human body is shown in (Figure 1.1). 
Women have 35 mg Fe /kg body weight, which is less than men 45 mg Fe /kg due to menstruation 
and pregnancy.
1, 2
 The greatest portion of iron, which amounts to about 60 – 70 %, of that found in 
the body is distributed in hemoglobin in the red blood cells (erythrocytes), while 10% of iron is 
present in myoglobin and other iron containing proteins. Approximately 20 – 30 % of iron is 
deposited in the liver, spleen, bone marrow and reticuloendothelial macrophages, which are the sites 
of ferritin storage and hemosiderins.
3
  
Iron is a cofactor for many proteins involved in oxygen transport, electron transfer, DNA 
synthesis, cell growth and proliferation and energy metabolism.
4
 The ability to fulfil these varied 
roles can be attributed to its flexible coordination chemistry and, in many cases, redox activity 
through its capacity to switch between its two most common oxidation states; ferric (Fe
III
) and 
ferrous (Fe
II
). This means iron can act as an electron donor or acceptor, allowing it to contribute to 
many oxidation–reduction reactions.5  On the other hand, an excessive level of iron is highly toxic. 
The deleterious effect of iron is linked to oxidative stress produced from Fenton chemistry in which 
endogenous hydrogen peroxide is broken down by iron(II) to form hydroxyl radicals (·OH).
6
 The 
simple form of this reaction, first reported more than 120 years ago
7
 is presented in (Equation 1.1) 
                                         Fe
2+
 + H2O2          Fe
3+
 +
 
·OH + OH
-
                                 (1.1)                  
The production of highly reactive hydroxyl radicals can result in several consequences, 
including damage to DNA, lipids and proteins
8
, causing formation of reactive aldehydes and 
impairment of cellular function.
9
 Therefore, iron levels need to be well maintained within cells by 
tight control of uptake, storage, transport and distribution to avoid accumulation (or deficiency) of 
iron. 
10
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Figure ‎1.1 Distribution of iron in the human body.
10
 
 
1.1.2 The metabolism of iron in normal cells  
1.1.2.1  Iron absorption from the gut 
 
Dietary iron is absorbed from the gut via enterocytes in two forms: heme (mainly from red 
meat) and non-heme (white meat, vegetables and cereals). Non-heme iron present in the ferric form 
may be transported across the enterocyte cell membrane by the divalent metal transporter 1 
(DMT1), but must be reduced to its ferrous form by a duodenal cytochrome b enzyme (Dcytb), 
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which possesses ferric reductase activity as shown in Figure 1.2.
11
 However, Gunshin and his group 
have investigated the function of the Dcytb in mice and they have suggested other compensatory 
mechanisms that could contribute in the intestinal absorption of non-heme iron.
12
 
On the other side, the exact mechanism of transportation of heme iron remains unclear and it 
is different to that of non heme iron. The uptake of heme was suggested to be facilitated by the 
heme carrier protein 1 (HCP1) which also has an ability to transport folate.
13
 Therefore, a 
competition between the folate and heme for absorption in the small intestine could occur. In fact, 
the precise function of the HCP1 is unknown, suggesting number of mechanisms involved in heme 
uptake in the gut.
14
 An example of these mechanisms is the diffusion and metabolization of 
enterocytes by heme oxygenase 1 (HO-1). This process degrades heme to free CO, Fe
II
 and 
biliverdin by acting with cytochrome P450 reductase (CPR) and biliverdin reductase.
15
  Fe
II
 can 
then enter the intracellular Fe pool or be stored in ferritin.
16
 
The transportation of Fe in the enterocytes and its delivery into the blood stream is being 
actively researched. Various proteins are involved in the trafficking and release of iron, such as 
multi-copper hephaestin
17
 and ferroportin-1, also known as iron regulated transport 1 (Ireg1)
18
 or 
metal transporter 1 (MTP1).
19
 The cooperation of ferroportin-1 with hephaestin, which possesses 
ferroxidase activity, could convert Fe
II 
to Fe
III
 and simplify Fe export from the intestinal enterocytes 
by allowing binding to plasma Fe transport protein transferrin (Tf)
20
. Recently, it has been found 
that peptide hormones known as hepcidins, which are synthesized by the liver, play a role in 
regulating enterocyte ferroportin 1 expression.
21
  
Iron overload in the liver or release of interleukin-6 (1L-6) causes increased hepicidin 
expression that decreases Fe release from the enterocyte by down-regulation of  ferroportin 1.
21
 
This may lead to a complete homeostatic loop and affect ferroportin expression on the cell 
surface.
21
 Another pathway that also could play an essential role in iron efflux is via the serum 
protein ceruloplasmin. The ferroxidase activity of this protein is vital in terms of removing excess 
iron from transport elements on the cell surface in patients suffering from aceruloplasminemia.
22, 23
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Figure ‎1.2 Schematic of intestinal iron absorption and metabolism.
24
   
 
1.1.2.2 Cellular iron uptake 
   
The vast majority of cells, including erythroid (red blood) cells, obtain iron from the plasma 
glycoprotein transferrin. Two Fe
III
 atoms are bound with high affinity by Tf and the protein loaded 
with two metal ions (Fe2Tf)  binds to the transferrin receptor 1 (TfR1) located on the cell surface.
25
 
The TfR1-Fe2Tf complex is internalized via clathrin-coated pits (Figure 1.3) into endosomes. There 
iron is released from Fe2Tf through acidification of the endosome to pH 5.5 by an endosomal 
membrane-bound proton pump.
25
 Once released, an endosmal ferrireductase reduces Fe
III
 to Fe
II
,
26
 
which is then transported to the cytosol, or utilized for protein synthesis such as ribonucleotide 
reductase (RR) or to the mitochondria in erythroid cells by divalent metal transporter 1 (DMT1) for 
synthesis of heme and Fe-S clusters. Excess of iron is deposited in ferritin using the human iron 
chaperone poly (rC)-binding protein 1 (PCBP1) (Figure 1.3).
27,28
 After Fe is released, Fe
II
 becomes 
part of the Fe pool there is a decrease in the affinity of the (apo)-Tf-TfR1 complex, resulting in its 
dissociation. Finally, apo-Tf (free from iron) is secreted into the plasma by exocytosis to recapture 
Fe
3+
 before returning to the cell surface in multiple cycles of iron binding and iron uptake.
29,
 
30
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Figure ‎1.3 Schematic of cellular iron transport. 
24
  
1.1.2.3 The labile iron pool and iron storage 
 
The cytosolic labile iron pool (LIP) has been suggested to be an important source of Fe for 
iron containing proteins such as ribonucleotide reductase (RR).
31
  Despite the fact that the identity 
of this LIP remains poorly defined, it is generally thought that the iron in this pool is bound to 
sugars, amino acids and nucleotides.
16
 In addition, the distribution of iron from the LIP to specific 
compartments within the cell is used to supply Fe for the active sites of proteins or iron storage in 
ferritin.
32
 Ferritin (Ft) is composed of H- and L-subunits that surround a central cavity capable of 
accommodating up to 4500 Fe atoms in a redox inactive form with phosphate and oxido/hydroxido 
anions.
33,34
 This sequestration of iron in a nontoxic mineralized form prevents the formation of 
reactive oxygen species (ROS) and protects the cell from oxidative damage.
31
 Ferritin also 
contributes to iron homeostasis by regulating its expression under conditions of iron abundance.
35
 
 
1.2 Iron chelation therapy 
 
The deregulation of iron homeostasis results in a number of diseases that have led researchers 
to design compounds which have ability to chelate iron in vivo. These chelators are ideally orally 
active, highly specific for iron and show minimal side effects.
36
  Some of these chelators have a 
potential for the treatment of iron overload and others act as anticancer therapies, this is discussed 
further below.  
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1.2.1 Iron chelators for Fe overload diseases 
 
Iron chelators play a therapeutic role in the treatment of a multitude of human diseases, 
including iron overload disorders.
37
 These diseases result from the excessive accumulation of iron 
in the body under conditions of high Fe uptake, especially since there is no pathway for the 
excretion of iron in humans, only a mechanism for switching off Fe uptake from the gut. The most 
serious causes are hereditary hemochromatosis, which is a genetic disease resulting in the 
unregulated absorption of Fe from the diet, and transfusional iron overload.
38
 The latter results from 
repeated blood transfusions for the treatment of anemias such as sickle cell anemia and β-
thalassemia that are linked to abnormal hemoglobin synthesis.
39
  
As mentioned previously, excess iron is associated with oxidative stress (Fenton chemistry) 
that leads to the production of free radicals, which can result in damage to tissues and organs and 
death if left untreated.
40
 Considering this, some natural and synthetic iron chelators are employed to 
overcome the toxic effects of Fe overload by the formation of redox-inactive Fe complexes that can 
be excreted from the body.
41
 
1.2.1.1 Desferrioxamine 
 
Desferrioxamine B (DFO) (Figure ‎1.4) is a naturally occurring hexadentate siderophore 
originally isolated from the bacterium Streptomyces pilosus, which utilizes the ligand to sequester 
Fe in a soluble form.
42
 In 1960, DFO was recognized as an effective biologically active Fe chelator 
and is still the ―gold standard‖ chelator for the treatment of  Fe overload and general promotion of 
patient survival and well-being.
43, 44
 In 1968, it was approved as a drug for the treatment of Fe 
overload by the US Food and Drug Administration (FDA).
45
 This hexadentate chelator binds Fe
III
 
with high affinity, forming a redox inert and stable 1:1 Fe:ligand  complex (pFe 26.6)
46
 (pFe = 
-log10[Feaq
3+
] at total concentrations of 1 µM Fe
III
 and 10 µM ligand). The ligand coordinates 
through its oxygen atoms and possesses a low Fe
III/II
 redox potential (-475 mV vs NHE at pH 7.5) so 
the production of ROS via Fenton chemistry is suppressed due to its redox inactivity under 
biological conditions.
47, 48
    
However, while DFO has had great success as a drug for Fe overload, it has many 
significant drawbacks. It is hydrophilic, which means it has poor membrane permeability, it is 
orally inactive and has a short plasma life (t1/2 ~ 10 min) which means it must be administered by 
long and frequent subcutaneous infusion (12-24 h/day, 5-7 days/week), leading to poor patient 
compliance.
38
 It is also very expensive, limiting its use in developing countries that coincidentally 
have high incidences of β-thalassemia. 
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Figure ‎1.4 Structure of desferrioxamine B (DFO) and its Fe
III 
complex (ferrioxamine B). 
 
1.2.1.2 Deferiprone  
 
The disadvantages associated with DFO have led to a search for an alternative orally active 
drug for Fe overload. The first orally active compound to have been approved for treating Fe 
overload was deferiprone (1,2-dimethyl-3-hydroxypyridine-4-one, L1, CP20 and more recently 
Ferriprox®) (Figure 1.5) which was synthesized by Hider et al. and patented in 1982 as a substitute 
for DFO.
49
 Deferiprone forms a charge neutral tris-bidentate-coordinated Fe
III
O6 complex via 
deprotonation of the hydroxyl group.
36
  
 
Figure ‎1.5 Structures of deferiprone (L1), its Fe
III 
complex and its analogues. 
 
 The Fe coordination chemistry of deferiprone and its analogues has been extensively 
investigated.
50
  Deferiprone possesses a high Fe
III
 complex formation constant (pFe 20.0) forming a 
tris-ligand complex (Figure 1.5).
47,51
  Also, the compounds are fairly hydrophilic with their 
octanol:water partition coefficients lying in the range -1 < logP < 1. They possess quite high acid 
dissociation constants (pKa 9-10) and so are charge neutral at physiological pH, which assists 
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passage across the cell membrane. Deferiprone is able to release Fe from the ferritin
52
 to a greater 
extent than DFO. This could be due to the fact that deferiprone is better able to access the outer 
shell of the protein to gain access to the ferric oxide/phosphate core of ferritin due to its smaller 
size.
53
 Despite the fact that deferiprone can compete with serum transport protein transferrin for 
Fe
III
 presenting at millimolar ligand concentrations, it is not competitive at the more clinically 
relevant micromolar concentrations.
50
  
The safety and efficacy of deferiprone for clinical use has been controversial.
54, 55
 After 
initial promising trials in the 1980s further human trials were discontinued by its then licensee Ciba-
Geigy due to toxicity concerns.
56
 The compound re-emerged in the 1990s marketed by a different 
company and it became available in many countries, including Australia, for use in the treatment of 
Fe overload but not in USA or Canada due to poor efficacy. In 2011, it was finally approved by the 
FDA for use in the United States for patients with iron overload when chelation therapy by DFO is 
inadequate.  
One issue with deferiprone is that some studies had found that the long term administration 
led to hepatic fibrosis and myelotoxicity (suppression of bone marrow) in a significant number of 
patients.
57
 To overcome these adverse effects, numerous deferiprone analogues have been 
synthesized (Figure ‎1.5). The combination of two drugs is another approach to overcome the side 
effects of deferiprone. To support this, it was found that the combination of deferiprone or 
analogues and DFO enhances the rate of Fe removal from transferrin compared to the slow rate in 
the presence of DFO alone,
58
 decreasing the time required to reduce iron overload. 
1.2.1.3 Deferasirox 
 
As mentioned previously, the use of deferiprone as an orally active Fe chelator has been 
plagued by poor efficacy and side effects. Therefore, a search for alternative orally active iron 
chelators has been ongoing for decades. Deferasirox (ICL-670, trade name Exjade® (Figure ‎1.6), 
developed by Novartis) offers a promising alternative for patients who cannot tolerate 
desferrioxamine.
59,
 
60
 It was first reported in 1999
61
 and approved by the FDA for use in the United 
States in 2005 and by the European Union in 2006.
62
 It acts as an ONO tridentate chelator and the 
binding of the metal centre occurs through one of the nitrogen atoms of the heterocycle and two 
phenolate groups, which are deprotonated upon binding
63
 (Figure ‎1.6). Deferasirox is orally active 
with a long serum half-life (t1/2~12h) that can be administered in a single daily dose, which is far 
superior to DFO, which must be administered by long periods of subcutaneous infusion, or 
deferiprone, which has to be delivered in very high doses.
37
 To support this, clinical studies have 
showed that deferasirox is a more effective Fe chelator than DFO
63
 and it is now sold by Novartis 
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worldwide as an orally active drug for the treatment of Fe overload. However, in 2006 there were 
reports linking deferasirox mortalities with renal failure and cytopenias (low blood cell count).
64
 In 
2010, a warning was added to the packaging of side effects of deferasirox including renal and liver 
damage and gastrointestinal effects. It is generally accepted that the adverse effects of deferasirox 
are outweighed by its benefits in terms of patient compliance, but regular monitoring is essential.
64
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎1.6 Deferasirox and its Fe
III
  complex. 
 
1.2.1.4 2-Pyridinecarbadehyde isonicotinoyl  hydrazone (HPCIH) analogues 
 
Another promising group of chelators are the tridentate ligands belonging to the 2-
pyridinecarbaldehyde isonicotinoyl hydrazone (HPCIH) family (Figure‎1.7). The analogues are 
monoprotic acids and bind Fe through the pyridyl nitrogen, imine nitrogen and carbonyl oxygen 
donor atoms (NNO) by deprotonation of the hydrazone NH group to coordinate as monoanionic 
ligands.
65
 Some of these ligands are highly effective in terms of mobilizing Fe from Fe-loaded cells, 
inhibiting
 
Fe uptake from diferric transferrin and increasing the RNA binding activity of the iron 
regulatory protein.
66
 Also, studies have shown that the Fe-chelation efficacy of these ligands in vitro 
is superior to DFO.
66
 In addition, these chelators display low toxicity and were orally active in a 
mouse model.
67
 However, some functional groups should be avoided, particularly hydrophilic non-
coordinating substitutes such as –NH2 and –OH on the aromatic ring that lead to poor biological 
activity.
68
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Figure‎1.7 The 2-pyridinecarbaldehyde isonicotinoyl hydrazone (HPCIH) anologues and their Fe 
binding mode.   
 
These ligands strongly favour Fe
II
 coordination, rather than Fe
III
. This is a result of the soft 
pyridyl and imine N-donors in stabilizing the lower oxidation state compared to the hard 
hydroxamate or phenolate O-donors found in Fe
III
 chelators like DFO, deferiprone and 
deferasirox.
68
 Furthermore, the aqueous electrochemistry of the [Fe
II
(PCIH)2] analogues have 
shown that redox potentials of these complexes are high (˃500 mV vs NHE) preventing oxidation to 
Fe
III
 by oxygen under physiological conditions.
68
 The HPCIH analogues show low cytotoxicity 
which makes them suitable for the treatment of Fe overload.
34, 67,
 
66
  Some studies have identified 
that the HPCIH analogues can undergo unusual ligand-based oxidation reactions, catalysed by Fe
III
, 
to generate the diaroylhydrazine, N-(isonicotinoyl)-N-(picolinoyl) hydrazine (H2IPH).
65
 This is 
explained in more detail below. 
1.2.1.5 Diaroylhydrazine (H2IPH) analogues        
 
The unexpected Fe-catalysed oxidation of HPCIH to its diaroylhydrazine (H2IPH) led to the 
design of a series of novel diaroylhydrazine chelators, as shown in (Figure ‎1.8). These chelators 
also bind Fe through a set of NNO donor atoms and their mono- and bis-ligand Fe
III
 complexes have 
been structurally characterised.
69
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Figure ‎1.8 Chemical structures of the H2IPH hydrazine analogues and their Fe binding mode. 
 
At physiological pH H2BPH, H2TPH, H2PPH and H2BBPH are more effective than DFO at 
mobilizing Fe from the cell and preventing Fe uptake from transferrin (Tf).
69
 In contrast, the 
hydrazine chelators H2IPH, H2NPH and H2IIH showed poor Fe chelation efficacy compared to 
other hydrazines. This can be attributed to their anionic charge (lower pKa) and the hydrophilic 
isonicotinoyl substituent, which hinders their ability to cross the cell membrane at physiological 
pH.
66-70
 
In contrast with the HPCIH Fe
II
 chelators, the H2IPH analogues exclusively form ferric 
complexes due to the deprotonated central N-donor of the coordinated hydrazine analogues which 
lowers the Fe
III/II
 redox potential substantially (Figure 1.8).
70
 While the Fe
III/II
 redox potentials of 
these diaroylhydrazine analogues (-250 to -310 mV vs NHE) are higher than DFO (-475 mV vs 
NHE), they still lie at the lower end of potentials accessible to biological reductants, and thus are 
poor catalysts of Fenton chemistry which requires the ferrous oxidation state to be present. These 
chelators exhibit low cytotoxicity, which makes promising candidates for effective treatment option 
for Fe overload disease.
70
  
1.2.2 Iron chelators for cancer therapy 
 
Iron chelation therapy was primary developed to treat the toxic effects of Fe overload as just 
described. More recently it has been discovered that some Fe chelators possess properties that make 
them suitable for use in cancer chemotherapy.
70,
 
71
 This is appealing considering that tumour cells 
can display resistance to standard chemotherapy. One important discriminator in biological activity 
of these chelators seems to be the redox activity of their Fe complexes. It appears that redox-
inactive Fe chelator complexes, with either very high or very low Fe
III/II
 redox potentials, are ideal 
for the treatment of iron overload, whereas chelators that form Fe complexes with redox potentials 
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in the range ca. -200 to +200 mV vs NHE, where both the ferrous and ferric complexes may 
coexist, and are more suitable for cancer chemotherapy.
72
 This is explained further below. 
1.2.2.1 Iron metabolism in neoplastic cells 
 
Iron plays a key role in cellular proliferation. This can be attributed to the active role of iron 
in the enzyme ribonucleotide reductase (RR) that catalyzes the rate limiting step of DNA synthesis; 
the conversion of ribonucleotides to deoxyribonucleotides.
73
 In addition to the effects of Fe 
chelators on RR, the impact on multiple molecular targets involved in cell cycle control has been 
identified by proteomic studies.
74
 Compared to normal cells, neoplastic (abnormally rapidly 
growing) cells have a greater Fe demand, rate of proliferation and DNA synthesis. In addition, the 
number of Tf receptors is higher relative to normal cells, leading to a higher rate of Fe uptake. The 
iron storage protein, ferritin is also upregulated in cancer cells.
74
 Hence, cancer cells become more 
vulnerable to the effects of cellular Fe depletion by chelating agents than normal cells because of 
their greater Fe demand driven by their rapid growth. 
1.2.2.2 Anti-proliferative activity, lipophilicity and redox activity 
 
Chelators with high lipophilicity lead to an increase in cytotoxic effects. This is actually a 
general feature in drug delivery because a higher lipophilicity increases the ability of the drug to 
cross the cell membrane and thus gain access to its target, in this case intracellular Fe pools (LIP) 
needed for cellular proliferation.
75
 In addition, it has been found that chelators with high anti-
proliferative activity form Fe complexes with redox activity; i.e. Fe
III/II
 redox potentials that are 
neither too low or too high to prevent redox cycling. Hence, the choice of donor atoms plays a vital 
role in the activity of these Fe chelators.
76
 Ligands capable of stabilizing both Fe
III 
and Fe
II
 possess 
the potential to promote redox cycling within cells.
77
 For instance, iron complexes that contain soft 
donor atoms, such as nitrogen and sulfur, have systematically higher redox potentials and stabilise 
their lower oxidation state relative to complexes of O-donor ligands.
70
 These Fe
II
 complexes can 
then promote Fenton chemistry (Equation (1.1)), producing damaging hydroxyl radicals and 
oxidative damage leading to cell death. In contrast, harder oxygen donor atoms stabilize the ferric 
state (favouring low Fe
III/II
 redox potentials) and are more appropriate for the treatment of Fe 
overload disease.
71
 For example, the Fe
III
 complex of DFO which bears an O6 donor set, cannot be 
reduced under physiological conditions (Fe
III/II
 -475 mV vs NHE).
78
 This illustrates the importance 
of ligand design for the treatment for either cancer or Fe overload disease. Additionally, some of 
these chelators have undergone structure–activity relationship studies in order to generate chelators 
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with low toxicity and marked anti-proliferative activity via different mechanisms, including metal 
depletion, redox activity, inhibition of ribonucleotide reductase, apoptosis and cell-cycle arrest.   
1.2.2.3 Pyridoxal isonicotinoyl hydrozone (H2PIH) analogues  
 
The compound DFO, although primarily used for the treatment for iron overload disease, 
has demonstrated anti-proliferative activity against the common childhood cancers, neuroblastoma 
(NB) and leukaemia in vitro, in vivo, in animal models and in clinical trials.
24,79
  However, DFO has 
many limitations already mentioned, including poor bioavailability.
80-82
 These drawbacks have 
prompted the search for other Fe chelators that are more effective than DFO in targeting Fe in 
cancer cells.   
Pyridoxal isonicotinoyl hydrozone (H2PIH) and analogues, were originally synthesised by 
Sah in 1954,
83
 and these chelators belong to the aroylhydrazone family of ligands. These ONO 
tridentate chelators bind iron via phenolic O-, imine N- and carbonyl O-donor atoms as shown in 
(Figure ‎1.9)84 and form Fe complexes of 1:2 metal:ligand stoichiometry85 with high affinity for FeIII  
rather than Fe
II
.
86
 A number of studies indicate that H2PIH has a high Fe chelation efficacy in vitro 
and in vivo models.
87-89
 Despite the fact that H2PIH has greater Fe chelation efficacy than DFO, the 
two ligands have comparable activity in terms of inhibiting DNA synthesis in SK-N-MC 
neuropithelioma cells.
90
 Therefore, there is no clear relationship between Fe chelation efficacy and 
prevention of DNA synthesis. This leads to the conclusion that different intracellular pools of Fe 
could be targeted by different chelators  to promote their anti-tumour effects.
91
 Further investigation 
on the H2PIH activities at inhibiting 
59
Fe uptake from Tf and mobilizing intracellular iron, indicated 
that H2PIH was more effective compared to DFO. These results were attributed to the lipophilicity 
of the chelator and its ability to permeate cell membranes in comparison to DFO.
 75,
 
92
  
Further studies assessed several H2PIH analogues derived from the combination of a variety 
of acid hydrazides and three parent aromatic aldehydes; pyridoxal, salicylaldehyde and 2-hydroxy-
1-naphthaldehyde comprising the so-called (100, 200 and 300 series, respectively).
75,  93
 Many of 
these analogues demonstrated significant anti-proliferative activity (IC50 = 1 to 7 µM)
1
 compared to 
DFO (IC50 = 22 µM). 
                                                 
 
1
 Concentration of compound required to kill 50% of cells relative to the control (0%). 
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The most efficient H2PIH analogues were derived from the lipophilic 2-hydroxy-1-naphthaldehyde 
(the 300 series) (Figure 1.9), whereas the compounds derived from the more hydrophilic pyridoxal 
(100 series) were the least active chelators in terms of anti-proliferative activity against SK-N-MC 
neuroepithelioma cells in vitro.
75
  
 
 
 
 
SIH  analogues (200 series)                                        PIH analogues (100 series) 
 
 
 
 
 
NIH analogues (300 series)                                      
 
Figure ‎1.9 Chemical structures of the PIH analogues.  
            
It was found that 2-hydroxy-1-naphthaldehyde isonicotinoyl hydrazone; NIH (311) was one 
of the most effective chelators of the 300 series, releasing 44% of 
59
Fe from Fe-loaded cells 
compared to only 15% by DFO.
91
 Moreover, 311 was the most effective at inhibiting Fe uptake 
from  transferrin (Tf).
91
 Administration of 311 resulted in decreased expression of proteins that 
regulate the cell cycle
74
 and increased the expression of molecules necessary for cell cycle 
progression, namely WAF1 and GADD45.
74, 91
 It should be noted that formation of the complex of 
311 with Fe prior to cellular treatment decreased its anti-proliferative activity. Therefore, the 
capacity of 311 to bind intracellular Fe is essential for its anti-proliferative activity.
94
  
1.2.2.4 Di-2pyridylketone isonicotinoyl hydrazones analogues (HPKIH) 
 
In addition to the H2PIH analogues, a novel series of aroylhydrazones based on HPCIH 
ligand was synthesized by Bernhardt et al.
95
 (Figure ‎1.10) with the goal of having the high  Fe 
chelation efficacy of the closely related HPCIH hydrazones
66
  combined with the crucial property of 
lipophilicity for chelation of intracellular Fe.
96
 The pyridine carbaldehyde moiety was replaced by 
the more lipophilic di-2-pyridylketone, forming HPKIH and its analogues. These ligands are 
tridentate NNO ligands bearing the same donor atoms as HPCIH, namely the pyridyl  nitrogen, 
NIH (311)                                            
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imine nitrogen and carbonyl oxygen.
77
 In addition, these ligands are neutral at physiological pH, 
permitting access across cell membranes.
77
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎1.10 Chemical structures of HPKIH and its analogues. 
 
The HPKIH series possesses cytotoxic activities (IC50 = 1 - 42 µM) much higher than 
HPCIH and are as effective as H2NIH in increasing iron efflux from pre-labelled cells and 
inhibiting iron uptake from Tf
97
 and this cytotoxic activity was found to be selective. The HPKIH 
series showed marked anti-proliferative activity against human SK-N-MC cells, whereas their 
activity was minimal on the normal fibroblast cell line, MRC-5.
97
 
Further studies on the chemistry and the redox activity of the HPKIH series indicated that 
they coordinate with Fe
II
 to form octahedral complexes that are oxidized to their Fe
III
 form only at 
relatively high potentials.
77
 The [Fe
II
(PKIH)2] complexes were active Fenton chemistry catalysts 
resulting in the in vitro hydroxylation of benzoate in the presence of hydrogen peroxide, indicating 
the formation of hydroxyl radicals. This can be translated to the cell where damage of DNA or other 
biomolecules may occur in the presence of complexed Fe
II
 and H2O2 which generate reactive 
oxygen species.
77,
 
98
 Indeed, the capability of HPKIH analogues was similar or surpassed NIH in 
terms of preventing cell proliferation and DNA synthesis and increasing the expression of GADD45 
and WAF1 m-RNA  leading to cell cycle arrest.
97
 Collectively, the cytotoxic effects of the HPKIH 
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series could be attributed to two mechanisms; binding iron from sensitive pools and the redox 
activity of the iron complexes formed.
77,
 
98
 
Becker et al. indicated that there was no significant correlation between the log P values and 
the anti-proliferative activity of the HPKIH series. However, it should be noted that analogues 
containing electron-donating substituents, including di-2-pyridylketone p-hydroxybenzoyl 
hydrazone (HPKHH) and di-2-pyridylketone-p-amino hydrazone (HPKAH) demonstrated low anti-
proliferative activity (IC50 ˃ 23 µM).
97
 Conversely, the analogue with an electron-withdrawing 
substituent, such as HPKIH, displayed high anti-proliferative activity, despite it being the most 
hydrophilic chelator of the series.
97
 
Kovaříková and co-workers indicated that aldehyde-derived aroylhydrazones possess 
relatively short half-lives of elimination despite having marked anti-proliferative activity.
99
 Hence, 
there could be instability of these agents in plasma with an effect on their pharmacokinetics.
100
 This 
has promoted researchers to design novel anti-tumour agents, which overcome this limitation, being 
more stable to hydrolysis such as thiosemicarbazones.     
1.2.2.5 Thiosemicarbazones 
 
Heterocyclic thiosemicarbazones were one of the first chelator classes to be examined as 
anticancer agents.
101, 102
 These chelators bind iron in a tridentate fashion utilizing NNS donor atoms 
forming octahedral iron complexes in a 2:1 (ligand:metal)  manner, in a similar fashion to the 
aroylhydrazone chelators. However, thiosemicarbazone ligands provide a sulfur atom instead of an 
oxygen atom in the coordination sphere.
101,103
 The thiosemicarbazones also  showed high affinity 
for iron and a range of metal ions such as Cu
II
, Zn
II
,  Ga
III
, Mn
II
 and Co
II
.
102
 Some studies by 
Sartorelli et al. and Antholine et al. demonstrated that metal complexes of thiosemicarbazones have 
greater antitumour activity than the free ligand themselves.
104, 105
 These thiosemicarbazone ligands 
produce their beneficial anti-cancer activity by inhibiting ribonucleotide reductase, a key enzyme in 
the synthesis of DNA precursors.
101,
 
104
 However, the mechanism of RR inhibition remains unclear. 
Early reports postulated that thiosemicarbazones may bind Fe at the active site of the enzyme or 
may act by complexation with Fe that destroyed the tyrosyl radical in the R2 subunit of RR.
101, 106
 
On the other hand, more recent investigations have suggested that depletion of intracellular label Fe 
pools could inhibit RR. Additionally, another investigation has suggested that the inhibition of RR 
could result from a change in the cell‘s thiol-based, anti-oxidant system promoted by ROS 
stimulated by iron and copper thiosemicarbazone complexes.
107
 Collectively, these chelators may 
act by various mechanisms to inhibit the RR enzyme. 
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1.2.2.5.1  3-Aminopyridine-2-carboxyaldehyde Thiosemicarbazone 
 
One of the best known thiosemicarbazone iron chelators with anti-tumour activity is 3-
aminopyridine 2-carboxyaldehyde thiosemicarbazone (3-AP or Triapine
TM
, Figure 1.11). 
 
 
Figure ‎1.11 Chemical Structure of Triapine
TM
, 3-AP and its Fe binding mode. 
 
As illustrated this tridentate chelator binds iron via the thiolate sulfur atom and two nitrogen 
donor atoms (the pyridine nitrogen and the imine nitrogen).
106
 Studies by Finch et al. and Chaston 
demonstrated that Triapine is a potent RR inhibitor in vitro and in vivo. 
106,108
 In cell culture studies, 
it was found that the efficiency of Triapine to mobilize Fe from prelabeled cells was twice that of 
DFO but it was less efficient than 311. In addition, Triapine had similar activity to DFO at 
preventing Fe uptake from Fe-Tf, but far less efficacy than 311.
106
 Further studies revealed that the 
anti-proliferative activity of Triapine (IC50 0.2 μM) can be attributed to the ability of its Fe complex 
to redox cycle, increase the oxidation of ascorbate as well as glutathione depletion and stimulate 
DNA degradation.
106
 The Fe
II
 complex of 3-AP has also been shown to be able to reduce O2 to give 
ROS that may quench the tyrosyl radical of the R2 subunit of RR rendering the enzyme inactive.
106
 
Other work by Shao et al. suggested that Triapine as a free ligand is less active than its Fe
II
 complex 
in terms of inhibition of RR.
109
 Collectively, the cytotoxicity of Triapine results from its redox 
active Fe complex, producing free radicals and mediating oxidative damage.
106
  
In animal studies,  Finch et al. revealed that  Triapine preformed as a selective anti-tumour 
agent.
108
 This study also showed that the compound inhibited leukemic cell growth (IC50 = 0.3 
μM)110 at concentrations lower than the clinically used RR inhibitor hydroxyurea (Hu).108 
Administration of Triapine (twice daily) was shown to be more effective against L1210 leukaemia 
xenografts in mice compared to that of hydroxyurea.
108
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In addition to animal studies, Triapine has been recently examined in a number of phase I 
and II clinical trials for cancer treatment in humans.
111-115 
 Phase I clinical trials of Triapine with 21 
patients resulted in a decrease in tumour marker associated with disease in four patients.
115
 
Furthermore, Triapine was well tolerated at a lower dose (120 mg/m
2
/day) administered every 2 
weeks whereas at higher doses (160 mg/m
2
/day), toxicity was observed, including 
thrombocytopenia, anaemia, leucopenia and, most importantly for this work, methemoglobinemia; 
the condition where an increased amount of oxyhemoglobin is oxidised to its non-oxygen binding 
ferric form methemoglobin.
115
 The phase II clinical trial, using 3-AP in conjunction with  the anti-
cancer agent gemcitabine (2,2-difluoro-2-deoxycytidine), given to patients with non-small-cell lung 
cancer was concluded with no response in two patients after two cycles of treatment but there was 
development of methemoglobinemia in four patients and hypoxia in three patients.
116
 Another 
evaluation of the toxicity of Triapine in a phase II trial was conducted with patients with metastatic 
renal cell carcinoma (RCC), treated with Triapine at the dose (96 mg/m
2
) four times per fortnight. 
79% of patients suffered from acute hypoxia and methemoglobinemia in addition to grade 3/4 
neutropenia.
112
 Further assessments of the activity of Triapine in clinical trials have also been 
performed, including studies investigating leukaemia, pancreatic carcinoma and myeloproliferative 
disorders. Phase II clinical trials utilising Triapine in combination with both chemotherapy naïve 
and gemcitabine-refractory (GR) patients with advanced pancreatic cancer have also been 
reported.
117
 Clearly, the results above suggest that in spite of its promising anticancer properties, 
Triapine has undesirable side effects including the oxidation of haemoglobin to methaemoglobin 
and hypoxia resulting from the redox activity of its iron complex. Hence, the development of other 
iron chelators that overcome the deleterious effects of Triapine should be considered.
118
 
1.2.2.5.2 Di-2-pyridylketone Thiosemicarbazones (HDpT series) 
 
The side effects associated with administration of Triapine have led to a search for more 
potent anti-proliferative agents with fewer undesirable effects, namely the di-2-pyridylketone 
thiosemicarbazone, HDpT series (Figure 1.12). The design of these chelators was based on a 
combination of the HPKIH aroylhydrazones and Triapine and their synthesis was achieved by 
Schiff base condensation reactions between dipyridyl ketone and a range of 
thiosemicarbazides.
119,120
 The HDpT series, like Triapine, bind iron through a NNS combination of 
donor atoms forming complexes with a 2:1 ligand to Fe ratio. 
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Figure ‎1.12 Chemical structures of the di-2-pyridylketone thiosemicarbazone (HDpT series) Donor 
atoms are indicated in bold and their Fe binding mode is shown.   
               
The anti-cancer activity of the HDpT series in vitro and in vivo relative to DFO, 311 and 
Triapine was reported. This study indicated that HDp44mt, HDp4at, HDp4et and HDp4pt showed 
higher anti-proliferative activity than DFO, 311 and Triapine, against a variety of cancer cell lines, 
including SK-N-MC neuroepithelioma cells, SK-Mel-28 melanoma cells and MCF-7 breast cancer 
cells.
120
 In addition, the HDpT chelators were capable of inhibiting the growth of SK-N-MC 
neuroepithelioma cells by 50% at concentrations between 0.03 and 0.06 μM  relative to an  IC50 5 
μM for DFO  and 0.3 μM  for 311.120  Interestingly, the negative control di-2-pyridylketone-2-
methyl-3-thiosemicarbazone Dp2mT (Figure 1.12) shows poor anti-proliferative activity. The 
presence of the methyl group at the N2-postion of the thiosemicarbazone prevents deprotonation 
and subsequent electron delocalisation across the N(2)-C-S moiety effectively removing its ability 
to bind Fe.
120
 Therefore, this study indicated that the ability of HDpT series to bind iron is coupled 
with anti-proliferative activity. The same study revealed that the capacity of the HDpT series to 
inhibit 
59
Fe uptake from 
59
Fe-Tf and mobilise intracellular 
59
Fe was far greater than DFO. The 
HDpT series was able to induce mobilization of  cellular 
59
Fe by 37-47% compared to 14% 
mobilized by DFO.
120
  These series also display selective anti-tumour activity in vitro, where all 
compounds significantly inhibited the growth of several cancer cell lines compared to little effect on 
the proliferation of MRC-5 fibroblasts, a normal cell line.
120
 For example, the most effective 
chelator of the HDpT  series is di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone (HDp44mT) 
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which showed potent anti-cancer effects (IC50 0.03 μM), yet little activity on fibroblast growth  ( 
IC50> 25 μM).
120
   
Further investigations to assess the HDpT series in vitro and vivo have been reported by 
Whitnall et al. These chelators were examined against a range of 28 tumour cell lines, HDp44mT 
being the most potent anti-tumour agent. This chelator was more effective than clinically used 
cytotoxic agent doxorubicin (DOX) and Triapine.  The IC50 value of HDp44mT is 0.03 ± 0.01 μM 
which is much lower than Triapine (IC50 1.41 ± 0.37  μM) as well as DOX (IC50 0.62).
118
 
Additionally, HDp44mT inhibited the growth of various solid human tumour xenografts in nude 
mice.
118
 Administration of HDp44mT at a dose of 0.75mg/kg per day exhibited markedly greater 
anti-proliferative activity than that of Triapine  (12 mg/kg per day), which is 10-fold  greater, in 
DMS-53 lung carcinoma xenografts.
118
 Recent a study by Liu and co-workers indicated that 
HDp44mT was effective at reducing the growth of metastatic breast cancer cells  in a metastasis 
mouse model without toxic effects.
121
 
Recently, there have been attempts to understand the key mechanisms involved in the 
inhibition of cellular proliferation by the HDpT chelators.
119
 Richardson et al. showed that the 
HDpT iron chelators possess substantial lipophilicity and were charge neutral at physiological pH, 
allowing access to intracellular Fe pools that are essential for proliferation. Electrochemistry studies 
of the Fe complexes of the HDpT series revealed totally reversible Fe
III/II
 couples of all complexes 
with redox potentials in the range 150 to 225 mV. The complex [Fe
III
(Dp44mT)2]
+
 had the highest 
redox activity, catalysing the oxidation of ascorbate  and the hydroxylation of benzoate (a Fenton 
chemistry assay). This activity is linked with ROS generation under physiological conditions, 
causing lysosomal membrane permeabilization, promoting apoptosis.
122
 By comparison with Fe 
complexes of the HPKIH hydrazones, the HDpT series Fe complexes exhibit lower redox potentials 
which could be the reason for their greater anti-proliferative activity.  The results above suggest that 
the HDpT analogues act through two mechanisms; depleting cellular Fe and their Fe complexes 
producing ROS. On the contrary, adverse effects of the HDpT analogues were identified by 
Whitnall et al., including cardiac fibrosis observed at non-optimal doses of HDp44mT.
118
 The side 
effects of HDp44mT led to the second-generation HDpT chelator, di-2-pyridylketone 4-cyclohexyl-
4-methyl-3-thiosemicarbazone (HDpC) (Figure ‎1.12).  Kovacevic et al. showed that HDp44mT and 
HDpC were more effective at inhibiting the growth of the pancreatic cancer cells in vitro than 
gemcitabine and 5-fluorouracil (the current chemo-therapy drugs).
123
 Moreover, HDpC was shown 
to be more effective at reducing the growth of pancreatic cancer xenografts of nude mice compared 
to HDp44mT and gemcitabine. The same study indicated that that HDpC was less toxic and did not 
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induce cardiac fibrosis compared to HDp44mT. considering the later results, HDpC is the most 
selective and effective chelator of the HDpt series. 
123
   
1.2.2.5.3 2-Benzoylpyridine Thiosemicarbazones (HBpT series) 
 
Other studies have made structural modification to the HDpT series to overcome their side 
effects by replacing the non-coordinating pyridyl ring of the HDpT series with a phenyl group, 
generating the 2-benzoylpyridine thiosemicarbazone (HBpT) series (Figure ‎1.13).124 This 
modification has the dual effect of increasing lipophilicity and lowering the Fe
III/II
 redox potential of 
its complex by replacing a strongly electron withdrawing pyridyl ring with a weakly electron 
withdrawing phenyl ring.
124
 The HBpT analogues in vitro were more potent anti-neoplastic agents 
than DFO, Triapine and most of the HDpT series. This was supported by studies against SK-N-MC 
neuroepithelioma cells, illustrating that HBp4eT has the greatest anti-proliferative activity (IC50 = 0 
.002μM) within the series.124 In addition, the novel HBpT series exhibited selective anti-tumour 
activity, having little effect on normal cells MRC-5 fibroblasts.
124
 The same study indicated that the 
HBpT series has ability to mobilize iron from prelabeled cells and inhibit iron uptake from Tf in 
SK-N-MC cells. While the HBpT series possess greater anti-proliferative activity (IC50 0.002-
0.005μM) than most of their parent HDpT analogues, they are less effective at inhibiting cellular Fe 
uptake and increasing Fe efflux.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎1.13 Chemical Structures of the 2-benzoylpyridine thiosemicarbazone (HBpT series). Donor 
atoms shown in bold. 
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Further investigation of the redox activity of the Fe-BpT complexes revealed totally 
reversible Fe
III/II
 redox couples at lower potential than their corresponding HDpT analogues. This 
also led to an increased ability to catalysed ascorbate oxidation and benzoate hydroxylation relative 
to the HDpT series, with a similar mechanism of  action.
124
 In this regard, it was found that redox 
cycling of BpT-Fe complexes play a vital role in increasing their anti-proliferative activity.  
In vivo investigations indicated that the administration of HBp44mT in mice did not induce 
cardiac fibrosis in contrast to HDp44mT.
125
 Furthermore, this chelator exhibits significant decrease 
in TfR1 expression and increase in ferritin H chain expression. Collectively, HBp44mT is a chelator 
with promising anti-tumour efficacy.
125
 Recently, an LC-MS/MS method for the quantification of 
HBp4eT and its main phase I metabolites in rat plasma was described. This study provides basic 
pharmacokinetic parameters for a lead compound of the HBpT series.
126
   
1.2.2.5.4 2-Acetylpyridine Thiosemicarbazones 
 
As mentioned previously, the iron chelators of the HDpT and HBpT series
119,
 
124
 are potent 
antitumour agents which form Fe complexes intracellularly that are capable of redox cycling. In this 
regard, further investigations were carried out to assess the influence of substituents at the imine 
carbon on anti-proliferative and redox activities. Introducing an inductively donating methyl group 
instead of the electron withdrawing pyridine ring (HDpT series) leads to development of the 2-
acetylpyridine thiosemicarbazones series (HApT) (Figure 1.14). This series was synthesized by a 
Schiff-base condensation of 2-acetyl pyridine with the same series of thiosemicarbazides utilized to 
prepare the HDpT and HBpT analogues.
127
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Figure ‎1.14 Chemical Structures of the 2-acetylpyridine thiosemicarbazones (APT series). Donor 
atoms shown in bold. 
Interestingly, four of the six HApT chelators showed potent anticancer activity against the 
human SK-N-MC neuroepithelioma cell line (IC50 = 0.001- 0.002 μΜ) and illustrated similar Fe 
chelation efficacy to the most active HBpT and HDpT chelators.
127
 However, the HApT parent 
ligand demonstrated the lowest anti-proliferative activity (IC50 = 3.53 μΜ), attributed to it is being 
the most hydrophilic of the series with a terminal –NH2 group being present. The same study also 
examined the redox activity of Fe complexes of the HApT series to examine possible links to 
cytotoxicity and biological activity. All complexes showed totally reversible Fe
III/II
  couples, having 
lower Fe
III/II 
redox potentials than the Fe complexes of the HDpT and HBpT series.
127
  It is 
important to note that the redox potentials of these HApT complexes lie within a range accessible to 
both cellular oxidants and reductants. In addition, the HApT series was effective at mobilizing 
intracellular 
59
Fe and preventing 
59
Fe uptake from Tf, which are linked to anti-proliferative activity 
of these ligands. Clearly, these results demonstrate the influence of substituents at the imine carbon 
on Fe
III/II 
redox potentials and hence anti-cancer activity. 
1.2.2.6 Thiohydrazone series 
 
Hydrazone Fe chelators utilising the NNO donor set, namely HPKIH, exhibit moderate anti-
proliferative effects whereas NNS thiosemicarbazone chelators demonstrate much greater anti-
proliferative ability.
119
 This led to the investigation of the effect of donor atom on anti-tumour 
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activity of hybrid ligands, namely the thiohydrazones.
76
 The thiohydrazones with an ONS donor set 
included  pyridoxal thiobenzoyl hydrazone (H2PTBH), salicylaldehyde thiobenzoyl hydrazone 
(H2STBH) and 2-hydroxy-1-naphthaldehyde thiobenzoyl hydrazone (H2NTBH) (Figure 1.15), 
exhibited decreased anti-proliferative effects and reduced redox activity in comparison to their 
parent ONO aroylhydrazones. In contrast, thiohydrazones utilising NNS donor atoms such as  di-2-
pyridylketone thiobenzoyl hydrazone (HPKTBH, IC50 = 0.012 μΜ ) and 2-benzoylpyridine 
thiobenzoyl hydrazone (HBPTBH, IC50 = 0.011 μΜ) (Figure 1.15), showed marked and selective 
anti-proliferative activity compared to their parent aroylhydrazones, making them as active as 
thiosemicarbazones (HDpT  and HBpT series).
76
 Further investigations on those NNS 
thiohydrazone and  the electrochemistry of their Fe complexes found that  iron complexes of these  
chelators (Fe(PKTBH)2 and Fe(BPTBH)2)  gave reversible Fe
III/II
  redox couples at +383 and +328 
mV  vs NHE respectively and showed increased ability to catalyse ascorbate oxidation and benzoate 
hydroxylation, and thus likely to generate  cytotoxic ROS in cells.
76
  
Collectively, these results emphasize the importance of donor atoms on the anti-proliferative 
and redox activity of iron chelators, particularly the NNS donor set that is associated with potent 
anti-tumour activity.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎1.15 Chemical Structures of the thiohydrazone series, donor atoms in bold. 
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1.2.2.7 Heterocyclic Dithiocarbazate Schiff bases 
 
Heterocyclic Schiff bases derived from S-alkyl or S-aryl esters of dithiocarbazic acid have 
also attracted attention due to their chemical and physical properties
128,129 
and potentially significant 
biological activity against microbes, viruses and  cancer.
130-133
  These Schiff bases are tridentate 
utilizing NNS donor atoms and consequently they  are readily able to coordinate  with a variety of 
transition metal ions such as Zn, Cd, Cu, Ni, Mn, Co and Cr, forming highly colored and stable 
complexes. These chelators have a ligand backbone similar to those of the heterocyclic 
thiosemicarbazones discussed above, differing only in the terminal non coordinating –SR functional 
group attached to thiocarbonyl moiety.
134
 It has been reported that some of these dithiocarbazate 
Schiff bases and their complexes show antifungal and antibacterial properties.
132
 Some crystal 
structures of these chelators and their complexes have been reported.
135-143
  
Although a large amount of information is reported on the coordination chemistry of 
dithiocarbazate Schiff bases with a variety of metal ions and their biological activity, 
134,136,137,144-149
 
the iron coordination chemistry of these Schiff bases was neglected.
150,151
 Therefore, the iron 
coordination chemistry and biological activities of dithiocarbazate Schiff bases (Figure 1.16) was 
undertaken as a part of this thesis and will be discussed in Chapter 3.   
 
 
 
 
 
 
 
 
Figure ‎1.16 Dithiocarbazate Schiff base ligands investigated in this thesis (donor atoms are in bold 
type).    
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1.3 Side effects of Fe chelation 
1.3.1 Oxidative stress (Fenton chemistry – catalysed by Fe) 
 
Depending on their redox potential and cellular location, Fe complexes are capable of 
participating in redox cycling leading to the production of reactive oxygen species via the Fenton 
reaction presented in (Equation 1.1).
6
 There are various other coupled reactions that have been 
proposed (including the Haber-Weiss reaction) but their true relevance has been shown to be 
questionable.
152
  
1.3.2 Damage to biomolecules by free radicals (OH) 
 
Radicals, most particularly the hydroxyl radical produced by the Fenton reaction, attack 
cellular membranes, DNA, proteins and lipids at diffusion controlled rates,
8,  9 
and as such they 
represent highly toxic compounds which are linked to various diseases. 
1.3.3 Myelo-suppression 
 
One of the side effects of iron chelation in patients is myelo-suppression.
153
 This serious 
condition can result in anemia, granulocytopenial/agranulocytosis, severe bleeding and life-
threating infection.
154
 The main reason of chelator linked myelo-suppression is the effect of the Fe 
chelator on ribonucleotide reductase (RR), decreasing DNA synthesis and cell growth.
155
 
1.3.4 Methemoglobinemia 
 
Under physiological pH and temperature conditions, 1-2% of total hemoglobin (Hb) in the 
blood is present as methemoglobin (metHb), a ferric form that cannot bind dioxygen. The  auto–
oxidation of formally ferrous oxyhemoglobin (HbO2) to ferric metHb is quote slow (t1/2 ~ hours).
156
 
Instead of binding dioxygen, metHb binds an aqua/hydroxido ligand in the same axial coordination 
site.
157
 In vivo, methemoglobin is reduced to its oxyferrous form HbO2 by the enzyme 
methemoglobin  reductase (NADH-cytochrome b5 reductase).
158
  The rate of HbO2 auto-oxidation 
depends on both concentration of dioxygen and pH.
159,
 
160
 In its native form Hb is an α2β2 tetramer 
comprising four heme cofactors (one in each subunit). A study by Mansouri et al. has determined 
the auto-oxidation rate of the isolated α- and β-chains at 25 ˚C and pH 7.2.161 Monomeric α-chains 
exhibits an enhanced autooxidation rate (7 × 10
-6
 s
-1) compared to the isolated β-chain (2.5 × 10-6 
s
-1
). The same study on the intact HbO2 tetramer at the 37 ˚C and pH 7.2 confirmed that the auto-
oxidation rate of α-chains (9 × 10-6 s-1) is faster than the β-chains (1 × 10-6 s-1).161  
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Lunelli et al. showed that at lower (sub-micromolar) concentrations, HbO2 dissociates from 
its native tetrameric (22) state to an  dimer.
162
  Further studies have determined the tetramer-
dimer dissociation constant to be ca. 0.1-1 µM depending on the degree of oxygenation, 
temperature and pH.
163, 164
 The dimeric form exhibits similar dioxygen-binding properties as the 
tetramer.
164
 The structures of the 22 tetramer and the  dimer are compared in Figure 1.17 in 
ribbon format. 
165
 
 
 
Figure ‎1.17 Crystal structure
165
 of (left) 22 tetrameric HbO2 viewed along its crystallographic C2 
axis and (right) the  dimeric oxyhemoglobin asymmetric unit with the  and  subunits shown in 
different colours. The heme cofactors are shown in ball and stick representation. 
 
As mentioned, metHb as the fully oxidised form of Hb has no affinity for dioxygen. Hence, 
compounds, particularly oxidants, that can promote metHb production are potentially toxic.
156
 It has 
been found that HbO2 can in fact be oxidised by iron(III) complexes.
166-168
 In this regard, the 
electron transfer between metal complexes and heme proteins is important and has been well 
studied.
166,167,169-173
 There are two mechanisms proposed for this electron transfer reaction (1) a 
simple outer-sphere mechanism in which electron transfer occurs over the exposed heme edge
166-168
 
(Equation 1.6, 1.7) and (2) an inner-sphere mechanism,  which has been challenged,
 175,170 
 requiring 
coordination of the metal complex to HbO2 to form an O2-bridged intermediate prior to electron 
transfer (Equations 1.8 and 1.9).
167,169
 These can be summarised in the following overall reactions 
which take into account the 4:1 Fe:HbO2 stoichiometry of the reaction with the 22 tetrameric 
protein. 
Outer sphere mechanism  
HbO2   ⇌  deoxyHb + 4 O2    (1.6) 
deoxyHb + 4 Fe
III
  → metHb + 4 FeII              (1.7)     
Inner-sphere mechanism  




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HbO2 + 4 Fe
III
 ⇌  Hb(4(O2:Fe
III
))    (1.8)     
Hb(4(O2:Fe
III
)) → metHb + 4 FeII + 4 O2   (1.9) 
Recently, there has been concern about side effects of anti-cancer therapies, including 
hypoxia and methemoglobinia. As discussed previously in Section (‎1.2.2.5.1), 3-amino-
pyridinecarboxaldehyde thiosemicarbazone (3-AP; Triapine) (Figure ‎1.11), which has been 
examined in a number of phase I and phase II clinical trials for the treatment various cancers,
111-
115,117,174
 induces the formation of metHb (methemoglobinemia) and hypoxia in patients, limiting its 
use.
112,175-178
  These side effects of Triapine administration are concerning for patients with 
compromised cardio-pulmonary function due to the inability of metHb to transport of dioxygen to 
the tissues.
156
 However, the mechanism of these effects has not been investigated. Hence, the 
investigation of the effects of these drugs on Hb and elucidation of the mechanism of formed metHb 
by these agents will play a crucial role in the development of more effective thiosemicarbazones as 
anti-cancer agents.
179
 Therefore, kinetic and mechanistic studies of methemoglobin formation by Fe 
heterocyclic thiosemicarbazones, including the HDpT, HBpT and HApT series will be discussed in 
Chapters 4 and 5. 
1.4 Fluorescent sensors for metal ions in cells  
 
As mentioned previously, iron plays important roles in a multitude of biological process, but 
is toxic when present in excess. This excess of iron leads to the medical condition referred to 
generally as Fe overload. Hence, administration of Fe chelating ligands is essential to alleviate the 
toxic effects of iron by facilitating its excretion.
41
 However, little is known about the intracellular 
location of these chelators or the mechanism of how these chelators access Fe in the cell. Therefore, 
various analytical techniques have been employed for the detection of intracellular iron, including 
fluorescence microscopy. 
180, 181,
 
182
   
1.4.1 Introduction to fluorescent sensors  
 
There has been great attention over the last 20 years on the synthesis of fluorescent 
chemosensors that are selective for certain metal ions. In 1997, Czarnik and his group
183
 reported 
the first rhodamine-based fluorescent chemosensor for Cu
II
 and then a large number of papers 
followed reporting similar methodology for different systems. The target metal ions have since 
included Cu
II
, Hg
II
, Fe
III
, Fe
II
, Zn
II
, Cr
III
, Ag
I
, Au
I
, Pb
II
, Pd
II
 and Pt
II
.
182
 Reaction between these 
metal ions and the sensor results in changing fluorescence properties including wavelength, 
emission intensity and even new fluorescence compared to the metal-free sensors. These fluorescent 
probes in combination with confocal optical microscopy have let to the visualization of metal ions 
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in particular subcellular and extracellular regions and have greatly assisted our understanding of 
metal ion location and homeostasis which is linked with health and disease.
180,181
 
1.4.2 Fundamental properties of effective fluorescent sensors 
 
Effective fluorescent sensors for cellular processes must meet several criteria.
184
 Most 
importantly, the probes must be compatible with cellular systems which mean they should be water 
soluble, non-toxic and cell-permeable. They should also be selective for specific metal ions over the 
host of other coexistent metal ions in a cellular system. In this regard, coordination chemistry 
including ligand geometry, size of the metal, donor number and hard-soft acid-base properties 
should be considered. In addition, probes that undergo an enhancement of emission signal (turn-on 
effect) or provide a shift in excitation/emission profile are favoured over probes that undergo 
quenching of fluorescence emission (turn-off effect) to enabling high spatial resolution and for 
quantification. Signals that emerge from a zero background upon metal complexation are easier to 
interpret than those that are attenuated by metal binding. Furthermore, fluorescent sensors should 
have suitable complex formation constants. Chelators might not bind any metal ions if they possess 
a weak binding affinity and might disturb the intracellular equilibrium of metal ions if they have a 
too strong binding affinity.
185
 Probes should also have visible-light excitation and emission, to 
minimize autofluorescence, and also high quantum yields and extinction coefficients. 
1.4.3    Fluorescent iron sensors 
 
There has been much interest in design and synthesis of selective and sensitive fluorescent 
sensors for Fe ions in recent years, due to the central role of Fe in many biochemical processes at 
the cellular level, as mentioned previously. However,  complexation of ferric ion by fluorescent 
ligands is mostly associated with fluorescence quenching which makes interpretation of 
fluorescence data difficult.
186
 The development of fluorescent probes that exhibit an increase in 
visible fluorescence upon the addition of iron(III) is still a challenge. Presently, the two commercial 
sensors for cellular iron detection rely on fluorescence quenching, namely Calcein and Phen Green 
SK (Figure ‎1.18). The structure of Calcein contains a fluorescein fluorophore with a bis 
iminodiacetate chelating group that was thought to selectively turn off in the presence of  Fe
2+ 
but 
not Fe
3+
.
187
 However, it has shown that there is significant interference from Fe
3+
 and other divalent 
metal ions including Co
2+
, Ni
2+
, and Mn
2+
.
187,188
 A second commercial probe that responds to 
intracellular Fe
2+ 
sensing is Phen Green SK.
189, 190
 Once again, non-specific binding of Phen Green 
SK remains a problem as other metal ions including Fe
3+
, Cu
2+
, Co
2+
 and Ni
2+
 can also quench the 
fluorescence. 
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Figure ‎1.18 Structures of commercially available iron sensors: Calcein and Phen Green SK. 
 
Synthesizing sensors selective for Fe
2+ 
over Fe
3+ 
is challenging because of its capacity for 
oxidation in aqueous solution and aerobic conditions. Thus, few fluorescent probes for Fe
2+ 
have 
been reported.
191-196 
 For example, pyrene-TEMPO and DansSQ (Figure 1.19) are Fe
2+
 turn-on 
sensors, but operate via different mechanisms. Pyrene-TEMPO exhibits a weak fluorescence 
emission at 430 nm
191
 and is  present as a nitroxide radical.  This radical is reduced by binding Fe
2+
, 
which enhances the pyrene fluorescence. However, the application of Pyrene-TEMPO in biological 
systems is restricted due to its reaction in acidic solutions and the existence of other cellular 
radicals. Another Fe
2+
 turn-on sensor is DansSQ which is weakly fluorescent due to an 
intramolecular charge transfer (ICT) from the quinoline nitrogen to the nitrostyryl group upon 
excitation.
193
 Chelating with Fe
2+
 prevents this transfer and increases the fluorescence 15-fold at 
460 nm by excitation at 365 nm. Nevertheless, DansSQ has insufficient aqueous solubility and only 
dissolves in MeCN containing 10% H2O and is not totally selective for Fe
2+
, particularly in the 
presence of large excess of Cu
2+
,  Fe
3+
, Hg
2+
or Cr
3+
. 
 
 
 
 
 
 
 
 
 
Figure ‎1.19 Structures of turn-on fluorescent sensors for Fe2+. 
Calcein 
Phen Green SK 
Pyrene-TEMPO 
DansSQ 
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1.4.3.1 Sensors selective for Fe3+ 
1.4.3.1.1 Chelation Enhanced Quenching effect (CHEQ) 
 
Various fluorescent turn-off sensors have recently appeared with greater selectivity for Fe
3+ 
than that found for calcein or Phen Green.  For instance, the Hider laboratory
197-199
 developed 
sensors 1 and 2 that are formed from a hydroxypyridinone (such as deferriprone) chelating 
backbone connected to a fluorescein or coumarin fluorophore (Figure 1.20). These sensors 
exhibited fluorescence quenching after binding Fe
3+ 
up to 90% and they were employed to 
determine cellular iron concentrations.
198,199
 
 
 
 
 
 
 
 
Figure ‎1.20 Structures of Fe
3+
 turn-off fluorescent sensors.  
 
Another example of a Fe
3+
 turn-off sensor utilises the fluorophore 4,4-difluoro-4-bora-3a,4a-
diaza-s-indacene, better-known as BODIPY or difluoroboron dipyrromethene (Figure 1.21). The 
first member of this family was investigated in 1968 by Treibs and Kreuzer
200
 and its potential as a 
biological label and fluorophore were identified in the mid-1990s. BODIPY has many favourable 
properties including a relatively high molar extinction coefficient (ε > 80,000 M-1 cm-1) high 
fluorescence quantum yields Φf > 0.50, and a moderate redox potential that is essential in designing 
fluorescent chemosensors dependent on electron transfer mechanisms.
184
 Combining BODIPY with 
chelating groups typically utilises intramolecular photoinduced electron transfer (PET)
201
 with 
ligand lone pairs quenching fluorescence while coordination of the donor atoms blocks PET and 
fluorescence is switched on. Additional favourable properties of BODIPY include 
excitation/emission wavelengths in the visible region (> 500 nm) and fluorescence lifetimes in the 
nanosecond range.
202
 
 
 
 
 
 Figure ‎1.21 Structure of 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene (BODIPY). 
 
1 
2 
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1.4.3.1.2 Chelation Enhanced Fluorescence effect (CHEF) 
 
A few turn-on sensors for Fe
III 
have been reported recently. For example, Lee et al. 
developed a new selective fluorescence chemosensors for intracellular  Fe
3+
 in hepatocytes.
203
 
Rhodamine B derivatives are other examples of (off-on) fluorescent chemosensors which have 
gained attention in recent years owing to their excellent photophysical properties.
204
 They offer low 
detection limit, long-wavelength emission, are readily available and are chemically simple.
205
 There 
is an equilibrium between a spirolactam (non-fluorescent) colourless and ring opened amide 
(fluorescent) coloured form of rhodamine derivatives that make them an ideal system if ring 
opening can be linked with metal ion coordination (Figure 1.22). Rhodamine B amide derivatives 
exhibit a red colour change and strong fluorescence upon the coordination of metal ions to the 
amide O-atom or by protonation as shown in (Figure 1.22).
206
 
 
 
 
Figure ‎1.22 Spirolactam ring-opening process of rhodamine B derivatives. 
 
In 1905, the preparation of rhodamine by Noelting and Dziewonsky was reported.
207
 
Rhodamine B hydrazide was first prepared by Czarnik and co-workers via two steps and the 
terminal –NH2 group is able to be further elaborated by extra chelating groups.
183
 Another study by 
Yang and co-workers synthesised the same probe with a different strategy via a one-step reaction 
and used the compound as a sensor for peroxynitrite.
208
 Later, several papers utilising related 
fluorescent sensors for detecting Fe
3+
 based on spirocyclic ring-opening have been published. Tong 
et al.  synthesized compound 3
209
  that  was claimed to show high selectivity for Fe
3+
 over other 
coexistent metal ions in both ethanol and buffered aqueous solution (pH 7.15, Tris-HCl) as shown 
in (Figure ‎1.23). While this probe could detect 10-5 M  Fe3+  ions it had only a moderate binding 
affinity for Fe
3+
 in aqueous media, limiting its usefulness in biological applications.
209
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Figure ‎1.23 Structure of Fe
3+
 sensor (compound 3).  
 
Another rhodamine based fluorescent chemosensor (compound 4) was synthesized by 
Shiraishi et al. (Figure 1.24). Addition of  Fe
3+
 to a colourless solution of probe 4 (spirocyclic form)  
lead to significant colour change to the pink (ring-opened form) and orange fluorescence.
210
 The 
complex stoichiometry was reported to be 1:2 metal:ligand based on Jobʼs plot analysis but no 
structural data were presented in support of this binding mode. 
 
 
 
 
 
 
 
Figure ‎1.24 Proposed bonding mode of compound 4 with Fe
3+
. 
 
A fluorescent iron chelator (compound 5), which detects micro molar concentrations of Fe
III
, 
was designed by Tae and Bae
211
 (Figure 1.25). This chelator contains rhodamine amide and 
hydroxamate units as binding sites for iron(III). Binding Fe
III
 to this rhodamine hydroxamate 
enhances fluorescence emission in MeOH-CH3CN (1:1, v/v) with the colour of the solution 
changing from colourless to red- purple. 
 
 
  
 
 
Figure ‎1.25 Proposed bonding mode of compound 5 with Fe
3+
. 
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Another fluorescent iron chelator (compound 6, Figure 1.26) based on a rhodamine-
benzimidazole conjugate was designed and synthesized by Junbo and his group.
212
 This compound 
displayed great selectivity and sensitivity to Fe
3+
 in MeCN over other metal ions while inducing a 
ring opening effect, turning on the fluorescence. This study showed that this probe coordinated with 
Fe
3+
 in a 1:1 stoichiometry (Figure 1.26) as indicated from both Job‘s plot and ESI-MS analysis and 
the calculated binding constant was 1.01×10
4
 M
−1
. 
212
 The fluorescence emission was found to be 
linearly dependent on the concentration of the Fe
III
 within the range of 6×10
−6 – 4×10−5 M with the 
detection limit of 1.5×10
−8
 M. However, the competition experiment for the detection of Fe
3+ 
ion 
showed that Cu
2+ 
interfered to some extent. 
 
Figure ‎1.26 Proposed bonding mode of compound 6 with Fe
3+
. 
 
One thing that is generally lacking in the reports of any proposed fluorescent Fe chelator is 
structural characterisation of the Fe:ligand complex. One crystallographically characterised example 
of a turn-on fluorescent iron complex was reported by Chartres et al.
213
 They synthesised a new 
fluorescent chelator utilizing rhodamine B grafted onto benzoyl picolinoyl hydrazine chelating 
group known to bind Fe
III
 (see Section ‎1.2.1.5). The chelator (compound 7, Figure 1.27) is non-
fluorescent in its uncomplexed form but becomes fluorescent in complex with Fe
III
.  Full structural 
and spectroscopic characterization of this ligand and its 1:2 Fe complex [Fe
III
(L)2]
3+
 was reported. 
In addition to that, this Fe complex when incubated with HeLa cells was detectable confocal 
fluorescent microscopy demonstrating that the complex was able to enter cells intact and localize 
within endosomes or lysosomes. This same compound will be investigated further in this thesis. 
 
 
 
 
 
 
 
Figure ‎1.27 Bonding mode of compound 7 with Fe
3+
. 
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During the course of this thesis a (turn on) fluorescent chelator based on rhodamine B 
hydrazide and 2-pyridinecarboxaldehyde (Figure 1.28) was synthesized by  Leite et al.
214
, using 
microwave irradiation without any organic solvents. This binding unit is based on the HPCIH series 
of hydrazone Fe chelators studied by Bernhardt and co-workers. It was designed to detect metal 
ions, particularly iron(III) which is unusual given the preference of HPCIH for Fe
II
 as discussed 
earlier. The authors characterised this ligand in the solution and solid state by different techniques 
including X-ray crystallography. They indicated that this ligand is non-fluorescent in its spirolactam 
form and becomes ring opened, inducing fluorescence, after addition of Fe
III
 or in acidic solution 
(see proposed structure in Figure 1.28). This compound has been synthesised concurrently in our 
group, and our own results with this compound and their interpretation will be reported in this 
thesis.   
 
 
 
 
 
 
 
Figure ‎1.28 Proposed bonding mode of compound 8 with Fe
3+
. 
 
A different study reported a turn-on fluorescent sensor for Fe
III
 by Bordini and co-
workers.
215
 They synthesized and characterized a selective and sensitive Fe
III
 sensor, namely 
rhodenal (Figure 1.29), also derived from rhodamine B and they indicated that this sensor is pH 
sensitive with two pKa values (pKa1 = 1.2, pKa2 = 2.8). Reaction of rhodenal with Fe
3+
 generated a 
violet complex with dissociation constant of 1.3×10
-6
 M. Additionally, the rhodenal ligand was 
shown to be cell permeable and fluorescence within cells was observed.
215
 
 
 
 
 
 
 
 
 
 
Figure ‎1.29 Proposed binding mode of rhodenal with Fe
3+
. 
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In a continuation of designing and developing of fluorescent chemosensors that are effective 
and selective for iron, the Fe coordination chemistry of a range of fluorescent chelators derived 
from heterocyclic hydrazone and hydrazine Fe chelators will be investigated and discussed in 
Chapter 6. 
1.4.4 Kinetic analysis of ring opened fluorescent rhodamine B derivatives by either 
protonation or complexation with iron. 
  
As mentioned previously, rhodamine B derivatives have attracted great attention as 
fluorescent probes due to their excellent photophysical properties.
204
 They undergo the equilibrium 
between a colourless, non-fluorescent spirolactam form and a coloured, highly fluorescent amide 
form.
182,206,216
 The spirolactam form is more stable at high pH. Nevertheless, Lewis acids including 
protons and metal cations can shift the equilibrium from spirolactam to the amide form.
220
 Despite 
the amount of work on the synthesis of rhodamine B based pro-fluorescent chelators, little attention 
has been considered to the kinetics of the lactam ring opening reaction leading to fluorescence.
217-
221
  Czaplyski and co-workers
220
 recently investigated the substituent effects (ranging from electron-
donating to electron-withdrawing) on the ring-opening of rhodamine B lactams induced by acid 
(HCl). They demonstrated that the ring-opening reaction of these rhodamine lactams occurs through 
a multistep mechanism; first step, the protonation of the carbonyl oxygen and delocalization of the 
positive charge across the oxygen, carbon and nitrogen of the lactam and the second step, ring- 
opening and formation of the iminol intermediate that then tautomerizes to the amide (Figure 1.30). 
They also hypothesized that the rate of ring opening of rhodamine B lactams induced by acid was 
affected by electronic properties of the spirolactam ring system.
 220
  
 
Figure ‎1.30 Mechanism of ring opening for rhodamine lactam derivatives. 
 
Further studies have indicated that the variation in the rate of the ring-opening to be < 1 s
-1
 
or even hour time scale can be attributed to various factors such as increased resonance, electron-
withdrawing on the rhodamine lactams and intramolecular proton transfer.
221
  The same work has 
studied the rate of the ring-opening reaction of four structurally similar rhodamine lactam 
derivatives (Figure 1.31) induced by Lewis acids which are trifluoroacetic acid (TFA) and 
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iron(III).
221
 The rates for the four derivatives were different, attributed to a combination of 
variations in the inductive ability of the N-aryl ring and the capacity of these derivatives to form 
transition state stabilizing resonance structures. The kinetic results observed with TFA were similar 
to those observed for iron (III). 
221
 
 
 
 
 
 
 
 
 
 
 
Figure ‎1.31 The pyridyl rhodamine B lactams (2AP, 3AP, 4AP), phenyl (APh), used for kinetic and 
thermodynamic studies. 
 
Additionally, this investigation focused on studying the turn-on rate alongside the structural 
effects, articulating that this was a crucial requirement for improved effective and selective sensors. 
Herein, kinetic analysis of ring-opening of new fluorescent rhodamine B derivatives by either 
protonation or complexation with iron has been undertaken and it will be discussed in Chapter 6. 
 
1.5 Research aims and outline 
 
The aim of this work is to characterize Fe coordination chemistry of some new chelators 
including heterocyclic dithiocarbazate and thioseimcarbazone Schiff bases (therapeutic agents) as 
well as related fluorescent chelators (for imaging iron in living cells). As some of these compounds 
have shown potential as anticancer agents, potentially adverse side effects such as oxidative stress 
are being also investigated. The specific aims of this thesis are: 
 Synthesis and characterization of new Fe complexes of biologically active heterocyclic 
dithiocarbazate Schiff base ligands (Chapter 3). 
 Understand the kinetics of methemoglobin (oxidative stress) formation promoted by FeIII 
complexes of the heterocyclic thiosemicarbazones  (Chapters 4 and 5). 
 Fe coordination chemistry of new fluorescent chelators (Chapter 6). 
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Chapter 2   Experimental  
 
 
 
2.1 Physical methods 
 
Solution UV-visible spectra were recorded on an Agilent 8453 UV-visible Spectrophotometer. 
Solutions were analysed immediately before any redox reactions occurred. This was particularly 
important for the Fe
II
 complexes which slowly oxidised in aerated solutions. Fluorescence and 
excitation spectra were measured on a Perkin-Elmer LS50B fluorescence spectrophotometer. 
Fourier Transform Infrared (FT-IR) spectra were recorded as undiluted solids on a Perkin 
Elmer 1600 FT-IR spectrometer in attenuated total reflectance mode. 
1
H NMR and 
13
C NMR 
spectra were acquired on a Bruker Avance 300 MHz (
13
C 75.4 MHz) and 400 MHz  (
13
C 100.6 
MHz) or 500 MHz (
13
C 125.7 MHz) instruments and all resonances were given relative to 
tetramethylsilane (TMS, δ= 0 ppm). Cyclic voltammetry was performed with a Bioanlytical 
Systems BAS100B/W potentiostat employing a glassy carbon, platinum or gold working electrode, 
a platinum wire auxiliary electrode. For experiments carried out in mixed aqueous solvents a 
Ag/AgCl reference electrode was used. For non-aqueous electrochemical experiments in MeCN or 
DMF, a Ag/AgClO4 (MeCN) or (DMF) reference electrode was used which was calibrated using 
the ferrocene/ferrocenium potential as an internal standard. The supporting electrolyte was 0.1 M 
Et4NClO4. All solutions were purged with N2 before measurement and approximately 1 mM 
solutions of analyte were used. Data analysis was performed with the software BAS100W version 2.3. 
UV-visible spectroelectrochemistry experiments were recorded in a thin-layer 
spectroelectrochemical cell (0.5 mm path-length, Bioanalytical Systems) containing a transparent 
gold grid working electrode (situated in the beam of the spectrometer), a Pt wire auxiliary electrode 
well removed from the thin layer region and a Ag/AgClO4 (MeCN) reference electrode. Spectra 
were acquired with an Ocean Optics PX-2 USB fibre optic spectrophotometer located within a Belle 
Technology glovebox under an atmosphere of nitrogen (O2 < 10 ppm). The potential of the cell was 
set with a BAS100B/W potentiostat in controlled potential electrolysis mode. Electrolysis was 
performed until no perceptible change in the UV-vis spectrum was observed (typically 5-15 min). 
Elemental Microanalyses (C, H, N) were performed on the Carlo Elemental Analyser model 
NA1500 by Mr George Blazak at the University of Queensland. X-Ray Crystallographic data 
were acquired at 23 °C on an Oxford Diffraction Gemini CCD diffractometer employing either Mo-
K (0.71073 Å) or Cu-K (1.5418 Å) radiation and operating in the ω-scan mode. Data reduction 
and empirical absorption corrections (multi-scan) or analytical absorption corrections were 
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performed with Oxford Diffraction CrysAlisPro software. Structures were solved by direct methods 
with SHELXS and refined by full-matrix least-squares analysis with SHELXL-97.
139
 All non-H 
atoms were refined with anisotropic thermal parameters. Molecular structure diagrams were 
produced with ORTEP3 or Mercury.
222,223
 All calculations were carried out within the WinGX 
graphical user interface.
224
 In the structure of [Fe(PCSME)(PSME)]·Me2CO the disordered acetone 
molecule was modelled as a diffuse contribution to the overall scattering without specific atom 
positions using SQUEEZE/PLATON.
225
 Full crystal data can be found in the Appendix. 
 
Kinetic studies  
Human HbO2 in reaction with [Fe
III
(DpxxT)2]
+
, [Fe
III
(BpxxT)2]
+
 and [Fe
III
(ApxxT)2]
+
 
Kinetic measurements were carried out between purified human HbO2 (Sigma) and each 
iron complex at least a 10-fold (15-60×10
–6
 M) molar excess over HbO2 concentration which was 
kept at 0.75×10
–6
 M tetramer (3×10
–6 
M total heme) for all kinetic measurements. All experiments 
were carried out at 25 °C in a thermostated cell. Stock solutions of the [Fe
III
(L)2]
+
 complexes 
(1×10
-3
 M) were prepared in MeOH (due to limited aqueous solubility) and the samples for kinetic 
measurements were prepared by dilution of the appropriate volume of the MeOH stock in buffer. 
Fast reactions (seconds timescale) were monitored on an Applied Photophysics SX20 MV Stopped-
flow instrument with photo-diode array detection, while slower reactions (minutes timescale) were 
monitored using an Agilent 8453 diode array UV-Visible spectrophotometer fitted with a multicell 
transporter for reactions conducted in parallel. In all cases, the full time resolved spectra were 
globally analysed by the program ReactLab Kinetics.226 The general kinetic technique has been 
previously described.
145,227
 
Experiments were set up in a way that spectral changes were generally consistent with a 
single first order (A→B) reaction within a certain time domain (long or short). The data were 
typically fit to a single fast exponential change for measurements carried out on the stopped flow 
instrument (< 50 s) and to a single slow reaction for experiments conducted with manual mixing (~ 
5 min). Nevertheless, for the slow reactions monitored by manual mixing, a two consecutive 
(A→B→C) first order reaction exponential process could be simulated using stopped flow data for 
the initial rapid reaction to produce an overall consistent profile comprising both steps. All the 
values of the observed pseudo-first order rate constants (kobs) obtained are presented in Chapter 4 
and Chapter 5 and they are typically the average of four replicate measurements. The oxidising iron 
complex concentration range was also limited to less than an order of magnitude due to the fact that 
at higher (or lower HbO2) concentrations no reliable spectral changes could be obtained due to the 
large background absorbance spectrum of [Fe(DpxxT)2]
+
, [Fe(BpxxT)2]
+
  and [Fe(ApxxT)2]
+
. 
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Protonation (ring-opening) of fluorescent rhodamine B chelators 
Kinetic runs were recorded using an Applied Photophysics SX20 MV Stopped-flow 
instrument with photo-diode array detection (< 50 s). For protonation reactions the concentration of 
trifluoroacetic acid (TFA) was kept in the range (2×10
-6 – 6×10-5) M in MeCN as solvent under 
pseudo-first-order conditions, while the concentration for all ligands remained constant at 2.5×10
-7 
M. All experiments were carried out at 25 °C in a thermostated cell. The time-dependence of the 
spectral changes were fitted to single (kobs1) exponential dependence by the use of the program 
ReactLab Kinetics226 as described previously. All the values of the observed pseudo-first order rate 
constants (kobs) obtained are presented in Chapter 6 and they are typically the average of four 
replicate measurements. 
 
Fe complexation by fluorescent rhodamine B derivatives and model ligand systems  
The kinetic measurements for the model (non-fluorescent) ligands (HAPBH, HPCBH and 
H2BPH) in reaction with either Fe(ClO4)2.6H2O or Fe(ClO4)3.6H2O were carried out at an Applied 
Photophysics SX20 MV Stopped-flow instrument with photo-diode array detection (< 10 s)  at 25 
o
C in a thermostated cell. All complexation reactions were recorded in the presence of Et3N (one 
equivalent per ligand) in MeCN under pseudo-first order conditions. The concentrations of ligand 
were kept in the range (4×10
-5 – 6×10-3) M and concentration of FeII or FeIII was 4×10-6 M. 
The kinetic processes of the complexation of the rhodamine containing ligands APRBH and 
PCRBH with Fe
II
 as well as HBPRBH with Fe
III
 were recorded by setting the value of the 
concentration of ligands within the (1–5) ×10-5 M range, while the concentration of FeII or FeIII was 
1×10
-6
 M. In some cases an excess of Fe was used in the range (5×10
-6
 – 6×10-5) M, while the 
concentration of ligands were 5×10
-7
 M. In all cases pseudo-first order conditions were maintained 
in a short time scale (stopped–flow) or in a long time scale (manual mixing).  At different time 
scales, the spectral changes as a function of time were fit to single (kobs1) or double (kobs1 and kobs2) 
exponential functions with the program ReactLab Kinetics226 as explained previously. All the 
values of kobs were determined for the different system as the average of four replicate 
measurements and they will be presented in Chapter 6.  
 
2.2 Materials 
2.2.1 Chemicals and reagents 
 
S-Methyldithiocarbazate,
228
 and S-Benzyldithiocarbazate
229
 were prepared according to 
literature syntheses. The di-2-pyridylketone thiosemicarbazones HDpT, HDp4eT, HDp4mT and 
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HDp44mT and their Fe
III 
complexes, [Fe(DpxxT)2]ClO4, were prepared and characterized, as 
described previously.
119,120
 The 2-benzoylpyridine thiosemicarbazones HBpT, HBp4eT, HBp4mT 
and HBp44mT and their Fe
III 
complexes, [Fe(BpxxT)2]ClO4, were prepared as described.
124
 The 2-
acetylpyridinepyridine thiosemicarbazones HApT, HAp4mT and HAp44mT and their Fe
III 
complexes, [Fe(BpxxT)2]ClO4, were prepared following literature procedures.
127
 Rhodamine B 
hydrazide
230
 and 4,4-difluoro-8-(4-(methoxycarbonyl)phenyl)-1,3,5,7-tetramethyl-4-bora-3a,4a-
diaza-s-indacene
231
 were synthesised using literature procedures. All other reagents and solvents 
were obtained commercially and used without further purification. 
2.2.2 Procedures 
 
Purification of commercial haemoglobin 
 
Commercial human hemoglobin (Sigma) was typically purified by dissolving ~43 mg of 
crude Hb in 1.5 mL of Hank's Balanced Saline Solution (HBSS) and reduction with sodium 
dithionite (~1 mg). The solution obtained after gel filtration over a HBSS-equilibrated PD-10 
column (Pharmacia; prepacked 8.3 mL of Sephadex G-25) was collected and used as 
oxyhemoglobin (HbO2) stock solution for subsequent measurements. Fresh stock solutions of HbO2 
were freshly prepared daily before every set of experiments. Concentrations of these HbO2 stock 
solutions were determined using the known extinction coefficient at 542 nm.
232
  
 
2.3 Syntheses 
 
Safety Note 
Perchlorate salts are potentially explosive. Although we experienced no problems with the 
compounds described below they should never be heated in the solid state or scraped from sintered 
glass frits.  
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2.3.1 Dithiocarbazate Schiff base free ligands syntheses 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chart 2.1  Dithiocarbazate Schiff base ligands investigated in chapter 3 of this thesis (donor atoms are in 
bold type).   
  
 
2-Acetylpyridine S-methyldithiocarbazate (HAPSMC): A suspension of S-Methyl 
dithiocarbazate (6.11 g, 0.05 mol) in 75 mL of isopropanol was heated until it dissolved. This 
mixture was cooled to room temperature then filtered and the residue was washed with isopropyl 
alcohol then discarded. The filtrate was treated with 2-acetylpyridine (6.05 g, 0.05 mol) added drop-
wise. The mixture was stirred for 24 h at room temperature. The resulting yellow precipitate was 
filtered off, washed with isopropanol and recrystallised from ethanol to give a yellow crystalline 
product. Yield (7.3 g, 65%). Microanalysis found C, 48.1; H, 5.0; N, 18.8%; Calculated for 
C9H11N3S2: C, 48.0; H, 4.9; N, 18.7%. IR: (cm
-1
); 3144m, 2913w, 2114w, 1665w, 1615w, 
1568m, 1562m, 1484m, 1460s, 1428s, 1366m, 1336m, 1254vs, 1144w, 115w, 1060vs, 1045m, 
990w, 949vs, 886w, 774vs, 734vs, 678m, 642s, 620w, and 562m. 
1
H NMR (DMSO-d6): δ 12.57 (s, 
1H, NH), 8.62 (m, 1H, py), 8.07 (m, 1H, py), 7.88 (m, 1H, py), 7.45 (m, 1H, py), 2.52 (s, 3H, S-
CH3), 2.45 (s, 3H, C-CH3). 
13
C NMR (DMSO-d6): 12.9, 17.0, 120.3, 124.6, 136.8, 148.8, 151.7, 
154.3 and 200.6 ppm. Electronic spectrum (MeCN), λmax, nm (ε, M
-1
 cm
-1
): 334 (30 100).  
2-Acetylpyridine S-benzyldithiocarbazate (HAPSBC): S-Benzyl dithiocarbazate (1.98 g, 
0.01 mol) was dissolved in hot absolute ethanol (50 mL). To this solution was added dropwise an 
equimolar amount of 2-acetylpyridine (1.21 g, 0.01 mol). The mixture was heated with stirring for 
30 min and allowed to stand at room temperature until the product precipitated. The product was 
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filtered off and washed with ethanol to afford dark yellow crystals. Yield (2.29 g, 76%). 
Microanalysis found C, 59.5; H, 5.1; N, 14.0%; Calculated for C15H15N3S2: C, 59.8; H, 5.0; N, 
13.9%. IR: (cm-1); 3171m, 2969w, 2120w, 1668w, 1600w, 1580m, 1563m, 1489s, 1461vs, 
1416s, 1367m, 1338m, 1268s, 1230m, 1146w, 1116m, 1062vs, 990w, 961m, 919w, 889w, 776vs, 
720s, 681m, 622vs, 589w, and 566m. 
1
H NMR (DMSO-d6): δ 12.61 (s, 1H, NH), 8.59 (m, 1H, py), 
8.01 (m, 1H, py), 7.83 (m, 1H, py), 7.25 (m, 1H, py), 7.43-7.27 (m, 5H, Ph), 4.48 (s, 2H, CH2), 2.45 
(s, 3H, CH3). 
13
C NMR (DMSO-d6): 12.9, 37.9, 120.4, 124.6, 127.2, 128.5, 129.3, 136.7, 136.8, 
148.8, 152.2, 154.2 and 198.8 ppm. Electronic spectrum (MeCN), λmax, nm (ε, M
-1
 cm
-1
): 335 
(34000). 
Di-2-pyridylketone S-methyldithiocarbazate (HPKSMC): S-Methyl dithiocarbazate 
(1.22 g, 0.01 mol) was dissolved in ethanol (25 mL) and added to a solution of di-2-pyridylketone 
in ethanol (15 mL). The mixture was refluxed for 1 h and then left it to stand overnight at room 
temperature. The product was filtered off and recrystallised from ethanol to give bright yellow 
crystals. Yield (2.19 g, 76%). Microanalysis found C, 54.2; H, 4.2; N, 19.8%; Calculated for 
C13H12N4S2: C, 54.1; H, 4.2; N, 19.4%. IR: (cm
-1
); 3042w, 2981w, 2910w, 1689w, 1564w, 
1584m, 1481m, 1452s, 1416vs, 1327s, 1281m, 1242s, 1130s, 1060vs, 998m, 962vs, 890m, 802s, 
733vs, 692s, 693m, 614m, and 589s. 
1
H NMR (CDCl3): δ 15.28 (s, 1H, NH), 8.78 (m, 1H, py), 8.61 
(m, 1H, py), 8.03 (m, 1H, py), 7.82 (m, 2H, py), 7.70 (m, 1H, py), 7.37 (m, 2H, py) 2.65 (s, 3H, 
SCH3). 
13
C NMR (CDCl3): 17.4, 123.9, 124.3, 124.5, 127.2, 137.1, 137.3, 142.1, 148.1, 151.1, 
155.4 and 202.3 ppm. Electronic spectrum (MeCN), λmax, nm (ε, M
-1
 cm
-1
): 289 (31 000), 358 
(10800). 
Di-2-pyridylketone S-benzyldithiocarbazate (HPKSBC): Di-2-pyridylketone (1.84 g, 
0.01 mol) was dissolved in EtOH (15 mL) and mixed with a hot solution of S-benzyl 
dithiocarbazate (1.98g, 0.01 mol) in EtOH (30 mL). The mixture was refluxed for 1 h and then left 
to stand overnight at room temperature. The product was filtered off and recrystallised from ethanol 
to obtain yellow crystals. Yield (2.94 g, 81%). Microanalysis found: C, 62.6; H, 4.4; N, 15.7%; 
Calculated for C19H16N4S2: C, 62.6; H, 4.4; N, 15.3%. IR: (cm
-1
); 3053.55w, 2083w, 1584m, 
1480m, 1451s, 1418s, 1326m, 1280m, 1246m, 1121s, 1053vs, 994m, 960m, 845w, 802s, 736m, 
690s, 639m, 614w, and 590s. 
1
H NMR (CDCl3): δ 15.33 (s, 1H, NH), 8.81(m, 1H, py), 8.61 (m, 1H, 
py), 8.03 (m, 1H, py), 7.82 (m, 2H, py), 7.72 (m, 2H, py), 7.45-7.27 (m, 5H, Ph and 1H, py) 4.57 (s, 
2H, CH2) 
13
C NMR (CDCl3): 39.2, 123.9, 124.4, 124.5, 127.3, 127.4, 128.6, 129.5, 136.2, 137.2, 
137.3, 142.2, 148.1, 151.1, 155.2 and 202.5 ppm. Electronic spectrum (MeCN), λmax, nm (ε, M
-1
 
cm
-1
): 292 (12 100), 359 (34 500). 
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2-Pyridinecarbaldehyde S-methyldithiocarbazate (HPCSMC): S-Methyldithiocarbazate 
(6.11 g, 0.05 mol) was suspended in isopropanol (75 mL) and refluxed until it dissolved. The 
solution was allowed to cool to room temperature and the residue was filtered off, washed with 
isopropyl alcohol and discarded. The filtrate was treated with pyridine-2-carbaldehyde (5.35 g, 0.05 
mol) added drop-wise and the mixture was stirred for 24 h at room temperature. Then the resultant 
pale yellow precipitate was filtered, washed with isopropanol then recrystallised from ethanol to 
give pale yellow crystals. Yield (7.08 g, 67%). Microanalysis found C, 45.6; H, 4.3; N, 20.1%; 
Calculated for C8H9N3S2: C, 45.5; H, 4.3; N, 19.9%. IR: (cm
-1
); 3090w, 2773m, 2081w, 1582m, 
1529s, 1465s, 1434m, 1311m, 1278vs , 1428s, 1145m, 1106m, 10340vs, 997s, 927s, 875m, 774vs, 
725m, 678s, and 596m. 
1
H NMR (DMSO-d6): δ 13.44 (s, 1H, NH), 8.62 (m, 1H, py), 8.26 (s, 1H, 
CH), 7.91 (m, 1H, py), 7.87 (m, 1H, py), 7.44 (m, 1H, py), 2.53 (s, 3H, SCH3). 
13
C NMR (DMSO-
d6): 16.8, 120, 124.9, 137, 146.4, 149.8, 152.3, and 199.3ppm. Electronic spectrum (MeCN), λmax, 
nm (ε, M-1 cm-1): 344(30 800). 
2-Pyridinecarbaldehyde S-benzyldithiocarbazate (HPCSBC): S-Benzyldithiocarbazate 
(1.98 g, 0.01 mol) was dissolved in 35 mL of absolute ethanol and mixed with pyridine-2-
carbaldehyde (1.08 g, 0.01 mol). The mixture was refluxed for 15 min and allowed to stand for 1 h. 
The yellow powder which formed was filtered off, washed with ethanol and dried in a vacuum 
desiccator. It was recrystallised twice from absolute ethanol to obtain light yellow crystals. Yield 
(2.29 g, 80%). Microanalysis found C, 58.3; H, 4.6; N, 14.6%; Calculated for C14H13N3S2: C, 58.5; 
H, 4.6; N, 14.6%. IR:  (cm-1); 2923w, 2794m, 1582w, 1566w, 1533s, 1464s, 1438w, 1366w, 
1317s, 1278vs, 1108m, 1044s, 1000m, 928s, 830w, 773vs, 714m, 680s, 633, and 600. 
1
H NMR 
(DMSO-d6): δ 13.49 (s, 1H, NH), 8.60 (m, 1H, py), 8.26 (s, 1H, CH), 7.86 (m, 2H, py), 7.45-7.25 
(m, 5H, Ph, 1H, py), 4.49 (s, 2H, CH2). 
13
C NMR (DMSO-d6): 37.7, 120.2, 124.9, 127.3, 128.5, 
129.3, 163.5, 137, 146.7, 149.8 and 152.2 ppm. Electronic spectrum (MeCN), λmax, nm (ε, M
-1
 cm
-
1
): 342(34 700).  
2.3.2 FeIII Complexes of dithiocarbazate Schiff bases 
 
[Fe
III
(APSMC)2](ClO4): HAPSMC (1.0 g, 4.4 mmol) was dissolved in 15 mL of hot 
ethanol and then triethylamine (0.62  mL, 4.4 mmol) was added. Solid Fe(ClO4)3.6H2O (1.02 g, 2.2 
mmol) was added directly to the basic ligand solution with stirring and the mixture was gently 
refluxed for 30 min. After cooling to room temperature, the resulting solid was filtered off and 
washed with ethanol (10 mL), followed by diethyl ether (10 mL). It was then dried in a vacuum 
desiccator and recrystallised from ethanol to give dark brown powder. Yield (1.09 g, 82%). 
Microanalysis found C, 36.1; H, 3.3; N, 14.2%; Calculated for C18H20ClFeO4 N6S4: C, 35.8; H, 3.3; 
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N, 13.9%. IR: (cm-1); 3078w, 2926w, 1700w, 1597m, 1481w, 1423s, 1310m, 1148w, 1084vs , 
1032vs, 945s, 818m, 774s, 742s, 621s, and 557w. Electronic spectrum (MeCN), λmax, nm (ε, M
-1
 
cm
-1
): 343 (23 400), 425 (11 300). 
[Fe
III
(APSBC)2](ClO4): HAPSBC (0.7 g, 2.3 mmol) was dissolved in 30 mL of hot ethanol 
and Fe(ClO4)3.6H2O (0.54 g, 1.2 mmol) was added directly to the solution. Et3N (0.32 mL, 2.3 
mmol) was added and the dark brown mixture was refluxed for 30 min. The reaction mixture was 
filtered while hot to obtain an initial crop of the desired product. The filtrate was allowed to cool at 
room temperature, and was then put in the refrigerator overnight. The brown precipitate was 
collected by vacuum filtration and washed with ethanol and diethyl ether to give a second crop. 
Total yield (0.62 g, 70%). Microanalysis C, 47.6; H, 3.7; N, 11.1%; Calculated for C30H28ClFe 
N6O4S4: C, 47.7; H, 3.7; N, 11.1%. IR: (cm
-1
); 3093w, 1598m, 1492w, 1427vs, 1330m, 1242w, 
1170m, 1077vs, 1027vs, 942s, 812w, 785s, 694s, and 620s. Electronic spectrum (MeCN), λmax, nm 
(ε, M-1 cm-1): 350 (25 600), 428 (8 530).  
[Fe
III
(PCSBC)2](ClO4)·1.5H2O: HPCSBC (0.7 g, 2.4 mmol) was dissolved in 300 mL of 
hot ethanol and then triethylamine (0.34 mL, 2.4 mmol) was added. Solid Fe(ClO4)3.6H2O (0.54 g, 
1.2 mmol) was added to the basic ligand solution with stirring and the mixture was gently refluxed 
for 1 h. The reaction mixture was cooled to room temperature and the resulting crude dark brown 
solid containing a mixture of compounds was filtered off, washed with 10 mL of ethanol followed 
by 10 mL of diethyl ether. A column of dry silica (100 x 32mm diameter, Scharlau or Merck Silica 
gel 60, 230-400 mesh) was prepared. The crude product (0.3 g) was dissolved in MeCN (~50 mL) 
and adsorbed onto Celite (~5 mL) by evaporation to dryness on a rotary evaporator at room 
temperature (see Safety Note). The resulting solids were packed dry onto the column which was 
tapped gently to remove air pockets. The column was eluted with a step-wise gradient of 
MeCN/DCM starting with 0.1% MeCN/DCM with the application of air pressure. A green band of 
[Fe
II
(PCSBC)2] began to elute with 5% MeCN/DCM. The polarity of the solvent mixture was 
gradually increased until all of this compound had eluted. This compound was characterised 
separately. The brown second component ([Fe
III
(PCSBC)2](ClO4)) began to elute with 25% 
MeCN/DCM. Evaporation to dryness at room temperature gave the product as a brown solid. Yield 
(0.4 g, 43%). Microanalysis found C, 44.76; H, 3.62; N, 10.77%; Calculated for C28H27ClFeO5.5 
N6S4: C, 44.5; H, 3.6; N, 11.1% or calculated for C28H24ClFeO5.5N6S4: C, 44.7; H, 3.2; N, 11.2% 
IR: (cm-1); 3029w, 2922w, 1602m, 1579m, 1477w, 1404s, 1342m, 1219w, 1066vs, 974s, 910m, 
883w, 680m, 619s, and 563w. Electronic spectrum (MeCN), λmax, nm (ε, M
-1
 cm
-1
): 352 (23 800), 
434 (8 130). 
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[Fe
III
(PCSMC)2](ClO4): HPCSMC (1.0 g, 4.7 mmol) was dissolved in 75 mL of hot 
ethanol and solid Fe(ClO4)3.6H2O (0.54 g, 2.4 mmol) was added directly to the solution. 
Triethylamine (0.66 mL, 4.7 mmol) was added to the dark brown mixture which was gently 
refluxed for 30 min. The reaction mixture was filtered while still hot to obtain an initial crop of dark 
brown compound. The filtrate was allowed to cool at room temperature and then refrigerated 
overnight. A second crop was obtained by vacuum filtration and was washed with ethanol and 
diethyl ether. Attempts to recrystallise the complex were unsuccessful. Column chromatography (as 
described in the previous synthesis) enabled separation of [Fe
II
(PCSMC)2] (green, first band) from 
the desired product [Fe
III
(PCSMC)2](ClO4) which was evaporated to dryness at room temperature 
(see Safety Note) to afford a brown solid. Yield (0.68 g, 50%). Microanalysis found C, 33.8; H, 2.9; 
N, 14.3%; Calculated for C16H16ClFeO4N6S4: C, 33.4; H, 2.8; N, 14.6%. IR:

(cm
-1
) 3098w, 
1603m, 1477w, 1405vs, 1344m, 1306m, 1216m, 1166w, 1062s, 978s, 914w, 766m and 619s. 
Vapour diffusion of diethyl ether into an acetone solution of the complex afforded crystals suitable 
for X-ray work. Electronic spectrum (MeCN), λmax, nm (ε, M
-1
 cm
-1
):  356 (20 100), 431 (9 370).  
[Fe
III
(PCSMC)(PSMC)]·2Me2CO·4H2O: HPCSMC (1 g, 4.7 mmol) was dissolved in 100 
mL of hot ethanol and then triethylamine (0.66 mL, 4.7 mmol) was added to the solution. Solid 
Fe(ClO4)3.6H2O (1.08 g, 2.41 mmol) was added to the basic ligand solution with stirring and the 
mixture was gently refluxed for 1 h. On cooling to room temperature the resulting crude dark brown 
solid was filtered off and washed with 10 mL of ethanol followed by 10 mL of diethyl ether. 
Column chromatography on silica (see previous synthesis) was carried out using a solvent gradient 
of MeOH (in increasing quantities) in DCM. After elution of a green band of [Fe
II
(PCSMC)2], the 
desired mixed-ligand complex [Fe
III
(PCSMC)(PSMC)] eluted. This was evaporated to dryness. 
Yield 50%. The complex was recrystallised with acetone/diethyl ether. Microanalysis found C, 
38.6; H, 4.1; N, 12.1%; calculated for C22H35FeN6O7S4: C, 38.9; H, 5.2; N, 12.4%. IR: (cm
-1
) ;  
3401m,  2921m, 1583vs, 1371s,  1283m, 1192w, 1073vs,  995m, 916m,  761, 686w and 620m cm
1
. 
Crystals suitable for X-ray crystallography were obtained by slow diethyl ether vapour diffusion 
into a concentrated acetone solution. Electronic spectrum (MeCN), λmax, nm (ε, M
-1
 cm
-1
): 300 (11 
300), 441 (3850), 618(1440). 
[Fe
III
(PKSMC)2](ClO4): HPKSMC (0.8 g, 2.8 mmol) was dissolved in 30 mL of hot 
ethanol and (0.64 g, 1.4 mmol) of solid Fe(ClO4)3.6H2O was added directly to the solution. Et3N 
(0.39 mL, 2.8 mmol) was added to the dark brown mixture which was gently refluxed for 30 min. 
The reaction mixture was filtered while still hot to obtain an initial crop. The filtrate was allowed to 
cool at room temperature and refrigerated overnight. The dark product was collected by vacuum 
filtration and washed with ethanol and diethyl ether to give a second batch of brown solid. Yield 
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(0.83 g, 83%). Microanalysis found C, 43.0; H, 3.2; N, 15.4%; Calculated for C26H22ClFe N8O4S4: 
C, 42.8; H, 3.0; N, 15.4%. IR: (cm-1); 3090w, 1620m, 1584m, 1529w, 1413s, 1340s, 1313m, 
1159m , 1073vs, 1000s, 821w, 792m, 743s, and 615vs Crystals of [Fe
III
(PKSMC)2].MPPT.(ClO4)2 
(MPPT being a triazinium product of HPKSMC desulfuration) suitable for X-ray work were 
obtained from diethyl ether vapour diffusion into a concentrated acetone solution of the crude first 
crop. Electronic spectrum (MeCN), λmax, nm (ε, M
-1
 cm
-1
): 362 (27 000), 445 (12 100). 
[Fe
III
(PKSBC)2](ClO4)·2.5H2O: HPKSBC (0.8 g, 2.2 mmol) was dissolved in 65 mL of 
hot ethanol and solid Fe(ClO4)3.6H2O (0.51 g, 1.1 mmol) was added directly to the solution. 
Triethylamine (0.31 mL, 2.2 mmol) was added to the dark brown mixture which was gently 
refluxed for 30 min. The reaction mixture was filtered while still hot and the filtrate was allowed to 
cool at room temperature and refrigerated overnight. The dark brown product was collected by 
vacuum filtration and washed with diethyl ether.  Yield (0.46 g, 48%).  Microanalysis found C, 
49.3; H, 3.6; N, 12.3%; Calculated for C38H35ClFe N8O6.5S4: C, 49.2; H, 3.8; N, 12.1%. IR: (cm
-
1
); 3059w,  1585m, 1494w, 1408vs,  1335s, 1243w, 1074vs,  989s , 820w, 745m, 700m, and 617vs 
Electronic spectrum (MeCN), λmax, nm (ε, M
-1
 cm
-1
): 356 (20 100), 431 (13 100). 
2.3.3 FeII Complexes of dithiocarbazate Schiff base 
 
The Fe
II
 complexes were synthesised by the following general method. 2.4 mmol of the 
appropriate dithiocarbazate ligand was dissolved in ethanol (30-150 mL) and the mixture was 
purged with nitrogen for 10 min. Et3N (0.34 mL, 2.4 mmol) was added followed by solid 
Fe(ClO4)2.6H2O (0.44 g, 1.2 mmol) with stirring. The mixture was gently refluxed for 30 min under 
nitrogen. Upon cooling, the green product was filtered off and washed with 10 mL of ethanol 
followed by 10 mL diethyl ether. 
[Fe
II
(APSMC)2]·H2O: Yield (0.93 g, 80%). Microanalysis found C, 41.0; H, 3.9; N, 15.9%; 
Calculated for C18H22FeN6S4: C, 41.4; H, 4.2; N, 16.1%. IR: (cm
-1
); 3414b, 2927w, 1629w, 
1589m, 1467w, 1395s, 1322vs, 1140m, 1093m, 1030vs, 933m, 816w, 738s, 647w, 627m, and 
556w. Electronic spectrum (MeCN), λmax, nm (ε, M
-1
 cm
-1
): 331 (28 300), 429 (sh, 15 100), 676 (7 
360). 
[Fe
II
(APSBC)2]·2H2O: Yield (0.58 g, 72%). Microanalysis found C, 51.4; H, 4.2; N, 
12.4%; Calculated for C30H32Fe N6O2S4: C, 52.0; H, 4.7; N, 12.1%. IR: (cm
-1
); 3395b, 1627w, 
1590s, 1400vs, 1323vs, 1286m, 1234w, 1142m , 1092m, 1031vs, 942s, 765s, 694s, 630m, and 567. 
Electronic spectrum (MeCN), λmax, nm (ε, M
-1
 cm
-1
): 333 (26 300), 429 (sh, 12 500), 679 (5 920). 
[Fe
II
(PCSMC)2]·2H2O: Yield (0.95 g, 81%). Microanalysis found C, 37.9; H, 3.5; N, 
16.0%; Calculated for C16H20Fe N6O2S4: C, 37.5; H, 3.9; N, 16.4%. IR: (cm
-1
); 3374b, 2970w, 
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2111m, 1594s, 1495m, 1463w, 1429vs, 1372vs, 1322m, 1204m, 1105m, 1049vs, 953s, 882m, 
844m, 754s, 666w and 566m. Electronic spectrum (MeCN), λmax, nm (ε, M
-1
 cm
-1
): 346 (17 800), 
441 (sh, 7 210), 684 (7 210). 
[Fe
II
(PCSBC)2]·0.5H2O: Yield (0.4 g, 52%). Microanalysis found C, 52.7; H, 4.0; N, 
12.9%; Calculated for C28H25Fe N6O.5S4: C, 52.7; H, 4.0; N, 13.2%. IR: (cm
-1
); 3374b, 2970w, 
2111m, 1594s, 1495m, 1463w, 1429vs, 1372vs, 1322m, 1204m, 1105m, 1049vs, 953s, 882m, 
844m, 754s, 666w and 566m. Electronic spectrum (MeCN), λmax, nm (ε, M
-1
 cm
-1
): 331 (28 400), 
429 (sh, 10 500), 664 (6 320). 
[Fe
II
(PKSMC)2]·1.5H2O:  Yield (0.8 g, 70%). Microanalysis found C, 47.4; H, 3.8; N, 
16.7%; Calculated for C26H25Fe N8O1.5S4: C, 47.5; H, 3.8; N, 17.0%. IR: (cm
-1
); 3059w, 2083w, 
1595s, 1496s, 1394vs, 1333m, 1287m, 1207.61m, 1153w , 1108s, 1040s, 968w, 852m, 759s, 699s, 
and 561w. Electronic spectrum (MeCN), λmax, nm (ε, M
-1
 cm
-1
): 344 (25 300), 429 (sh, 10 500), 682 
(6 320). 
[Fe
II
(PKSBC)2]·0.5H2O: Yield (0.5 g, 64%). Microanalysis found C, 57.5; H, 3.9; N, 
14.4%; Calculated for C38H31FeN8O0.5S4: C, 57.6; H, 4.0; N, 14.2%. IR: (cm
-1
); 3063w, 2119w, 
1581m, 1481m, 1379vs, 1322s, 1239w, 1112w , 1061vs, 1015w, 980vs, 858w, 785s, 766m, 740s, 
699m, 601s, and 556w. Electronic spectrum (MeCN), λmax, nm (ε, M
-1
 cm
-1
): 331 (17 800), 441 (sh, 
8 000), 684 (7 120). 
2.3.4 Fluorescent iron Chelators  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chart 2.2 Fluorescent iron chelators investigated in Chapter 6 of this thesis.  
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 3',6'-Bis(diethylamino)-2-((pyridin-2-ylmethylene)amino)spiro[isoindoline-1,9'-
xanthen]-3-one (PCRBH): Rhodamine B hydrazide  (2.28 g, 5.00 mmol) was dissolved in toluene 
(100 mL) and pyridine-2-carbaldehyde (0.589 g, 5.50 mmol) was added. The reaction mixture was 
refluxed for 7 h while water was separated via a Dean-Stark trap. The reaction mixture was cooled 
to room temperature and the solvent was evaporated under reduced pressure. The residue was 
dissolved in dichloromethane and adsorbed onto neutral aluminium oxide (Merck, activity I). The 
resulting solids were chromatographed on neutral alumina eluting with 20% to 100% 
dichloromethane/hexane. The PCRBH compound was obtained as a colourless glass which turned 
pink on exposure to air (2.4 g, 88%) (Found: C, 74.3 H, 6.49; N, 12.6%. C34H35N5O2 requires C, 
74.8; H, 6.5; N, 12.8 % ); 
1
H NMR (500 MHz, CDCl3) δH 1.14 (t, J = 7.1 Hz, 12 H, CH3), 3.30 (q, J 
= 7.1 Hz, 8 H, CH2), 6.23 (dd, J = 8.8 Hz and J = 2.6 Hz, 2 H, H-2‘/7‘), 6.45 (d, J = 2.6 Hz, 2 H, H-
4‘/5‘), 6.54 (d, J = 8.8 Hz, 2 H, H-1‘/8‘), 7.11 (overlapping m, 2 H, isoindoline H-7, pyridine H-5), 
7.46 (m, 2 H, isoindoline H-5 and H-6), 7.60 (m, 1 H, pyridine H-4), 8.00 (overlapping m, 2 H, 
isoindoline H-4 and pyridine H-3), 8.37 (s, 1 H, N=CH), 8.45 (m, 1 H, pyridine H-6); 
13
C NMR 
(100 MHz, CDCl3) δC 12.6 (CH3), 44.3 (CH2), 66.0 (spiro C), 97.7 (C-2‘/7‘), 104.5 (C-8a‘/9a‘), 
108.0 (C-4‘/5‘), 122.8 (pyridine C-3), 123.5 (isoindoline C-4), 123.9 (isoindoline C-7), 126.4 
(pyridine C-5), 128.1 (isoindoline C-6), 128.5 (isoindoline C-7a), 129.2 (C-1‘/8‘), 133.0 
(isoindoline C-5), 137.0 (pyridine C-4), 147.9 (pyridine C-6), 148.8 (pyridine C-2), 148.9 (C-3‘/6‘), 
152.4 (isoindoline C-3a), 153.5 (C-4a‘/10a‘), 161.9 (picolinamide C=O), 165.0 (isoindoline C-3); 
IR:ν  (cm-1); 2971s, 1721vs, 1615vs, 1515vs, 1467m, 1429m, 1364s, 1304vs, 1259vs, 1219vs, 
1117vs, 1020m, 969m, 916m, 889m, 819vs, 775vs, 701vs and 624m; Electronic spectrum (MeCN), 
λmax, nm (ε, M
-1
 cm
-1
): 239 (89000), 277 (61000), 308 (51000). 
 
3',6'-Bis(diethylamino)-2-((1-(pyridin-2-yl)ethylidene)amino)spiro[isoindoline-1,9'-
xanthen]-3-one (APRBH): Rhodamine B hydrazide  (2.28 g, 5.00 mmol) was dissolved in toluene 
(100 mL) and 2-acetylpyridine (1.34 g, 11.0 mmol) was added. The reaction mixture was refluxed 
for 48 h while water was separated via a Dean-Stark trap. Analysis of the reaction mixture by 
1
H 
NMR showed the reaction to be incomplete. Tosic acid (20 mg) was added to the reaction mixture 
and reflux was continued for a further 24 h, after which time the reaction was complete. The 
reaction mixture was cooled to room temperature and the solvent was evaporated under reduced 
pressure. The residue was dissolved in DCM and adsorbed onto neutral aluminium oxide (Merck, 
activity I). The resulting solids were chromatographed on neutral alumina eluting with 20% to 
100% DCM/hexane. The semi-purified product was dissolved in a minimum volume of DCM and 
hexane was added. The resulting solution was subjected to gentle vacuum for 2 days resulting in a 
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small amount of colourless crystals. The filtrate was diluted with further hexane and the DCM was 
evaporated under reduced pressure. The resulting suspended solid was filtered, washed with hexane 
and dried to give the compound APRBH as a pale pink powder (2.2 g, 79%) (Found: C, 75.05; H, 
6.7; N, 12.4%. C35H37N5O2 requires C, 75.0; H, 6.6; N, 12.7% ); 
1
H NMR (500 MHz, CDCl3) δH 
1.15 (t, J = 7.1 Hz, 12 H, CH2CH3), 2.38 (s, 3 H, N=CCH3), 3.33 (q, J = 7.1 Hz, 8 H, CH2), 6.29 
(dd, J = 8.8 Hz and J = 2.5 Hz, 2 H, H-2‘/7‘), 6.38 (d, J = 2.5 Hz, 2 H, H-4‘/5‘), 6.60 (d, J = 8.8 Hz, 
2 H, H-1‘/8‘), 7.2 (overlapping m, 2 H, isoindoline H-7, pyridine H-5), 7.5 (overlapping m, 3 H, 
isoindoline H-5 and H-6, pyridine H-4), 7.81 and 7.96 (2 x m, 2 H, isoindoline H-4, pyridine H-3), 
8.52 (m, 1 H, pyridine H-6); 
13
C NMR (100 MHz, CDCl3) δC  12.5, 17.2, 44.2, 66.9, 97.7, 106.7, 
107.7, 122.0, 123.0, 123.9, 124.2, 128.2, 128.4, 130.7, 132.3, 135.9, 148.1, 148.5, 151.6, 153.5, 
155.2, 160.4, 169.3; IR:ν  (cm-1); 2969s, 1692vs, 1614vs, 1515vs, 1465m, 1426s, 1360m, 1305vs, 
1217vs, 1117vs, 1080w, 1014m, 953ms, 867m, 816vs, 786vs, 699vs and 579m. Electronic spectrum 
(MeCN), λmax, nm (ε, M
-1
 cm
-1
): 235(11 4000), 274 (73 000), 313 (38 000). A sample of the product 
was dissolved in a minimum amount of dichloromethane. The resulting solution was layered with 
hexane and allowed to stand for 2 days which gave crystals suitable for X-ray structure 
determination. 
4,4-Difluoro-8-(4-(hydrazinecarbonyl)phenyl)-1,3,5,7-tetramethyl-4-bora-3a,4a-diaza-
s-indacene (BODIPYH): 4,4-difluoro-8-(4-(methoxycarbonyl)phenyl)-1,3,5,7-tetramethyl-4-bora-
3a,4a-diaza-s-indacene (1.20 g, 3.14 mmol) was suspended in ethanol (100 mL) and hydrazine 
sesquihydrate (5.56 g, 94.2 mmol) was added. The reaction mixture was refluxed for 14 h before 
being cooled to room temperature. The solvent was evaporated under reduced pressure and the 
residue was suspended in dichloromethane. The solvent was again evaporated to dryness and the 
residue was suspended in diethyl ether. The solid was filtered, washed with diethyl ether and dried 
to give the hydrazide as a red solid (2.4 g, 88%) (Found: C, 62.7; H, 5.3; N, 14.6 % . C20H21BF2N4O 
requires C, 62.9; H, 5.5; N, 14.7%); 
1
H NMR (500 MHz, DMSO-d6) δH 1.32 (s, 6 H, 
C(1)CH3/C(7)CH3), 2.44 (s, 6 H, C(3)CH3/C(5)CH3), 4.53 (br s, 2 H, NH2), 6.18 (s, 2 H, H-2/H-6), 
7.46 (d, J = 8.3 Hz, 2 H, H-2'/H-6'), 7.99 (d, J = 8.3 Hz, 2 H, H-3'/H-5'), 9.94 (CONH);
 13
C NMR 
(100 MHz, DMSO-d6) δC 14.0, 14.2, 121.5, 127.8, 128.0, 130.4, 133.8, 136.7, 141.1, 142.7, 155.1, 
165.0; IR:ν  (cm-1); 3411s, 1669vs, 1541vs, 1504vs, 1406m, 1306vs, 1186vs, 1156vs, 1084m, 
964vs, 836s, 814s, 730vs, and 697vs; Electronic spectrum (MeCN), λmax, nm (ε, M
-1
 cm
-1
): 232 (43 
425), 312 (12 843), 499 (90 225). 
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4,4-Difluoro-8-(4-(2-(pyridin-2-ylmethylene)hydrazinecarbonyl)phenyl)-1,3,5,7-
tetramethyl-4-bora-3a,4a-diaza-s-indacene (HPCBODIPYH): BODIPY hydrazide (previous 
synthesis, 1.20 g, 3.14 mmol) was suspended in ethanol (50 mL) and pyridine-2-carbaldehyde 
(0.336 g, 3.14 mmol) was added. The reaction mixture was refluxed for 16 h before being cooled to 
room temperature. The solvent was evaporated under reduced pressure and the residue was 
chromatographed on neutral alumina eluting with 1% to 10% methanol/dichloromethane. The 
partially purified product was dissolved in a minimum volume of dichloromethane and then 200 mL 
ether was added. The volume was reduced to 50 mL on the rotary evaporator and further ether (200 
mL) was added. The volume was again reduced to 50 mL and the resulting precipitate was filtered, 
washed with ether and dried to give the hydrazone as an orange/brown powder (0.48 g, 39%) 
(Found: C, 66.0; H, 5.4; N, 14.9%). C26H24BF2N5O requires C, 66.3; H, 5.1; N, 14.9%); 
1
H NMR 
(500 MHz, DMSO-d6) δH 1.36 (s, 6 H, C(1)CH3/C(7)CH3), 2.46 (s, 6 H, C(3)CH3/C(5)CH3), 6.20 
(s, 2 H, H-2/H-6), 7.43 (m, 1 H, pyridine H-5"), 7.59 (d, J = 8.1 Hz, 2 H, H-2'/H-6'), 7.89 (m, 1 H, 
pyridine H-4"), 8.00 (m, 1 H, pyridine H-3"), 8.12 (d, J = 8.1 Hz, 2 H, H-3'/H-5'), 8.51 (s, 1 H, 
N=CH), 8.62 (m, 1 H, pyridine H-6"), 12.20  (s, 1 H, CONH);
 13
C NMR (100 MHz, DMSO-d6) δC 
14.1, 14.2, 120.0, 121.6, 124.5, 128.3, 128.6, 130.4, 133.7, 136.9, 137.6, 140.8, 142.6, 148.4, 149.5, 
153.2, 155.2, 162.6; IR:ν  (cm-1); 3300w, 1646vs, 1543vs, 1511vs, 1467s, 1438m, 1407s, 1302vs, 
1181vs, 1152vs, 1080m, 1014m, 975vs, 840s, 807s, 775vs, 738vs, 702m, 636m and 584m; 
Electronic spectrum (DMF), λmax, nm  (ε, M
-1
 cm
-1
): 307 (27519), 369 (9391) and 502 (86726) . 
2.3.5 FeIII complexes of rhodamine B derivatives 
 
Fe
III
 complexes were synthesized by the following general method. To a solution of ligand 
(300 mg, 0.54 mmol) in EtOH (15mL) was added a solution of Fe(ClO4)2 6H2O (97 mg, 0.27 
mmol) in ethanol (5 mL), resulting in a dark red/purple solution. The mixture was gently refluxed 
for 30 min and then allowed to stand at room temperature overnight. Then, the solvent was reduced 
to half volume on a rotary evaporator. Upon cooling, the product was filtered off and washed with 
10 mL ethanol followed by 10 mL diethyl ether. After drying under vacuum conditions, the 
complex was obtained as a dark red solid. 
[Fe(PCRBH)2](ClO4)3·9H2O: Yield (180 mg, 46%). Microanalysis found C, 50.4; H, 5; N, 
8.3%; Calculated for C68H88Cl3FeN10O25: C, 50.8; H, 5.5; N, 8.7%. IR:ν  (cm
-1
); 3433b, 2977vw, 
1645w, 1584vs, 1465m, 1410m, 1334s, 1273m, 1180s, 1064vs, 1011vw, 922m, 820w, 790w, 682m, 
620s and 581vw. Electronic spectrum (MeCN), λmax, nm (ε, M
-1
 cm
-1
): 239 (80 000), 253 (75 000), 
352 (28 000), 557 (129 000). 
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[Fe(APRBH)2](ClO4)3]·H2O: Yield (160 mg, 40%). Microanalysis found C, 56.4; H, 5.2; 
N, 9.3%; Calculated for C70H76Cl3FeN10O17: C, 56.4; H, 5.1; N, 9.4%. IR:ν  (cm
-1
); 3533b, 
2976vw, 1647w, 1586vs, 1464w, 1411m, 1334s, 1274m, 1179s, 1067vs, 1008w, 923m, 820s, 
782m, 680m, 620s and 580vw. Electronic spectrum (MeCN), λmax, nm (ε, M
-1
 cm
-1
): 239 (83 000), 
255 (76 000), 354 (30 000), 558 (154 000). 
2.3.6 FeII complexes of BODPY chelator  
 
[Fe(PCBODIPYH)2]·2MeCN.5.5H2O: (200 mg, 0.42 mmol) of HPCBODIPYH was 
dissolved in MeCN (30 mL). To this solution (77 mg, 0.21 mmol) of Fe(ClO4)26H2O and (0.06 mL, 
0.42) of Et3N were added and the dark green mixture was refluxed for 30 min and allowed to cool at 
room temperature overnight. The green product was collected by vacuum filtration and washed by 
10 mL MeCN followed by 10 mL diethyl ether.  Yield (184 mg, 87%). Microanalysis found C, 57; 
H, 5; N, 13.8%; Calculated for C56H63B2F4FeN12O7.5: C, 57.1; H, 5.4; N, 14.3%. IR:ν  (cm
-1
); 
3405b, 2971vw, 1599vw, 1544s, 1509m, 1446s, 1407w, 1357vs, 1305s, 1192s, 1158s, 1051m, 
973vs, 918m, 824m, 736vs, 637w, and 579vw. Electronic spectrum (DMF), λmax, nm (ε, M
-1
 cm
-1
): 
308 (35259), 364 (51550), 502 (142710), 666 (3691). 
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Chapter 3   Iron Coordination Chemistry and Biological Activity of 
Heterocyclic Dithiocarbazate Schiff base Ligands   
 
 
 
3.1 Overview 
 
Heterocyclic dithiocarbazate Schiff bases derived from S-alkyl or S-aryl esters are well 
known sulfur-nitrogen chelating agents. These chelators are similar to the thiosemicarbazone 
analogues presented in Chapter 1, having both unsaturated nitrogen and sulfur donor atoms, but 
they differ in the terminal non-coordinating functional group attached to the thiocarbonyl moiety. 
Therefore, thiosemicarbazones and dithiocarbazate Schiff bases are able to coordinate with a range 
of metal ions forming stable and intensely coloured metal complexes, some of which display 
interesting physico-chemical properties,
128
 varied structure features
233
 and significant biological 
activities.
234
  Although there are reports of  the coordination  chemistry of dithiocarbazate Schiff 
bases with a variety of metal ions and their biological activity,
134,136,137,144-149
 little is known about 
their reactions with iron,
150,151
 in comparison to the highly active thiosemicarbazone Fe 
chelators.
64,119,124,179,235
  
In this chapter the iron chelation efficacy of dithiocarbazate Schiff base analogues (Figure 
‎1.16 in Chapter 1) will be presented. These ligands are potentially tridentate, utilizing the same 
NNS donor set as for the HDp44mT and HPKTBH analogues, but with substitutions of 
mercaptomethyl or mercaptobenzyl groups, instead of an amine or aromatic ring. The main focus 
of this chapter is to comprehensively characterize the Fe coordination chemistry and redox 
properties of the Fe complexes. It is apparent that redox properties are affected by substituents 
adjacent to the donor group in compounds from the heterocyclic thiosemicarbazone
119,124,235
 and 
hydrazone series,
68,77,95
 due to extended conjugation along the ligand backbone. Replacement of 
the terminal amino group with a thioether brings the same inductive and resonance effects, which 
then are communicated to the coordinated metal ion. An investigation of the effectiveness of these 
ligands at mobilizing intracellular Fe and their anti-proliferative activity is also an important 
component. The results obtained in this study are essential for understanding Fe coordination 
chemistry and biological activity of the dithiocarbazate analogues.  
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3.2 Free ligand and their iron complexes characterization 
3.2.1 Synthesis of dithiocarbazate Schiff base Ligands and their   FeII and FeIII complexes 
 
The heterocyclic dithiocarbazate Schiff base ligands as presented in Chapter 2 were 
prepared according to published procedures
136,137
 and were synthesized by condensation between S-
methyl (or S-benzyl) dithiocarbazates and an aldehyde or ketone. These Schiff base ligands 
coordinate using a common NNS donor set. 
The iron coordination chemistry of the heterocyclic dithiocarbazate Schiff base chelators 
remains largely unexplored and the biological Fe coordination chemistry of these ligands has not 
been investigated. Thus, the isolation and characterization of both Fe
II
 and Fe
III 
complexes of these 
chelators were the focus of this chapter. Each dithiocarbazate Schiff base binds Fe after 
deprotonation of the thioamide N atom (N3), affording a tridentate coordination mode. The 
chemical and biological properties are reminiscent of analogues from the HPCIH (hydrazone)
68
 and 
HDp44mT (thiosemicarbazone) series.
119
 Fe
II
 complexes of the dithiocarbazate series were readily 
synthesised by reacting two equivalents of ligand and base (triethylamine) with one equivalent of 
ferrous perchlorate under an inert atmosphere. This avoided oxidation to the ferric state during 
synthesis, giving bis-ligand Fe
II
 complexes in good yields. The ferric complexes were readily 
prepared in the same way, using ferric perchlorate instead of ferrous perchlorate.  
Generally, the purification of the Fe complexes can be achieved by recrystallization. 
However, in some cases column chromatography (silica) was used to separate mixture of Fe
II 
and 
Fe
III
 complexes that co-precipitated, affording single crystals suitable for X-ray work. 
3.2.2 IR spectroscopy 
 
Heterocyclic dithiocarbazate Schiff bases containing the thioamide (–NH-C=S) functional 
group can be present in thione (–NH-C=S) or thiol (–N=C–SH) tautomeric forms or an equilibrium 
mixture of both (Figure ‎3.1). However, IR spectra of these free ligands does not show any νSH band 
in the region 2500-2700 cm
-1
, but they do exhibit medium to weak bands in the range 2981-3171 
cm
-1
, corresponding to νNH of  the  thione form. This indicates that these Schiff bases remain as the 
thione form in the solid state.
137, 236
 Nonetheless, in basic ethanolic solution they deprotonate and 
convert to the anionic ene-thiolate form which is present when they coordinate to iron. 
Thiosemicarbazones, structurally similar to dithiocarbazate Schiff- base ligands, coordinate to metal 
ions in both the protonated (thione form) and  the deprotonated (thiolate form).
237,238,239
 In addition, 
there are examples of  metal complexes of thiosemicarbazones  in their protonated and deprotonated 
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forms in the same complex.
240,241
 To date, almost all metal complexes of Schiff bases derived from 
S-alkyldithiocarbazates present in a charge deprotonated form.
141
   
  
 
    
 
 
 
 
 
 
 
 
 
Figure ‎3.1 The thione (A) and the thiol (B) tautomeric forms of dithiocarbazate analogues. 
 
The IR spectra also indicate that theν C=N bands of the free ligands HAPSMC and 
HAPSBC at ca. 1614 and 1600 cm
-1
 respectively are shifted to lower frequencies in the spectra of 
iron complexes. In contrast, HPCSMC and HPCSBC exhibitν C=N bands at ca. 1582 cm
-1
  that are 
shifted to higher wave numbers in the spectra of iron complexes. This can be attributed toν C=N 
bands expected to couple with other bands and the shifting will depend on the degree of 
combination with these bands. This shifting to lower or higher frequency is evidence for 
coordination via the imine nitrogen atoms as previously reported with other metal ions.
137
 However, 
the azomethineν C=N bands in the IR spectra of the iron complexes of HPKSMC and HPKSBC, 
display a very small shift relative to that of free ligand (ca. 1584 cm
-1
). Other evidence for the 
coordination via the imine nitrogen atoms is shifting of theν N–N (ca. 1060 cm
-1
) bands of the free 
ligands to higher frequency in the spectra of the iron complexes. This is further supported by the 
absence of theν C=S band of the free ligands (ca. 950 to 960 cm
-1
) in the spectra of the complexes, 
indicating deprotonation and the coordination of the thiolate sulfur atom.  
The most obvious feature in the IR spectra to differentiate between Fe
II
 and Fe
III
 complexes 
is the absence or presence of the absorptions of the perchlorate counter ion at ca. 1066-1084 cm
-1
 
(very strong) and  ca.  620 cm
-1
 (medium intensity). Generally, the IR spectra of the complexes are 
markedly different to their free ligands. 
3.2.3  NMR spectroscopy 
 
1
H and 
13
C NMR spectra of the heterocyclic dithiocarbazate Schiff bases were reported as 
described in the experimental chapter. 
1
H NMR spectra of these Schiff bases exhibit no peak at ca. 
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4 ppm (SH signal), thus they exist only as thione tautomer in solution. These free ligands possess 
the -RC=N- functional group, thus they may exist as either the E or Z isomer (Figure 3.2). However, 
their 
1
H NMR spectra display only one isomer in contrast to structurally related thiosemicarbazones 
which exist as a mixture of E or Z form. 
127
 The resonance of the NH proton in the 
1
H NMR 
spectrum of the dithiocarbazate ligands can be used to distinguish between these two isomers. 
Chelators in the E isomeric form generally display the NH signal in the range 9-12 ppm while those 
possessing the Z isomer exhibit this signal in the range 12-14 ppm due to H-bonding with the 
pyridyl group (Figure 3.2).
242
 The 
1
H NMR spectra of the dithiocarbazate Schiff bases from 2-
acetylpyridine or 2- pyridinecarbaldehyde in DMSO-d6 exhibit the NH signal at ca. 13 ppm 
whereas those derived from dipyridylketone display this signal at ca. 15 ppm. These results suggest 
that the dithiocarbazate Schiff bases exist as the Z isomer in solution. These chemical shifts are 
similar to those found in dithiocarbazate derived from 2-acetylpyrazine.
140
 In contrast, the HPCIH 
(hydrazone) series show the NH signal at ca. 12 ppm which is more characteristic of the E 
isomer.
243
 The absence of intramolecular H-bonding in the E isomer leads to an upfield shift of the 
1
H NMR resonance of the NH group. 
 
 
 
 
 
 
 
 
 
Figure ‎3.2 The E and Z isomeric forms of the dithiocarbazate Schiff bases.  
 
3.2.4 X-ray crystal structure analysis 
3.2.4.1 Structure of the free ligand (HAPSMC) 
As a representative member of the dithiocarbazate series, the crystal structure of HAPSMC 
has been determined and a view of the chelator is shown in Figure 3.3. The compound adopts an 
approximately planar conformation and the E isomeric form is recognized, in contrast to its solution 
Z isomeric form, but similar to the crystal structures that have been identified in the HApT 
(thiosemicarbazone)
127
 and HPCIH (hydrazone) series.
243
 This Schiff base ligand crystallises with 
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the pyridine N-atom (N1) anti to the dithiocarbazate group, indicating rearrangement is required 
prior to binding a metal in a tridentate fashion (through N1, N2 and S1). The N2-N3 1.374(3) Å and 
N2-C6 1.282(3) Å distances are similar to those found in HAp4aT and HPCIH (Figures 3.4 and 
3.5).
127,243
  
The C8-S1 bond has double bond character (1.645(3) Å) which is ca. 0.02 Å shorter than 
that found in the thiosemicarbazone HAp4aT (1.667(2)); a significant influence of the –SR 
substituent on C8 compared with the -NHR substituents in the HApT thiosemicarbazones series. 
The S-methyl S2-C9 single bond 1.791(3) Å is slightly longer than S2-C8 1.762(3) Å indicating 
some electronic delocalisation across S1-C8-S2. 
Replacement of the –NHR group by a mercaptomethyl (-SR instead of -NHR) prevents 
formation of an intramolecular H-bond with the terminal amido (N4) nitrogen atom, which was 
observed in the structure of HAp4aT (Figure 3.4, N4-H…N2  2.18 Å 108.5ᵒ). Selected bond lengths 
and angles appear in Table ‎3.1. 
 
 
 
 
    
  
 
 
 
 
       
Figure ‎3.3 ORTEP view of the free ligand HAPSMC (30% probability ellipsoids shown at 293 K).  
 
 
 
 
 
 
 
Figure ‎3.4 ORTEP view of the free thiosemicarbazone ligand HAp4aT (30% probability ellipsoids 
at 293 K) as its Z isomer. Atomic coordinates taken from the published crystal structure.
127
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Table ‎3.1 Selected Bond Lengths Å and Angles (o) (ligands ‗a‘ and ‗b‘ defined by labels in Figures 
3.6 to 3.9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎3.5 ORTEP view of the free hydrazone ligand HPCIH as its E isomer (30% probability 
ellipsoids shown at 293 K). Atomic coordinates taken from the published crystal structure.
243
 
 
 
 
 
 
 
HAPSMC 
[Fe(PCSMC)2]
 
Ligand a, b 
[Fe(APSMC)2] 
Ligand a, b   
[Fe(PKSMC)2]
+ 
Ligand a, b 
[Fe(PSMC)(PCSMC)] 
PSMC,    PCSMC 
C8-S1 1.645(3) 1.720(3), 1.713(3) 1.714(14), 1.742(16) 1.735(3), 1.735(3) 1.73(1), 1.751(9) 
C8-S2 1.762(3) 1.710(3),1.713(3) 1.734(11), 1.755(13) 1.738(3), 1.733(3) 1.765(9), 1.740(9) 
C8-N3 1.333(3) 1.282(4), 1.288(4) 1.293(15), 1.278(16) 1.291(4), 1.301(4) 1.29(1), 1.26(1) 
C9-S2 1.791(3) 1.764(3), 1.767(4) 1.79(2), 1.86(2) 1.794(4), 1.796(4) 1.75(1), 1.78(1) 
N2-N3 1.374(3) 1.368(3), 1.371(3) 1.392(11), 1.381(12) 1.384(3), 1.385(3) 1.365(9), 1.369(9) 
N2-C6 1.282(3) 1.277(3), 1.277(3) 1.310(13), 1.315(14) 1.308(4), 1.309(4) 1.38(1), 1.27(1) 
Fe-N1a/b - 1.968(2), 1.956(3) 1.984(7), 1.967(8) 1.984(3), 1.984(2) 1.992(6), 1.990(7) 
Fe-N2a/b - 1.880(2), 1.879(2) 1.918(8), 1.924(8) 1.910(2), 1.912(2) 1.911(7), 1.942(7) 
Fe-S1a/b - 2.189(9), 2.201(1) 2.223(3), 2.235(3) 2.225 (9), 2.227(9) 2.223(2), 2.265(3) 
N1a/b-Fe-
N2a/b 
- 80.9(1), 80.5(1) 80.3(4), 79.9(4) 80.4(1), 80.4(1) 81.6(3), 79.7(3) 
N2a/b-Fe-
S1a/b 
- 84.97(7), 85.03(8) 85.8(3), 85.4(3) 85.37(8), 85.56(8) 84.8(2), 82.8(2) 
N2a-Fe-N2b - 176.5(1) 179.6(4) 177.8(1) 176.5(3) 
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3.2.4.2 Structures of [FeIII(PCSMC)2](ClO4) and [Fe
III
(APSMC)2](ClO4)   
A summary of the crystal structure data for all Fe structures appears in Table ‎3.2. The 
crystal structures of the ferric complexes [Fe
III
(PCSMC)2](ClO4) and [Fe
III
(APSMC)2](ClO4)  have 
been determined and a view of  both complex cations appears in Figure ‎3.6. The bond lengths and 
angles are listed in Table ‎3.1. 
 In both complexes, the meridional configuration of each ligand is apparent, producing a 
complex with approximate C2 symmetry. Tridentate NNS coordination of each monoanionic ligand 
is apparent to give a six-coordinate cis-Fe
III
N4S2 complex. The Fe-N and Fe-S  coordinate bond 
lengths (Table ‎3.1) are characteristic of low-spin FeIII and are essentially the same as low-spin 
[Fe(Ap4mT)2]
+
 
127
 and [Fe(PKTBH)2] 
124
 (Figure ‎3.7), but are in contrast to the much longer 
coordinate bonds found in the high spin Fe
III 
complexes of aroylhydrazones, such as pyridoxal 
isonicotinoyl hydrazone (H2PIH) namely [Fe(HPIH)2]
+
 and [Fe(H2PIH)Cl2]
+
.
244,245
 This change in 
spin state results from the influence of  the relatively soft S- and N- donor atoms of the 
dithiocarbazates and thiosemicarbazones. There is no conformational flexibility in the complex 
cation except for the S-methyl groups which each adopt an anti-conformation with respect to the 
adjacent coordinated S-donor. The most significant variations in intraligand bond lengths (going 
from free ligand to complex) are in the region of the coordinated S-donors. Of particular note are 
the bonds lengths C8-S1 and C8-S2 in [Fe
III
(PCSMC)2]
+
 and [Fe(APSMC)2]
+
 , which are equal in 
the complexes, indicating electron delocalisation over the N3-C8(S1)-S2 moiety, in contrast to the 
free ligand HAPSMC where the C8=S1 bond has definite double bond character (Table ‎3.1). The 
influence of an imine-thiolate (-N=C-S
-
) resonance form of the coordinated ligand anion shortens 
the C8-N3 bonds in each ligand upon complexation. There are no obvious differences in the N2-N3 
or N2-C6 bonds on deprotonation and complexation.  
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Figure ‎3.6 ORTEP view of (a) the [Fe(PCSMC)2]
+
 and (b) the [Fe(APSMC)2]
+
 cations  (30% 
probability ellipsoids shown at 293 K). 
 
a 
b 
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Figure ‎3.7 ORTEP views of (a) the [Fe(AP4MT)2]
+
 cation
127
 and (b) the [Fe
II
 (KPTBH)2] 
124
   (30% 
probability ellipsoids shown at 293 K).  
a 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
b 
Fe1 
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Table ‎3.2 Crystal and refinement data. 
 
 HAPSMC [Fe(PCSMC)2](ClO4) [Fe(APSMC)2](ClO4) 
[Fe(PKSMC)2](MPPT) 
(ClO4)2 
[Fe(PSMC)(PCSMC)]
·Me2CO 
Formula C9H11N3S2 C16H16ClFeN6O4S4 
 
C18H20ClFe N6O4S4 
 
C39H33Cl2FeN12O8S5 C19H21FeN6O2S4 
Mol. wt 225.33 575.89 603.94 1084.82 549.51 
Crystal system Triclinic Monoclinic Monoclinic Triclinic Trigonal 
a (Å) 5.8633(5) 33.437(2) 34.995(5) 7.9883(3) 36.376(5) 
b (Å) 8.148(1) 8.8580(4) 10.9177(14) 14.5465(7)  
c (Å) 11.757(2) 14.865(1) 14.831(3) 20.3055(9) 9.3420(7) 
(°) 81.91(1)   89.484(4)  
 (°) 79.334(9) 90.851(5) 105.883(15) 82.777(4)  
 84.497(8)   84.060(4)  
V (Å3) 545.1(1) 4402.4(4) 5450.0(14) 2328.2(2) 10705(2) 
Å) 0.71073 0.71073 0.71073 1.54184 0.71073 
T (K) 293 293 293 293 293 
Z 2 8 8 2 18 
Space group P1 C2/c C2/m P1 R3 

(mm-1) 
0.452 1.224 0.993 6.302 1.014 
Total refs 3488 14700 5679 21135 8404 
Indep. refs 
Rint 
1905 
0.0292 
3881 
0.0425 
3846 
0.0416 
7365 
0.0398 
4169 
0.0729 
R1 (obs. data) 0.0432 
 
                0.0406 0.0958 0.0424 0.0933 
wR2 (all data) 0.0826 0.0908 0.2698 0.1120 0.2546 
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3.2.4.3 Structure of [FeIII(PKSMC)2](ClO4)  
The crystal structure of the complex [Fe
III
(PKSMC)2]
+
 was also determined (Figure 3.8). It 
is apparent that the geometry of the complex cation mirrors that of [Fe
III
(PCSMC)2]
+
. Again the 
coordinate bonds and angles are consistent with low spin Fe
III
 complexes of the dithiocarbazate 
Schiff base ligands (Table ‎3.1). Nevertheless, the Fe-N and Fe-S bonds are slightly longer than 
those seen in [Fe(PCSMC)2]
+
. This can be attributed to electron withdrawing effects of the non-
coordinating pyridyl rings that may slightly weaken the donor strength of the PKSMC
-
 ligand and 
the interligand repulsion brought about by introduction of these groups. 
 
Figure ‎3.8 ORTEP view of the [Fe(PKSMC)2]
+
 and MPPT
+
 cations (30% probability ellipsoids at 
293 K). 
 
Interestingly, the complex [Fe
III
(PKSMC)2]
+
 co-crystallised (in the same crystal) with a 
cationic pyrido-triazinium derivative (MPPT
+
, Figure 3.8); as a result of ligand desulfuration. It is 
not known whether Fe catalyses this reaction, although the loss of sulfide (or hydrogen sulfide) is 
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probably assisted by the presence of free metal ions. The suggested mechanism is shown in Scheme 
3.1. It is known that elimination of methanethiol followed by ring closure is an alternative 
possibility in dithiocarbazates of this type, leading to an exocyclic thioamide, rather than a 
thioether, group.
246
 
 
 
 
 
 
 
 
3.2.4.4 Structure of [FeIII(PCSMC)(PSMC)] 
It is worthy to note that in the synthesis of the Fe
III
 complex of HPCSMC, different products 
were recovered depending on the order of addition of reagents (ligand, ferric perchlorate and base). 
When the ferric salt was added last, an unusual mixed-ligand Fe
III
 complex was obtained following 
column chromatography as described in Chapter 2, namely [Fe
III
(PCSMC)(PSMC)]. The ligand 
dianion PSMC
2-
 is a hydroxylated form of PCSMC
-
. The neutral complex, [Fe
III
(PCSMC)(PSMC)] 
exhibited an intense C=O vibrational band in the IR spectrum at 1583 cm
-1
, a band that was not 
present in all other IR spectra of the Fe
III
 complexes described here.  
The crystal structure of this complex was determined and a view of the neutral complex 
[Fe
III
(PCSMC)(PSMC)] is shown in Figure ‎3.9. Some significant structural effects on the complex 
and on the PCSMC
-
 co-ligand are caused by the presence of O1a in the PSMC
2-
 ligand. In 
particular, the Fe-N2b and Fe-S1b bonds lengthen compared to the symmetrical [Fe(PCSMC)2]
+
 
and [Fe(PKSMC)2]
+
 complexes. A trans influence of the dianionic PSMC
2-
 ligand may be 
responsible. The Fe-N2b bond (from PCSMC
-
) is trans to the Fe-N2a bond (from PSMC
2-
), and 
N2a formally carries a negative charge due to amide deprotonation. The extension of the Fe-S1b 
bond may be a consequence of Fe-N1b elongation, as both donor atoms are part of the same rigid 
chelate ring. Another structural feature is the change in bond order of C6-N2 from a formal (imine) 
double bond in the dithiocarbazate Schiff bases (1.28-1.31 Å) (Table ‎3.1), to an intermediate bond 
order closer to one (C6a-N2a 1.38(1) Å), characteristic of a deprotonated amide in PSMC
2-
. 
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The hydroxylation reaction leading to PSMC
2-
 is unusual but has been observed in other 
related ligands. A similar type of reaction was observed on hydrazone Schiff base ligands derived 
from pyridinecarbaldehyde (specifically HPCIH or 2-pyridylcarbaldehyde isonicotinoylhydrazone) 
which experienced an unexpected oxidation to isonicotinoyl (picolinoyl) hydrazine when 
complexed with Fe
III
 (the H2IPH analogs, Chapter 1).
65
  The mechanism of this reaction is very 
complicated,
247
 but nucleophilic attack on the C6=N2 double bond by H2O or OH
-
 followed by 
dehydrogenation of the carbinol are involved. This reaction is catalyzed by Fe
III
, but not O2. Fe
 
complexes of the H2IPH series have very different properties, forming only stable Fe
III
 complexes, 
in contrast to the Fe
II
 complexes from the corresponding HPCIH series as discussed in Chapter 1. 
        
 
 
 
 
 
 
 
 
 
 
 
Figure ‎3.9 ORTEP view of [Fe(PCSMC)(PSMC)] (30% probability ellipsoids shown at 293 K ). 
 
3.2.5 Electronic spectra of Fe complexes of dithiocarbazate Schiff base Ligands 
 
The electronic spectra of Fe complexes of dithiocarbazate Schiff base ligands in comparison 
with some thiosemicarbazones and hydrazones are listed in Table 3.3. The electronic spectra of the 
Fe
II
 complexes in MeCN solution exhibit a broad, asymmetric and intense maximum around 670 
nm (Figure ‎3.10). This transition is most likely of metal-to-ligand charge-transfer origin MLCT 
(Fe
II  pyridine), giving the complexes their characteristic green colour. The same phenomenon 
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was found in the Fe
II
 complexes of the HPCIH
68,77,95
 (hydrazone) and HDp44mT 
(thiosemicarbazone) series.
119,124,235, 95
 The  dithiocarbazate series  show a MLCT band at a much 
longer wavelength between 664 and 684 nm. As examples, the electronic spectra of the Fe
II
 
complexes of HAp4mT, HDp4mT and HPCIH in MeCN are shown in Figures 3.11 and 3.12 in 
comparison to that of dithiocarbazate. It is worth noting that the Fe
II
 complexes in the solid state are 
stable and do not undergo oxidation. The Fe
III
 complexes exhibit a series of broad, overlapping and 
intense electronic transitions in the visible region, giving the complexes their dark brown 
appearance. In comparison with the FeIII complexes of thiosemicarbazone series, the electronic 
transitions of Fe
III
 complexes of the dithiocarbazate analogues appear at slightly shorter 
wavelengths, between 425 and 445 nm. The pale yellow free ligands exhibit no electronic maxima 
in the visible region (Figure 3.10). 
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 Figure ‎3.10 UV-vis spectra of HAPSBC and its FeII and FeIII complexes in CH3CN. 
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Table ‎3.3 Electronic spectral data (MeCN, 298 K) of heterocyclic dithiocarbazate, 
thiosemicarbazone and hydrazone Fe complexes. 
 
 
 Complexes λmax [nm] (ε[L mol
-1
 cm
-1
]) 
[Fe
III
(Ap4MT)2]ClO4 460 (12276), 358 (32360), 327 (30931) 
[Fe
II
 (Ap4MT)2] 643 (4320), 360 (24955), 320 (23831) 
[Fe
III
(APSBC)2]ClO4 428 (8530), 350 (25600) 
[Fe
II
 (APSBC)2] 679 (5920), 429 (sh, 12500), 333 (26300) 
[Fe
III
(DP4MT)2]ClO4 475 (1480), 371 (35069) 
[Fe
II
 (DP4MT)2] 650 (5145), 382 (12551), 255 (14444) 
[Fe
III
(PKSMC)2]ClO4 445 (12100), 362 (27200) 
[Fe
II
 (PKSMC)2] 682 (6320), 445 (sh, 10500), 344 (25300) 
[Fe
II
 (PCIH)2] 662 (5400), 345 (42636), 269 (20558)  
[Fe
II
 (PCSMC)2] 684 (7210), 441 (sh, 7210), 346 (17800) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎3.11 Comparison between the UV-vis spectra of Fe
III
 complexes of HAp4mT, HDp4mT and 
HAPSBC in MeCN.  
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Figure ‎3.12 Comparison between UV-vis spectra of Fe
II
 complexes of HAp4mT, HDp4mT, 
HAPSBC, and HPCIH in MeCN. 
 
3.3   Redox properties 
 
Determination of the redox potentials of the iron complexes plays an important role in 
defining the biological activity and affinity for Fe in each of its common oxidation states. Under 
physiological conditions complexes with low (large negative) redox potentials will be most stable in 
the Fe
III
 form, while those with high redox potentials will be most stable in the Fe
II
 form. Between 
these extremes, both Fe
III 
and Fe
II
 may co-exist and interconvert. Redox-active Fe complexes may 
exhibit cytotoxicity by catalyzing the production of hydroxyl radicals via an outer sphere 
mechanism (Fenton chemistry, Equation 3.1) which are capable of damaging important 
biomolecules.
6
   
[Fe
II
L2] + H2O2  [Fe
III
L2]
+
 + ·OH + OH
-
         ( 3.1) 
  [Fe
III
L2]
+
 + red  [FeIIL2] + ox         (3.2) 
This is possible if the redox potentials lie in the appropriate range (ca. -200 to 200 mV),
248
 
not too high so that oxidation by H2O2 is prevented and not too low so that the ferrous complex 
cannot exist in an oxygenated solution. Therefore, redox potentials outside this window are 
inaccessible to physiological oxidants and reductants.   
Previously, Fe complexes of thiosemicarbazone complexes
124, 127, 119
 exhibited redox 
potentials in the range 0 to +200 mV vs NHE that can catalyse the production of hydroxyl radicals 
in the presence of hydrogen peroxide. For Equation 3.1 to be catalytic, the Fe
III
 complexes must be 
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E (mV vs NHE)
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2
]
+
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]
+
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2
]
+
[Fe(APSMC)
2
]
+
2 A
able to be reduced by intracellular reductants (Equation 3.2) so the rates of both Equation 3.1 and 
3.2 will be important in determining the overall yield of ·OH. The higher potential Fe
II
 complexes 
will be less reactive toward H2O2 but more easily reduced from their reactive Fe
III
 form.  
Cyclic voltammetry of the Fe complexes of the dithiocarbazate ligands was achieved in a 
mixture of MeCN and water (70:30) (v/v) due to insufficient solubility of the complexes in pure 
water and the results are summarized in Figure 3.13 for the Fe
III
 complexes only (the Fe
II
 complexes 
gave identical results). Totally reversible Fe
III/II
 redox couples were identified in all cases with E° 
values varying from +229 to +401 mV vs NHE (Table ‎3.4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎3.13 Cyclic voltammetry of the Fe
III 
dithiocarbazate Schiff base complexes: sweep rate 100 
mV s
-1
, MeCN: H2O 70:30 (V/V) solvent, 0.1 M Et4NClO4 supporting electrolyte, glassy carbon 
working electrode and an aqueous Ag/AgCl reference electrode. 
 
The inductive effects of the substituents result in the differences in redox potentials of these 
complexes. There is little effect (ca. 10 mV) on the Fe
III/II  
redox potential by altering the terminal S-
substituent (from methyl to benzyl), compared to the stronger influence of the substituent on atom 
C6 (as shown in Figure 3.13), as found in previous investigations of the HPCIH
95
 and HDpT
235
 
families and their Fe complexes. The highest redox potentials of the series are of the PKSMC
-
 and 
PKSBC
-
 complexes due to the electron–withdrawing non-coordinating pyridyl rings. In contrast, the 
Fe complexes of APSMC
-
 and APSBC
-
 exhibit the lowest potentials, resulting from the electron-
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donating methyl groups. Hence, [Fe
II
(APSMC)2] and [Fe
II
(APSBC)2] are air-sensitive in MeCN 
solution and may oxidise to their ferric complexes in aerated solution. 
 
Table ‎3.4 Fe
III/II
 redox potentials (mV vs  NHE) for relevant 1:2 Fe:ligand complexes in comparison 
with data for the Fe complexes of DFO
249
,  HPCIH,  HDp4mT,
119
 HAp4mT
127
  in MeCN:H2O 
70:30 (V/V) solvent. 
 
 
 
 
 
 
 
 
 
 
 
The Fe
III/II
 redox potentials of the thiosemicarbazone complexes [Fe(Dp4mT)2]
+
,  
[Fe(Ap4mT)2]
+
 and the hydrazone complex [Fe(PCIH)2] in comparison to their corresponding 
dithiocarbazate Schiff base analogue Fe complexes is apparent from Figures 3.14, 3.15 and Table 
3.4. [Fe(Ap4mT)2]
+
 has the lowest Fe
III/II  
redox potential of any thiosemicarbazone complex from 
this family (-3 mV) which is about 200 mV lower than the analogous dithiocarbazate Schiff base 
complex also derived from 2-acetylpyridine. Another example, [Fe(Dp4mT)2]
+
, has a redox 
potential +153 mV vs NHE, which is about 200 mV lower than that of the analogous thiocarbazate 
complexes [Fe
III
(PKSMC)2]
+
 and [Fe
III
(PKSBC)2]
+
. In contrast, the thiohydrazone analogue 
[Fe
III
(PKTBH)2]
+
 (as discussed in Chapter 1, Section ‎1.2.2.6) shows a redox potential +383 mV vs 
NHE
76
 which is basically the same as that of the dithiocarbazate complex derived from di-2-pyridyl 
ketone. Substituting an S-donor (e.g. in the thiohydrazone [Fe
III
(PKTBH)2]
+
) with an O-donor, 
[Fe
III
(PKBH)2]
+
, a hydrazone) shifts the of  Fe
III/II
 couple to very high potential (ca. +500 mV) and 
in fact the highly oxidizing Fe
III
 complexes of these and related hydrazone ligands are not stable in 
aqueous solution.
68,77,95
 [Fe(PCIH)2] is another example of a hydrazone with an O-donor which 
exhibits a slightly higher redox potential  (ca. +595 mV) compared to the thiocarbazate Schiff base 
complex derived from di-2-pyridyl ketone. However, cyclic voltammetry of [Fe(PCIH)2] in 7:3 
Complex E'(Fe
III/II
) (mV vs NHE) 
[Fe(DFO]
- 
-475 
[Fe(Ap4mT)2]
+ 
-3 
[Fe(Dp4mT)2]
+ 
+153 
[Fe(PSMC)2]
+ 
+229 
[Fe(PSBC)2]
+ 
+239 
[Fe(PKSMC)2]
+
 +383 
[Fe(PKSBC)2]
+
 +401 
[Fe(PCSMC)2]
+ 
+357 
[Fe(PCSBC)2]
+ 
+367 
         [Fe(PCIH)2] +595 
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MeCN:H2O (v/v)  displays totally irreversible redox responses (Figure 3.15), as found in a previous 
investigation of [Fe(PCIH)2] in 1:1  DMF:H2O.
68
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+
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+
 
Figure ‎3.14 Comparison of cyclic voltammetry of the [Fe(APSMC)2]
+
 and  [Fe(Ap4mT)2]
+
: sweep 
rate 100 mV s
-1
,  MeCN:H2O 7:3 (V/V) solvent, 0.1 M Et4NClO4 supporting electrolyte, glassy 
carbon working electrode and an aqueous Ag/AgCl reference electrode. 
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Figure ‎3.15 Comparison of cyclic voltammetry of the [Fe(PCIH)2], [Fe(PKSMC)2]
+ 
and 
[Fe(Dp4mT)2]
+
: sweep rate 100 mV s
-1
,  MeCN:H2O 7:3 (V/V) solvent, 0.1 M Et4NClO4 supporting 
electrolyte, glassy carbon working electrode and an aqueous Ag/AgCl reference electrode.  
 
 
3 Iron Coordination Chemistry and Biological Activity of Heterocyclic Dithiocarbazate Schiff base Ligands 
72 
 
E (mV vs NHE)
-600 -500 -400 -300 -200 -100 0 100 200 300
100 mV s
-1
50 mV s
-1
20 mV s
-1
2 A
The unusual mixed-ligand complex [Fe
III
(PSMC)(PCSMC)] exhibits a totally reversible 
Fe
III/II
 couple at much lower potential (-100 mV vs NHE) than the symmetric bis-dithiocarbazate 
complexes; ca. 450 mV  below the related [Fe
III
(PCSMC)2]
+
 complex. The voltammetry at three 
different sweep rates is shown in Figure ‎3.16. This large stablisation of the FeIII form is a result of 
the PSMC
2-
 ligand which presents two formally anionic donor atoms; the deprotonated amide N2a 
(Figure ‎3.9) and the thiolate S-donor. A similar cathodic shift was observed going from the related 
hydrazone (HPCIH)
68
 to hydrazine (H2IPH) series,
69
 where the Fe
III/II
 redox potential of 
[Fe
III
(IPH)2]
-
 is ca. 750 mV lower than [Fe
III
(PCIH)2]
+
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎3.16 Cyclic voltammetry of [Fe(PSMC)(PCSMC)] at 20, 50 and 100 mV s
-1
 sweep rate: 
MeCN:H2O (70:30) (v/v), 0.1 M Et4NClO4 supporting electrolyte, glassy carbon working electrode 
and an aqueous Ag/AgCl reference electrode.  
 
As discussed, the redox potentials of the Fe complexes of dithiocarbazate Schiff base 
chelators in the range +229 to +401 mV are relatively high compared to Fe
III 
thiosemicarbazone 
complexes. Therefore, in the solution these Fe
III
 complexes of dithiocarbazate series could undergo 
reduction reactions and form more stable Fe
II
 complexes as presented in Equation 3.3. 
                                       
2[Fe
III
L2]
+
 +2OH
-
 2[FeIIL2] +H2O2     (3.3) 
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Considering the above, time-dependent spectrophotometric experiments were undertaken to 
monitor spontaneous reduction of the Fe
III
 complexes of the dithiocarbazate chelators (for example 
HAPSBC) in either 100% MeCN or a mixture of MeCN and pH 7.4 buffer (50:50 v/v) over a 
period of 2 h.  The reactions were followed in the 250-800 nm wavelength range. In 100% MeCN, 
no reaction occurs and the ferric complex is stable. However,  in the 50% aqueous MeCN there is a 
decrease in the intensity of Fe
III
 peak at 428 nm with an increase in the intensity of the characteristic 
Fe
II
 peak at 679 nm, indicating the reduction of [Fe
III
(APSBC)2]
+
 to [Fe
II
(APSBC)2] (Figure 3.17). 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎3.17 Time resolved UV-Vis spectral changes of a solution 25 μM of [FeIII(APSBC)2]
+
 (a) in 
MeCN and (b) in a mixture of MeCN and water (50:50) (V/V) under the conditions (pH = 7.4,  
spectra show ~12.2 s  intervals ) over a period of 2 hours. 
 
In addition, kinetic modeling of these spectral changes was achieved by using ReactLab 
Kinetics.
226
 Accomplishing a proper agreement between the calculated and experimental data 
requires two steps (Figure ‎3.18). The first step is a first order reaction that generates an intermediate 
species which lacks the broad band at 670 nm of the starting Fe
III
 complex (k1= 1.73 ×10
-3 
s
–1
). It is 
not certain what this intermediate is but it could be a partially dissociated Fe
III
 complex. The second 
phase is formation of the corresponding bis-ligand complex Fe
II
 (k2= 1.853 × 10
-4 
s
–1
). Furthermore, 
we carried out the same experiment, monitoring the reduction reaction of [Fe
III
(APSBC)2]
+
 in a 
mixture of MeCN and water (50:50) (v/v) but at different ranges of pH (2.5 to 7.4).  Unexpectedly, 
the results show that there are no obvious changes in the observed rate constants with pH. The 
reason for such behavior is unclear. However, the important conclusion is that the Fe
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the dithiocarbazate Schiff base series are only stable in water in their Fe
II
 form which parallels the 
properties of the HPCIH hydrazone series. At physiological pH, their Fe
III
 complexes are
 
converted 
to Fe
II
 and probably do not participate in any form of redox chemistry once formed. The Fe
III
 forms 
of these complexes may be considered irrelevant under physiological conditions and unable to 
participate in any oxidative processes such as the oxidation of oxy-hemoglobin (HbO2) which is an 
important reaction in thiosemicarbazone Fe complexes to be discussed in the next chapter (Chapter 
4). 
 
 
 
 
 
 
 
 
 
Figure ‎3.18 (a) ReactLab Kinetics calculated time dependent concentrations of [Fe
III
(APSBC)2]
+
 
(black), reaction intermediate (red), and [Fe
II
(APSBC)2] (dark blue)  and (b) calculated spectra for 
[Fe
III
(APSBC)2]
+
 (black), reaction intermediate (red), [Fe
II
(APSBC)2] (dark blue).  
 
3.4 Biological activity 
 
The biological activity data of the heterocyclic dithiocarbazate Schiff bases was collected by 
the group of Prof. Des Richardson (University of Sydney). Successful iron chelators have the ability 
to mobilise intracellular iron (iron efflux) and to offset the effects of cells becoming Fe-loaded (iron 
uptake) from the plasma protein diferric transferrin (Fe2-Tf).  In this study, iron efflux and uptake 
experiments were carried out using radioactive 
59
Fe. Also, the human SK-N-MC neuroepithelioma 
cell line that was chosen for the iron uptake and efflux studies because  iron metabolism of these 
cells was characterised by Richardson et al.
90
  and they were found to contain iron-rich ferritin
250
 
and are also especially sensitive to iron chelation.
82
 This is explained further below. 
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3.4.1 Cellular 59Fe mobilization activity 
  
The ability of the heterocyclic dithiocarbazate Schiff bases (Figure ‎1.16) to chelate 
intercellular Fe was examined in two ways. The Fe efflux assay tests the ability of these chelators to 
mobilize (radioactive) 
59
Fe from human SK-N-MC neuroepithelioma cells pre-labelled with 
59
Fe2-
Tf. 
75,251
 In this assay,  the (dithiocarbazate Schiff base) chelator removes 
59
Fe from the cell. The 
more effective Fe chelators will increase the percentage of cellular 
59
Fe release, which is quantified 
by measuring the change in the level of radioactivity before and after incubation. The results 
(Figure 3.19) were expressed relative to the negative control (medium alone with no chelator). Fe 
chelators DFO, HDp44mT and H2NIH (311) were included for comparison as positive 
controls.
75,98,251
 Naturally, in the negative control only a small amount (~ 4%) of 
59
Fe was released 
from the cell over the time course of the experiment. All dithiocarbazate ligands were more 
effective than DFO in mobilizing 
59
Fe from the cell, with HPCSMC being the most active of the 
dithiocarbazate tested compounds and as effective as HDp44mT (Figure 3.19). It is interesting to 
note that the three S-benzyl dithiocarbazates (HAPSBC, HPCSBC and HPKSBC) were less 
effective at mobilising intracellular 
59
Fe than the S-methyl analogues (HAPSMC, HPCSMC and 
HPKSMC).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎3.19 The effect of the dithiocarbazate chelators on cellular 
59
Fe release from pre-labelled     
SK-N-MC neuroepithelioma cells. Results are mean + SD (3 experiments).  
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3.4.2 Chelator-mediated inhibition of 59Fe uptake from 59Fe2-Tf 
 
The ability of the chelators to inhibit cellular 
59
Fe uptake from 
59
Fe2-Tf was examined and 
results are shown in Figure 3.20. In this case the chelators intercept 
59
Fe after release from 
transferrin thus lowering the amount of 
59
Fe delivered to the cell. All results were expressed relative 
to untreated control (100% uptake). The results mirror those obtained with the Fe efflux assay.  The 
three S-methyl dithiocarbazates are more effective at decreasing 
59
Fe uptake from 
59
Fe2-Tf than the 
three S-benzyl chelators. Furthermore, these chelators were more active than DFO, but less effective 
than H2NIH (311) or HDp44mT (Table 3.5). 
 
 
 
 
 
 
 
      
 
 
Figure ‎3.20 
59
Fe uptake from 
59
Fe2-Tf by SK-N-MC neuroepithelioma cells. Results are mean + SD 
(3 experiments). 
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Table ‎3.5 Biological data for the dithiocarbazate chelators. 
 
 
IC50  
59
Fe Efflux 
(% total cell iron released) 
 
59
Fe Uptake 
(% control) 
 
Control --- 4 + 0.5 100 + 4 
DFO 
11.4 ± 0.8 10 ± 2 86 ± 7 
H2NIH (311) 
0.75 ± 0.26 40 ± 3 7 ± 1 
HDp44mT 
0.009 ± 0.004 40 ± 2 4.9 ± 0.8 
HAPSMC 
0.05 ± 0.02 32 ± 1 18 ± 1 
HAPSBC 
0.05 ± 0.02 22.4 ± 0.7 46 ± 7 
HPKSMC 
0.37 ± 0.11 36 ± 2 21 ± 1 
HPKSBC 
0.09 ± 0.06 28 ± 1 43 ± 11 
HPCSMC 
> 10 38.4 ± 0.9 17 ± 2 
HPCSBC 
> 10 27 ± 3 42 ± 7 
 
3.4.3 Cytotoxicity of dithiocarbazate chelators 
 
Fe overload disorders as discussed previously in Chapter 1 need frequent administration of 
the drug. Hence, chelators for the treatment of this condition must be non-toxic.
41,252
 The toxicity of 
the dithiocarbazate chelators was assessed against the same SK-N-MC neuroepithelioma cell line 
using DFO as a negative control and the highly cytotoxic ligand, HDp44mT, as a positive 
control.
75,98,124
 The results were expressed as IC50 values and are summarized in Table 3.5.  
The two dithiocarbazates derived from 2-pyridinecarbaldehyde showed no significant 
cytotoxicity (IC50 > 10 ). This property, together with their high cellular Fe mobilization 
activity, makes them ideal chelators in the treatment of Fe overload. The four dithiocarbazates 
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derived from 2-acetylpyridine and di-2-pyridylketone exhibited significant anti-proliferative 
activity, suitable for the treatment of cancer but not for Fe overload. These results mirror the trend 
observed with the  HPCIH and HPKIH hydrazones.
95
 That is the presence of an alkyl or aromatic 
substituent on the imine C-atom (for Schiff bases derived from ketones) is correlated with 
cytotoxicity while analogous Schiff bases from aldehydes are invariably much less cytotoxic and 
mostly non-toxic. It is still not clear why this feature persists now across three different series 
(thiosemicarbazones, hydrazones and now dithiocarbazate Schiff bases). 
3.5 Summary 
 
The iron coordination chemistry and biological activity of a new series of biologically active 
heterocyclic dithiocarbazate Schiff base ligands have been presented and discussed. These ligands 
utilize a set of NNS donor atoms to form stable bis tridentate low spin ferric and ferrous complexes 
similar to heterocyclic hydrazone
77,95
 and thiosemicarbazone
235,119,124
 chelators that have been 
studied previously. Both Fe
II 
and Fe
III
 complexes of these dithiocarbazate ligands were isolated and 
structurally, spectroscopically and electrochemically characterized. In all cases, totally reversible 
Fe
III/II
 couples in mixed aqueous solvent were identified at a potential higher than that found in 
analogues thiosemicarbazone iron complexes. Also, an unusual hydroxylated ligand derivative has 
been identified, formed via an Fe-induced oxidation reaction. 
In this regard, Fe
III
 complexes of dithiocarbazate Schiff base ligands convert to the more 
stable Fe
II
 form in the presence of water and at physiological pH. Therefore, Fe
II
 complexes are 
likely the only form present in the cell, with no effect on inducing oxidation of oxy-hemoglobin 
(HbO2) to methemoglobin (Met-Hb), compared to thiosemicarbazone complexes as will be 
discussed in the next chapter (Chapter 4).  
The effectiveness of these dithiocarbazate ligands to mobilize intracellular iron and to 
prevent iron uptake from transferrin as well as their anti-proliferative activity have also been 
reported. All ligands were more effective in chelating intracellular iron than the clinically proven 
chelator desferrioxamine (DFO). The Schiff base ligands derived from 2-pyridinecarboxaldehyde 
exhibited no marked anti-proliferative activity and were non-toxic to SK-N-MC neuroepithelioma 
(cancer) cells in contrast to those derived from the ketones 2-acetylpyridine and di-2-pyridylketone, 
which exhibited significant anti-proliferative activity. Clearly these results suggest that Schiff bases 
derived from aldehydes (bearing an H-atom at C6) are an ideal Fe chelator for Fe overload, whereas 
ketone-derived Schiff bases bearing a methyl, phenyl or pyridyl group at C6 are advantageous in the 
treatment of cancer.  
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Chapter 4   Kinetics and Mechanistic Studies on the Oxidation of 
Oxyhemoglobin to Methemoglobin by Biologically Active Iron(III) 
Thiosemicarbazone Complexes Derived from Di-2-pyridyl ketone 
 
 
 
4.1 Overview 
 
The protein, hemoglobin (Hb) plays a vital role in the transport of oxygen to the tissues.
253
 
In its natural state, oxy-hemoglobin (HbO2) is an 22 tetramer, where each of the four hemes are 
formally in a ferrous form binding a single oxygen molecule. There has been an enormous amount 
of  research on  the structure of  Hb and its kinetic and thermodynamic properties over the last 100 
years in order to understand how Hb binds and releases oxygen.
254
  It is known that the binding of 
four oxygen molecules by Hb is cooperative with successive O2 binding constants increasing with 
the addition of each oxygen molecule. That is, the last bound oxygen molecule has a greater affinity 
for the protein than the first one. This is can be achieved by conformational changes that are 
coupled with oxygen binding.
254
   
As described previously in Chapter 1  Section  ‎1.3.4, under physiological conditions auto–
oxidation of HbO2 occurs at a slow rate, resulting in formation of methemoglobin (metHb), a ferric 
form that cannot bind oxygen and  represents about 1-2%  of total  Hb in the blood.
255
 Synthetic 
drugs can increase the normal levels of metHb through electron transfer reactions with 
HbO2.
166,167,169-173
  In this regard, an emerging anti-cancer drug, the Fe chelator 3-amino-2-
pyridinecarbaldehyde thiosemicarbazone (3-AP; Triapine) (Chart 4.1), which has been examined in 
a number of Phase I and Phase II clinical trials for the treatment various cancers,
111-115,117,174
 induces 
the formation of metHb and hypoxia in patients, limiting its usefulness.
112,175-178
 Given the high 
affinity of 3-AP for Fe and the fact that this complex is redox active, it appears that the Fe
III
 
complex of 3-AP may be responsible for the oxidation of HbO2 to metHb in vivo. However, the 
mechanism producing such effects has not been investigated, and its elucidation should play a 
crucial role in the development of more useful thiosemicarbazones as anti-cancer agents that avoid 
the side effects of hypoxia and methemoglobinemia.
179
 
The structurally related family of thiosemicarbazones, the di-2-pyridylketone 
thiosemicarbazone (HDpT)
119
 series (Chart 4.1), which exhibit selective and potent anti-tumour 
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activity in vitro and in vivo
118,119
 are more active than 3-AP. As discussed in Chapter 1 Section 
‎1.2.2.5.2, these ligands deprotonate at N2 upon coordination (see H-atoms in bold type in Chart 4.1) 
and bind as a NNS tridentate mode to iron.  The HDpT analogs form highly stable complexes with 
both Fe
II
 and Fe
III
 but only 6-coordinate 1:2 Fe:ligand complexes have been isolated to date.
179
 It is 
worthy to note that the free ligands are capable of removing Fe
III
 from potent iron chelators such as 
EDTA or desferrioxamine (DFO, Chart 4.1).
141
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chart 4.1 Di-2-pyridylketone thiosemicarbazones ligands investigated in this Chapter.  
 
In this regard, preliminary investigations on a selection of Fe
III
 complexes of biologically 
active thiosemicarbazones, in terms of  their enhancement on the oxidation of HbO2 
(Fe
II
O2Fe
III
(O2
-
)) to metHb (Fe
III
-OH)  in vitro and in vivo have been carried out.
256
 It was 
identified that [Fe
III
(Dp44mT)2]
+
 and related thiosemicarbazone redox-active Fe
III
 complexes were 
cabable of inducing HbO2 oxidation on intact erythrocytes (red blood cells), erythrocyte lysates, 
purified oxyhemoglobin and a mouse model. The mechanism of these reactions remains unclear and 
quantitative information on the rates of these reactions is lacking. Given the four redox active 
hemes in HbO2 and the known cooperative effects inherent to the 22 HbO2 tetramer, no 
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satisfactory mechanism has been proposed so far that takes into account a possible multiphasic 
reaction.  
In this chapter a kinetic study on the ability of the HDpT series of Fe
III
 complexes to 
promote metHb generation in vitro (i.e. a process linked with oxidative stress in vivo) was reported. 
The findings from this in vitro investigation will contribute to the development of 
thiosemicarbazone chelators as anti-cancer agents. 
4.2 Oxidation reactions 
 
The kinetic studies on the oxidation reactions of HbO2 by the iron complexes of  DpT series 
(HDpT, HDp4eT, HDp4mT and HDp44mT, Chart 4.1) have been carried out at initial 
concentrations of α22-HbO2 of 7.5×10
-7 
M (3×10
-6
 M total heme). As reported by Griffon et al. the 
tetramer/dimer dissociation constant is approximately 2×10
-7
 M
164
 so at equilibrium  and at the 
concentrations used the protein contains 74% α22-HbO2 tetramer and 26% α-HbO2 dimer. 
Clearly, this tetramer/dimer ratio is highly sensitive to the accuracy of KD under the conditions of 
our experiments. For instance, a slightly higher KD value (8×10
-7
 M) will result in a significant 
change in the tetramer/dimer ratio (53% dimer and 47% tetramer).  
Therefore, we should consider two possible conditions for analysis of the overall oxidation 
reaction. Firstly, the α- and -chains may react at different rates in line with published auto-
oxidation studies,
161
 while the α-chains (or -chains) within the same tetramer react independently 
from one another. This will give biphasic kinetics, i.e. two consecutive reactions; both -chains 
oxidsed concurrently then both -chains oxidised concurrently. Alternatively, it is possible that all 
four hemes in the α22-HbO2 tetramer are oxidised sequentially at four different rates; a tetra-phasic 
reaction. The separation of four sequential reaction steps as a function of time is challenging 
especially given the fact that the spectral changes of the four heme chromophores are almost the 
same upon oxidation. As we will show in this chapter, the kinetics are consistent with a biphasic 
reaction and we only need to consider the dimeric α-HbO2 unit (either being within its tetramer or 
in isolation) as the reactive species in all cases.    
Following this assumption, the two heme groups of the α dimer react stoichiometrically 
with two Fe
III
 thiosemicarbazone complexes to fully reach their metHb form (Equation 4.1). 
αHbO2 + 2 [Fe
III
(DpxxT)2]
+
        αmetHb + 2 [FeII(DpxxT)2]
+
 + 2 O2                   (4.1) 
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Of course the reaction indicated in Equation 4.1 corresponds to the overall redox process 
including release of two molecules of O2. The full set of intervening steps is much more 
complicated and involves oxy/deoxy-hemoglobin equilibria, as well as the redox reaction of the 
deoxy species (Scheme 4.1). Direct oxidation of the oxyheme cofactors has not been considered in 
Scheme 1 due to the fact that dioxygen binding stabilises the heme against oxidation to metHb 
through electronic delocalisation (Fe
II
O2Fe
III
(O2
-
)).
257
 This is consistent with other studies which 
indicate that dissociation of dioxygen from Fe
II
 must occur first followed by deoxy-heme 
oxidation.
166
  Perrella et al. showed that the oxidation of deoxy-hemoglobin (in the absence of 
dioxygen) was much faster than the reaction with oxyhemoglobin.
258
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 The reactions were followed by time-resolved UV-Vis spectrophotometry in the 400-800 
nm wavelength range, which revealed the existence of spectral changes (Figures 4.1 and 4.2) in 
good agreement with a sequential oxidation of the two heme groups in the α HbO2 species. The 
decrease in intensity of the characteristic HbO2 peaks at 577 and 539 nm occurs concomitantly with 
an increase in intensity and hypsochromic shift of the Soret band at 404 nm which is due to the 
conversion of oxyHb into metHb.
232
 Furthermore, the increase in absorbance of the broad maximum 
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around 620 nm can be attributed to a combination of bands from metHb and the Fe
II 
 
thiosemicarbazones complex product, which exhibits a maximum around 650 nm in all known 
[Fe
II
(DpxxT)2]
+
 complexes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎4.1 Time resolved UV-Vis spectral changes of a solution 27 M of (a)[FeIII(Dp4mT)2]
+
, (b) 
[Fe
III
(Dp44mT)2]
+
, (c) [Fe
III
(Dp4eT)2]
+
, (d) [Fe
III
(DpT)2]
+
and HbO2 (3.0 M total heme) under the 
conditions indicated in the experimental chapter (Total time 50 s, cycle time 0.25 s) 
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Figure ‎4.2 Time resolved UV-Vis spectral changes of a solution 27 M of (a)[FeIII(Dp4mT)2]
+
,  (b) 
[Fe
III
(Dp44mT)2]
+
, (c) [Fe
III
(Dp4eT)2]
+
, (d) [Fe
III
(DpT)2]
+
and HbO2 (3.0 M total heme) under the 
conditions indicated in the experimental chapter (Total time 300 s, cycle time 6.4 s). 
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4.3 Kinetic analysis 
 
The time-dependent spectral changes were modelled by global analysis of the  wavelength 
range 400-800 nm using ReactLab Kinetics.
226
 Achieving a good agreement between the calculated 
and experimental data required a model comprising two consecutive pseudo-first order reaction 
steps (Figure ‎4.3). This indicates that each heme group is oxidized sequentially in an electron 
transfer reaction that is first order in both heme and Fe
III
 complex. Pseudo-first order conditions 
were achieved by using at least a tenfold higher concentration of Fe
III
 complex relative to heme. 
The final spectra of all three forms of the protein (HbO2, half-metHbO2 (50% oxidised HbO2) and 
metHb) agree with the stoichiometry of the reaction (Equation 4.1) if the spectral background of the 
[Fe
III
(DpxxT)2]
+
 complex (in excess) is taken into consideration. Even though the spectral signature 
of the [Fe
II
(DpxxT)2] product increases while that of the HbO2 reactant decreases at the same 
time,
160,259
 the spectrum calculated for the reaction intermediate half-metHbO2 species is in good 
agreement with 50% oxidation of HbO2, which is consistent with the spectral similarity of the 
hemes in the α- and -chains. 
The faster reaction rate (kobs(f)) was determined generally from data acquired with a stopped 
flow instrument and collected over a period of less than 50 s. During this period, the fast step is 
dominant and the interference from the subsequent oxidation reaction is negligible. That is, a single 
exponential fit could be applied to this initial phase of the reaction (Figure ‎4.3 a and c). The slower 
reaction (kobs(s)) was monitored over a period of 300 s using standard manual mixing procedures 
(see experimental chapter section) and another a single exponential fit could be applied to the final 
phase of the reaction (Figure ‎4.3 b and d).  It is important to note that for the slower reactions a 
sequential two consecutive exponential function could be employed to fit all the data over this 
interval, an example illustrated in Figure ‎4.4. 
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Figure ‎4.3 ReactLab Kinetics calculated time dependent concentrations (a) fast step (50 s) of HbO2 
(dark red), half-metHbO2 (green), and (b) slow step (300 s) of half-metHbO2 (green) and metHb 
(blue). Calculated spectra (c) fast step HbO2 (dark red), half-metHbO2 (green), and (d) slow step for 
half-metHbO2 (green), and metHb (blue). Note: all spectra include a contribution of the 27 M of 
[Fe
III
(Dp4eT)2]
+
 solution which remains constant during the reaction (pseudo-first order 
conditions). 
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Figure ‎4.4 (a) ReactLab Kinetics calculated time dependent concentrations of HbO2 (red), half-
metHbO2 (green), and metHb (darkyellow) and (b) calculated spectra for HbO2 (red), half-metHbO2 
(green), and metHb (dark yellow). Note: all spectra include a contribution of the 27 M of 
[Fe
III
(Dp4mT)2]
+
 solution which remains constant during the reaction (pseudo-first order 
conditions). 
 
The first and second oxidation steps are clearly separated but the differences in rate 
constants are close to what would be expected from statistical kinetics
260,261
 for two independently 
reacting hemes (i.e. kobs(f) ~ 2kobs(s)). Nevertheless the second oxidation reaction rate constant is 
generally less than half of the first indicating that the  and -chains exhibit inherently different 
reactivity in line with previous studies on the biphasic auto-oxidation kinetics of HbO2,
161
 and the 
cooperative effects expected in the protein. In this regard, care must be taken on considering the 
reaction as a sequential fast-then-slow processes, mathematically the inverse (slow-then-fast) 
sequence should be indistinguishable when the spectral changes involved are equivalent.
262,263
 
The values obtained for kobs(f) and kobs(s) (Table ‎4.1) are found to be linearly dependent on the 
concentration of the Fe
III
 complexes, as expected. The plots of these values versus [Fe
III
(DpxxT)2]
+
 
(Figure ‎4.5) produced a series of straight lines with zero intercept, (i.e. equivalent  to the auto-
oxidation rate constant  10-6 s-1 within error, as expected for redox processes.264,265 No curvature in 
the plots under lower concentration condition was seen, indicating a strong outer-sphere association 
pre-equilibrium (see experimental chapter Section ‎2.1). Furthermore, these plots show a rather large 
(a) (b) 
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scatter that can be associated with the proximity of kobs(f) and kobs(s) which prevents a clean 
separation of the two steps, especially at low concentrations. It was noticed that there are baseline 
instabilities for reactions run over the period of minutes, resulting from dioxygen bubbles in the 
reaction medium as presented in Equation 4.1. 
Table ‎4.1 Values of kobs obtained for the redox processes between the α HbO2 dimer and the 
[Fe
III
(DpxxT)2]
+
  complexes studied, T = 25 ºC, [HbO2] = 1.5×10
–6
 M. The errors in all kobs values 
were less than 10
-3
 s
-1
. 
 
L [ [Fe
III
(L)2]
+ 
] /M kobs(f) /s
–1
 (stopped-flow) kobs(s) /s
–1
 (manual mixing) 
DpT 15 2.5×10
-2
 - 
 21 3.6×10
-2
 - 
 27 4.5×10
-2
 3.1×10
-2
 
 30 - 2.8×10
-2
 
 33 6.9×10
-2
 3.6×10
-2
 
 36 - 3.0×10
-2
 
 39 8.1×10
-2
 3.4×10
-2
 
 42 - 3.9×10
-2
 
 45 7.7×10
-2
 3.8×10
-2
 
 51 1.0×10
-1
 - 
 57 1.0×10
-1
 - 
Dp4mT 15 1.9×10
-2
 - 
 21 1.2×10
-2
 - 
 27 2.1×10
-2
 1.1×10
-2
 
 30 - 1.2×10
-2
 
 33 3.2×10
-2
 1.2×10
-2
 
 36 - 1.3×10
-2
 
 39 4.0×10
-2
 1.4×10
-2
 
 42 - 1.5×10
-2
 
 45 4.3×10
-2
 1.6×10
-2
 
 51 5.1×10
-2
 - 
 57 4.6×10
-2
 - 
 63 6.6×10
-2
 - 
Dp4eT 15 1.7×10
-2
 6.8×10
-3
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 18 - 7.2×10
-3
 
 21 1.7×10
-2
 7.6×10
-3
 
 24 - 8.7×10
-3
 
 27 2.0×10
-2
 9.4×10
-3
 
 30 - 1.1×10
-2
 
 33 3.2×10
-2
 1.0×10
-2
 
 36 - 1.2×10
-2
 
 39 3.6×10
-2
 1.3×10
-2
 
 42 - 1.2×10
-2
 
 45 4.5×10
-2
 1.3×10
-2
 
 51 4.6×10
-2
 - 
Dp44mT 18 - 9.0×10
-3
 
 21 1.2×10
-2
 1.0×10
-2
 
 24 - 1.1×10
-2
 
 27 2.3×10
-2
 1.2×10
-2
 
 30 - 1.3×10
-2
 
 33 3.1×10
-2
 1.3×10
-2
 
 36 - 1.4×10
-2
 
 39 3.2×10
-2
 1.6×10
-2
 
 42 - 1.6×10
-2
 
 45 4.5×10
-2
 1.7×10
-2
 
 51 4.1×10
-2
 - 
 57 4.0×10
-2
 - 
 63 5.0×10
-2
 - 
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Figure ‎4.5 Plots of the values of observed first order rate kobs(f) (circles) and kobs(s) (squares) for the 
HbO2 oxidation reaction as a function of [Fe
III
(DpxxT)2]
+
 concentration under the condition 
indicated in the experimental chapter; (a) [Fe(Dp4mT)2]
+
; (b) [Fe(DpT)2]
+
, (c) [Fe(Dp4eT)2]
+
 and 
(d) [Fe(Dp44mT)2]
+
.  
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As a whole the data shown corresponds typically to an average of 3-run replicates (on a 300 
s timescale with manual mixing) or 5-run (stopped flow, 30-50 sec). Table 4.2 shows the derived 
second order rate constants (kf and ks) for the reactions studied from the slopes of the lines in Figure 
4.5. 
 
Table ‎4.2 Second order rate constants for the oxidation reaction of α HbO2 by [Fe
III
(DpxxT)2]
+
  
under the conditions indicated in the experimental chapter. 
 
Oxidant E[FeIII/II(DpxxT)2]+/0 /mV kf /M
–1
s
–1
 ks /M
–1
s
–1
 
[Fe(DpT)2]
+ 
+165 1.9(6) × 10
3
 9.2(4) × 10
2 
[Fe(Dp4mT)2]
+ 
+153 9.5(4) × 10
2 
3.7(1) × 10
2 
[Fe(Dp4eT)2]
+ 
+173 9.2(3) × 10
2 
3.2(1) × 10
2 
[Fe(Dp44mT)2]
+ 
+166 8.1(4) × 10
2 
4.1(1) × 10
2 
 
 
4.4   Biological significance 
 
In previous investigations it has been found that, both the high stability and the redox activity 
of thiosemicarbazone iron complexes [Fe
III
(DpxxT)2]
+
 is linked with their anti-proliferative activity 
against a variety of cancer cell lines.
119,
 
118,
 
124
 This was supported by an experiment with the 
analogue Dp2mT (Chart 4.1) where a methyl group occupies the position normally taken by the 
labile proton on N2. This ligand cannot be deprotonated, does not form a stable iron complex and 
the ligand did not promote metHb production.
120
 Redox activity of the Fe complex is undoubtedly a 
requirement for the catalysed formation of metHb in addition to Fe complexation (Equation 4.1). 
Administration of uncomplexed thiosemicarbazone ligands such as 3-AP or the HDpxxT analogues 
may lead to the formation of Fe complexes in vivo through sequestration of weakly bound Fe in the 
cell or in serum.
256
 Thus, the Fe complexes of 3-AP and the HDpxxT analogues are the cause of 
methemoglobinemia.
256
 The high affinity of the HDpT analogues for Fe over strong Fe chelators 
such as desferrioxamine B (DFO, Chart 4.1) has already been demonstrated.
141
 However, highly 
stable Fe complexes are not enough to explain the HbO2 oxidation reactivity. For example, 
ferrioxamine B (the Fe
III
 complex of DFO) has a low Fe
III/II
 redox potential and has no significant 
redox activity in biological systems; certainly administration of free DFO does not induce metHb 
formation despite its high ability to bind iron.
256
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Considering the mechanism of oxidation of HbO2, we suggest outer–sphere electron transfer 
occurs between all iron complexes [Fe
III
(DpxxT)2]
+
 and the exposed edge of the heme cofactor 
bound to the protein. The structure of  the thiosemicarbazone Fe
III
 complexes are well understood 
and all comprise six-coordinate complexes with no labile coordination sites.
119,
 
124
 Santucci et al. 
determined the deoxyHb/metHb redox potential which is +0.160 V vs NHE at pH 7,
266
 but this 
redox potential should be interpreted cautiously as the actual precursor in this case (and in vivo) is 
HbO2 and not deoxyHb and dioxygen binding stabilises the protein against oxidation to metHb. 
Although deoxyHb has been shown to undergo direct outer sphere oxidation by small molecular 
weight compounds such as ferricyanide,
258
 it is still theoretically possible that HbO2 reacts with an 
oxidant before oxygen dissociation. Indeed it has been shown in the redox reaction between 
ferricyanide and oxymyoglobin (MbO2) that both deoxyMb and MbO2 must be considered as redox 
active precursors to metMb.
172
  Eguchi and Saltman found that deoxyHb was three orders of 
magnitude more reactive than HbO2
166,167
 which is consistent with the mechanism illustrated in 
Scheme 4.1. That is oxygen dissociation (reactions 1 and 3 in Scheme 4.1) proceedes the redox 
reaction (reactions 2 and 4). In addition to that the first order rate constant for dissociation of the 
first oxygen molecule from tetrameric α22-HbO2 is ca. 20 s
-1
 which is much faster than the overall 
reaction observed in this investigation,
267
 indicating that oxygen dissociation is not rate limiting. 
However, in this previous study
166
 the overall stoichiometry of the reaction (one Fe
III
 complex 
required for every oxyheme cofactor) and the possibility of partially (de)oxygenated Hb proteins 
was not addressed. Also, it was assumed the  and  chains of HbO2 reacted independently. 
Nevertheless, our results do not agree with this finding and two distinct reactions are seen in all 
cases with second order rate constants differing generally by at least a factor of two. 
Interestingly, it appears that [Fe
III
(DpT)2]
+  
is the most reactive complex of the series toward 
HbO2 oxidation (Table ‎4.2).  The differences in rate constants indicated in Table 4.2 (both fast and 
slow) do not correlate with the previously determined Fe
III/II
 redox potentials of the [Fe(DpxxT)2]
+
 
complexes.
119
 It would be expected that an increase in HbO2 oxidation rate with the strength of the 
oxidant should be seen from Marcus theory for a series of structurally related complexes 
undergoing the same outer sphere redox reaction.
268
 However, the four Fe complexes examined 
here exhibit very similar redox potentials (Table ‎4.2), highlighting that other factors appear to be 
responsible for the differences in the rate constants for the oxidation reactions. 
The ligand structures in Chart 4.1 indicate that HDpT is the only one not having any 
substituents on the terminal N-atom (N
4
), enabling its complex  [Fe
III
(DpT)2]
+  
to approach the heme 
cofactor more closely. Also the terminal –NH2 group is an excellent H-bond donor and may interact 
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(4.2) 
with the solvent exposed heme propionate groups. Each heme cofactor bears two of these 
propionate groups and H-bonding with these strong acceptors can be expected as the Fe
III
 complex 
approaches the heme. [Fe
III
(DpT)2]
+
 has no substituents that might interfere with this interaction 
while the other three compounds bear methyl (one or two) or ethyl groups at this terminal amine 
thus hindering a close approach of  the complex (Figure ‎4.6). It appears that the distances between 
the heme and Fe complex determine the rates of oxidation of HbO2 by [Fe
III
(DpxxT)2]
+
.
269
 In 
addition, strong outer-sphere complexes have also been proven to be a determinant in the tuning of 
the redox potentials of otherwise endergonic (thermodynamically unfavourable) redox processes.
145,
 
270,
 
141
 In this regard, a curvature in the relationship between kobs and iron complex concentration is 
expected according to equation 4.2 where Kcomp is the outer sphere association constant between 
HbO2 and the [Fe(DpxxT)2]
+
 complex.
271,
 
272
  
 
However, the observation of any curvature in a plot of kobs versus [Fe] requires a larger 
concentration range than was experimentally possible. The [Fe(DpxxT)2]
+
 complexes are strongly 
coloured and this limited the maximum complex concentration that could be used in our 
experiments in order to still be able to see observe changes in the heme spectrum. Under these 
conditions Kcomp[Fe] « 1 so the denominator in Equation 4.2 is essentially unity and a linear 
increase in kobs is found as a function of Fe complex concentration.  
 
 
 
 
 
 
Figure ‎4.6 Qualitative representation of the H-bonding capability of the -NH2 groups of 
[Fe
III
(DpT)2]
+
 with the heme propionates in HbO2. Coordinates of each unit were taken from 
published crystal structures of HbO2
165
 and [Fe
III
(DpT)2]
+
 
235
 then merged. No energy minimisation 
has been attempted. 
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4.5 Summary 
 
The oxidation of dimeric oxyhemoglobin (HbO2) to methemoglobin (MetHb) by 
biologically active iron-thiosemicarbazone complexes has been identified. It has been found that the 
reaction proceeds with two distinct time-resolved steps corresponding to separate oxidation of the 
α- and β-chains in the protein. The changes in the spectra with time indicate the existence of an 
intermediate half metHbO2 that is eventually oxidised to the final product metHb. [Fe
III
(DpT)2]
+  
is 
the most reactive complex and exhibits a two-fold enhanced oxidation rate of HbO2 relative to other 
complexes in the series although all complexes have very similar redox Fe
III/II
 potentials. This is can 
be attributed to desirable steric and H-bonding effects that enable iron thiosemicarbazone complex 
to more closely approach the heme co-factor, making outer-sphere electron transfer more rapid.  
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Chapter 5   Kinetics and Mechanism of Methemoglobin Generation by 
Iron(III) Complexes of 2-Benzoylpyridine Thiosemicarbazone Series 
(HBpT) and 2-Acetylpyridine Thiosemicarbazone Series (HApT). 
 
5.1 Overview 
 
As discussed in Chapter 4, the HDpT family of thiosemicarbazones in complex with Fe
III
 
induce the oxidation of oxy-hemoglobin (HbO2) to met-hemoglobin (metHb). This oxidation 
reaction proceeds with two different time resolved steps corresponding to separate oxidation of the 
α and β- chains in the protein. Therefore, in a continuation of the study of the mechanism and the 
kinetics of this reaction, we examined the Fe
III
 complexes of the related HBpT and HApT series, 
which are structurally similar to HDpT analogues. 
As described in Chapter 1, the HDpT series may be altered by choice of a different parent 
ketone. Using 2-benzoylpyridine (instead of di-2-pyridyl ketone) a phenyl ring may be introduced at 
the imine carbon (instead of a non-coordinating pyridyl ring), generating the 2-benzoylpyridine 
thiosemicarbazone series (HBpT) (Chart 5.1). These chelators similarly bind iron through a set of 
NNS donor atoms, forming highly stable Fe
II 
and Fe
III
 complexes with a 2:1 ligand to Fe ratio.
124
 
Furthermore, many of the HBpT chelators were found to exhibit more potent anti-cancer activity 
than the corresponding HDpT series.
124
 Moreover, these ligands showed high selectivity for cancer 
cells IC50 value (> 1500 fold) over normal cells.  
Replacing the electron withdrawing (non-coordinating) pyridyl ring in the HDpT series with 
an electron donating methyl group is achieved by using 2-acetyl pyridine which leads to the 2-
acetylpyridine thiosemicarbazone analogues (HApT) (Chart 5.1). Once again, these chelators utilize 
the same NNS donor set and form 1:2  Fe:ligand complexes. Some of these chelators displayed even 
greater anti-proliferative activities (IC50 = 0.001-0.002 μM) that was comparable to the most 
effective ligand HDpT and HBpT analogues.
127
  
Although preliminary investigations on selected Fe
III 
complexes of biologically active 
thiosemicarbazone indicated that [Fe
III
(Dp44mT)2]
+
 and  [Fe
III
(Bp4eT)2]
+
 induced HbO2 oxidation 
on intact human erythrocytes (red blood cells), erythrocyte lysates and purified oxyhemoglobin, the 
mechanism of such oxidation has not been investigated.
256
  
Considering the above, in this chapter we report a kinetic study on the ability of the Fe
III
 
complexes of HBpT and HApT series to promote metHb generation in vitro (i.e. a process linked 
with oxidative stress in vivo).  
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Chart 5.1 2-Benzoyl pyridine and 2-acetyl pyridine thiosemicarbazones ligands investigated in this 
Chapter.  
 
5.2 Oxidation reactions 
 
Kinetic investigations of the oxidation reactions of HbO2 by the iron complexes of HBpT 
series (HBpT, HBp4eT, HBp4mT and HBp44mT) and HApt series (HApT, HAp4mT and 
HAp44mT) (Chart 1.5) have been undertaken under the same conditions as the HDpT series 
(Chapter 4). Initial concentration of α22-HbO2 was  7.5×10
-7 
M (3×10
-6
 M total heme) and the α- 
and -chains react at different rates (biphasic process) in line with known auto-oxidation kinetics;161 
each α-HbO2 dimer being in equilibrium with its tetramer. Hence, we consider α-HbO2 (within 
its tetramer or isolated dimer) as the reactive species in all cases and no more than two phases of the 
reaction were identified. Reaction of the two heme groups of the α dimer with two FeIII 
thiosemicarbazone complexes (HBpT and HApT series) is required to reach fully oxidised metHb 
(Equation 5.1).   
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αHbO2 +  2 [Fe
III
(L)2]
+
 αmetHb + 2 [FeII(L)2] + 2 O2                                  (5.1)    
2 [Fe
II
(L)2] +   O2 + 2H
+
             [Fe
III
L2]
+
  + H2O2      L= BpT
-
 or ApT
- 
series      (5.2)   
 
 The mechanism of the Hb oxidation reaction (Equation 5.1) is complicated and involves 
oxy/deoxy-hemoglobin equilibria, and oxidation actually involves the deoxyHb form as the reactive 
intermediate (not shown here), as found in the previous investigation of the HDpT series. The 
reactions have been followed by time-resolved UV-Vis spectrophotometry in the 400-800 nm 
wavelength range, which show a set of spectral changes (Figure 5.1 to 5.4) consistent with 
sequential oxidation of the two heme groups in the α HbO2 moiety. These results mirror those of 
the HDpT series which show the decrease in intensity of the HbO2 bands at 577 and 539 nm with an 
increase in intensity and hypsochromic shift of the Soret band at 404 nm which is due to the 
conversion of HbO2 into metHb.
232
 Furthermore, the increase in absorbance of the broad maximum 
around 620 nm can be attributed to metHb although the Fe
II 
thiosemicarbazones complexes also 
absorb in this region. However, oxidation of the second heme by Fe
III 
of the HApT series yields a 
significantly less intense band at ~650 nm compared to the HDpT series. The reason for such 
observations is that there is another reaction followed the formation of metHb and [Fe
II
(ApxxT)2] 
complexes which is the oxidation of the [Fe
II
(ApxxT)2] complex to [Fe
III
(ApxxT)2]
+
 as shown in 
Equation 5.2. The iron complexes of this series display quite low redox potentials
127
 making the 
second reaction (Equation 5.2)  much faster compared to that of  the HDpT and HBpT series. The 
HBpT series Fe complexes give spectra somewhere between the HDpT and HApT series due to 
their intermediate redox potentials. 
124
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Figure ‎5.1 Time resolved UV-Vis spectral changes (first step) of a solution 27 M of (a) 
[Fe
III
(Bp4mT)2]
+
, (b) [Fe
III
(Bp44mT)2]
+
, (c) [Fe
III
(Bp4eT)2]
+
, (d) [Fe
III
(BpT)2]
+and α HbO2 
(1.5M heme) under the conditions indicated in the experimental chapter (Total time 50 s, 
cycle time 0.25 s). 
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Figure ‎5.2 Time resolved UV-Vis spectral changes (second step) of a solution 27 M of (a) 
[Fe
III
(Bp4mT)2]
+
, (b) [Fe
III
(Bp44mT)2]
+
, (c) [Fe
III
(Bp4eT)2]
+
, (d) [Fe
III
(BpT)2]
+
 and α HbO2 
(1.5M heme) under the conditions indicated in the experimental chapter(Total time 300 s, 
cycle time 6.4 s). 
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 Figure ‎5.3 Time resolved UV-Vis spectral changes of a solution 33 M of (a) [FeIII(Ap4mT)2]
+
,  
(b) [Fe
III
(Ap44mT)2]
+
, (c) [Fe
III
(ApT)2]
+
 and αHbO2 (M; 3.0 M heme) under the conditions 
indicated in the experimental chapter (Total time 50 s, cycle time 0.25 s). 
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Figure ‎5.4 Time resolved UV-Vis spectral changes of a solution  of (a)[FeIII(Ap4mT)2]
+
,  (b) 
[Fe
III
(Ap44mT)2]
+
, (c) [Fe
III
(ApT)2]
+
 and αM; 3.0 M heme) under the conditions 
indicated in the experimental chapter(Total time 300 s, cycle time 6.4 s). 
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5.3 Kinetic analysis 
 
Modelling the time-resolved spectral changes was achieved by global analysis (of the entire 
wavelength range) with ReactLab Kinetics.
226
 In all cases at least a 10-fold excess of Fe
III
 complex 
over heme was used so that the concentration of Fe
III
 remained effectively constant i.e. pseudo first 
order kinetics. The results are consistent with a biphasic reaction comprising two consecutive 
(pseudo) first order reactions (Figures 5.5 to 5.8). In this regard, the Fe
III
 complexes of both 
HBpxxT and HApxxT series oxidised each heme group in a second order outer sphere electron 
transfer reaction. Consistent with this is the observation of the intermediate, half-metHbO2 species 
whose calculated spectrum is consistent with a convolution of 50% HbO2 and 50% metHb, 
indicating an independence of the two chromophores. 
A stopped flow instrument was used to determine the faster reaction rate (kobs(f)) and the 
data were collected over a period of 50 s while standard manual mixing procedures were used to 
determine the slower reaction (kobs(s)) over a period of 300 s.  During the 50 s period, the faster step 
is dominant and overlap with the subsequent oxidation reaction is minor. An example is shown in 
Figures 5.5 and 5.6. In some cases, two consecutive exponential functions could be used to fit all 
the data over a period of 300 s (slow reaction); an example illustrated in Figures 5.7 and 5.8. The 
consistent differences between these two steps can be attributed to the distinctly different reactivity 
of the  and -chains,161 and also cooperative effects expected in the protein where 
conformational changes coupled to oxygen release affect the other chains within the protein. The 
same phenomenon was found in the oxidation of HbO2 by Fe
III
 complexes of the HDpxxT series 
(Chapter 4).  
However, it is interesting to note that  the calculated (composite) spectra of both metHb and 
the Fe
II
 product exhibited only a very weak  Fe
II
-to-ligand charge-transfer band at 650 nm in 
comparison to that of [Fe
III
(Dp44mT)2]
+
 and [Fe
III
(Bp44mT)2]
+
 (Figure 5.9). As discussed in the 
previous Section (‎5.2),  the [FeIII(ApxxT)2]
+
  series have the lowest redox potential, highlighting  
that the second reaction (Equation 5.2), where the Fe
II
 complexes are oxidized by dioxygen to more 
stable Fe
III 
 complexes rapidly in contrast to those with the highest redox potential [Fe
III
(DpxxT)2]
+
  
series as illustrated in Figure ‎5.9.  
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Figure ‎5.5 ReactLab Kinetics calculated time dependent concentrations (a) fast step (50 s) of HbO2 
(dark red), half-metHbO2 (green), and (b) slow step (300s) of half-metHbO2 (green) and metHb 
(blue). Calculated spectra (c) fast step HbO2 (dark red), half-metHbO2 (green), and (d) slow step for 
half-metHbO2 (green), and metHb (blue). Note: all spectra include a contribution of the 27 M of 
[Fe
III
(Bp4mT)2]
+
 solution which remains constant during the reaction (pseudo-first order 
conditions). 
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Figure ‎5.6 (a) ReactLab Kinetics calculated time dependent concentrations (a) fast step (50 s) of 
HbO2 (dark red), half-metHbO2 (green), and (b) slow step (300 s) of half-metHbO2 (green) and 
metHb (blue). Calculated spectra (c) fast step HbO2 (dark red), half-metHbO2 (green), and (d) slow 
step for half-metHbO2 (green), and metHb (blue). Note: all spectra include a contribution of the 
33M of [FeIII(Ap4mT)2]
+
 solution which remains constant during the reaction (pseudo-first order 
conditions).            
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Figure ‎5.7 (a) ReactLab Kinetics calculated time dependent concentrations of HbO2 (dark red), 
half-metHbO2 (green), and metHb (blue) and (b) calculated spectra for HbO2 (dark red), half-
metHbO2 (green), and metHb (blue). Note: all spectra include a contribution of the 27 M of 
[Fe
III
(BpeT)2]
+
 solution which remains constant during the reaction (pseudo-first order conditions). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎5.8 (a) ReactLab Kinetics calculated time dependent concentrations of HbO2 (dark red), 
half-metHbO2 (green), and metHb (blue) and (b) calculated spectra for HbO2 (dark red), half-
metHbO2 (green), and metHb (blue). Note: all spectra include a contribution of the 27 M of 
[Fe
III
(ApT)2]
+
 solution which remains constant during the reaction (pseudo-first order conditions). 
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Figure ‎5.9 Comparison between the calculated spectra of the slow step for half-metHbO2 (green), 
and metHb (blue) of (a) [Fe
III
(Dp44mT)2]
+
, (b) [Fe
III
(Bp44mT)2]
+ 
and (c) [Fe
III
(Ap44mT)2]
+
. Note: 
all spectra include a contribution of the 27M of FeIII complexes. 
 
As expected, it was found that both oxidation steps are dependent on the concentration of 
the Fe
III
 complex in excess. The values for kobs(f) and kobs(s) as presented in Table 5.1 follow a 
linear relationship with the concentration of  the  Fe
III
 complexes  (Figure ‎5.10 and Figure ‎5.11) 
with essentially a zero intercept which is equivalent to the relatively insignificant auto-oxidation 
rate constant  (10-6 s-1). Across all Fe concentrations, there was no sign of any curvature in the 
plots, and thus no evidence for a significant pre-equilibrium between HbO2 and the Fe
III
 complex 
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prior to electron transfer. In addition, the data display a rather large scatter due to the proximity of 
kobs(f) and kobs(s) which prevents a clean separation of the two steps. Dioxygen bubbles evolved in the 
reaction medium as presented in Equation 5.1 also result in baseline instabilities for reactions run 
over periods of minutes.  
 
 
L [ [Fe
III
(L)2]
+ 
] /M kobs(f) /s
–1
 (stopped-flow) kobs(s) /s
–1
 (manual mixing) 
BpT 15 2.8×10-2 - 
 18 3.1×10
-2
 - 
 21 3.5×10
-2
 - 
 24 - 1.8×10
-2
 
 27 4.1×10
-2
 1.9×10
-2
 
 30 - 2.0×10
-2 
 33 6.4×10
-2 2.2×10-2 
 36 - 2.5×10
-2 
 39 6.8×10
-2 2.6×10-2 
 42 - 2.6×10
-2
 
 45 8.3×10-2 2.7×10-2 
 51 - - 
Bp4mT 15 1.7×10-2 - 
 18 2.3×10
-2
 - 
 21 2.1×10-2 - 
 24 2.0×10
-2
 - 
 27 2.7×10
-2
 1.2×10
-2
 
 30 2.6×10
-2 1.5×10-2 
 33 3.4×10
-2
 - 
 36 - 1.7×10
-2
 
 39 3.7×10
-2
 - 
 42 - 1.9×10
-2
 
 45 5.0×10
-2
 1.9×10
-2
 
 51 4.9×10
-2
 - 
 57 5.8×10
-2
 - 
Bp4eT 15 - - 
 18 - - 
 21 2.3×10
-2
 - 
 24 - - 
 27 3.1×10
-2
 8.7×10
-3
 
 30 - - 
 33 3.8×10
-2
 1.1×10
-2
 
 36 - - 
 39 4.1×10
-2
 1.0×10
-2
 
 42 - - 
 45 4.2×10
-2
 9.8×10
-3
 
 51 5.3×10
-2
 1.2×10
-2
 
(c) 
Table ‎5.1 Values of kobs obtained for the redox processes between the αHbO2 dimer and the 
[Fe
III
(BpxxT)2]
+
  and [Fe
III
(ApxxT)2]
+
  complexes studied, T = 25 ºC, [HbO2] = 1.5×10
–6
 M. 
\ 
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Bp44mT 15 1.3×10-2 - 
 18 - - 
 21 2.3×10
-2
 8.4×10
-3
 
 24 - 6.4×10
-3
 
 27 2.3×10
-2
 9.8×10
-3
 
 30  9.4×10-3 
 33 4.2×10
-2
 9.6×10
-3
 
 36 - 8.2×10
-3
 
 39 3.9×10
-2
 1.2×10
-2
 
 42 - - 
 45 3.6×10
-2
 - 
 51 4.1×10
-2
 1.8×10
-2
 
ApT 15 2.7×10
-2
 5.8×10
-3
 
 18 - 8.0×10
-3
 
 21 4.6×10
-2
 - 
 24 - 9.7×10
-3
 
 27 6.2×10
-2
 1.0×10
-2
 
 30 - 1.1×10
-2
 
 33 - - 
 36 - - 
 39 6.2×10
-2
 - 
 42 - - 
 45 - - 
 51 8.1×10
-2
 - 
Ap4mT 15 1.2×10
-2
 - 
 18 - - 
 21 - 4.1×10-3 
 24 - 5.6×10
-3
 
 27 - 5.1×10
-3
 
 30 - 5.3×10-3 
 33 2.4×10
-2
 6.8×10
-3
 
 36 - 6.0×10
-3
 
 39 - - 
 42 - - 
 45 3.4×10
-2
 - 
 51 4.3×10
-2
 - 
Ap44mT 15 - - 
 18 - - 
 21 1.5×10
-2
 8.4×10
-3
 
 24 - 6.4×10
-3
 
 27 2.1×10
-2
 9.8×10
-3
 
 30 - 9.4×10
-3
 
 33 2.4×10
-2
 9.6×10
-3
 
 36 - 8.2×10
-3
 
 39 3.7×10
-2
 1.2×10
-2
 
 42 - - 
 45 3.3×10
-2
 - 
 51 3.5×10
-2
 1.8×10
-2
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Figure ‎5.10 Plots of the values of observed first order rate kobs(f) (circles) and kobs(s) (squares) for the 
HbO2 oxidation reaction as a function of [Fe
III
(BpxxT)2]
+
 concentration under the condition 
indicated in the experimental chapter; (a) [Fe(Bp4mT)2]
+
; (b) [Fe(BpT)2]
+
, (c) [Fe(Bp4eT)2]
+
 and 
(d) [Fe(Bp44mT)2]
+
.  
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Figure ‎5.11 Plots of the values of observed first order rate kobs(f) (circles) and kobs(s) (squares) for the 
HbO2 oxidation reaction as a function of [Fe
III
(ApxxT)2]
+
 concentration under the condition 
indicated in the experimental chapter; (a) [Fe(Ap4mT)2]
+
; (b) [Fe(ApT)2]
+ 
and  (c) [Fe(Ap44mT)2]
+
. 
 
 
 
 
 
 
(a) (b) 
(c) 
0.0 1.0x10
-5
2.0x10
-5
3.0x10
-5
4.0x10
-5
5.0x10
-5
6.0x10
-5
0.00
0.01
0.02
0.03
0.04
 kf
 ks
[Fe(Ap4mT)
2
]
+
+ HbO
2
k
o
b
s(
s-
1
)
[Fe]
 
(M)
0.0 1.0x10
-5
2.0x10
-5
3.0x10
-5
4.0x10
-5
5.0x10
-5
6.0x10
-5
0.00
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
0.09
[Fe(ApT)
2
]
+
 + HbO
2
kf
ks
k
o
b
s
(S
-1
)
[Fe]
 
(M)
0.0 1.0x10
-5
2.0x10
-5
3.0x10
-5
4.0x10
-5
5.0x10
-5
6.0x10
-5
0.00
0.01
0.02
0.03
0.04
[Fe(Ap44mT)
2
]
+
 + HbO
2
 kf
ks
k
o
b
s(
S
-1
)
[Fe] (M)
5 Kinetics and Mechanism of Methemoglobin Generation by Iron(III) Complexes of 2-Benzoylpyridine Thiosemicarbazone Series 
(HBpT) and 2-Acetylpyridine Thiosemicarbazone Series (HApT). 
 
111 
 
All the data are shown as an average of 5-runs (on 50 s time scale with a stopped flow 
instrument) or 3-run replicates (manual mixing, 300 s) and the derived second order rate constants 
(kf and ks) are presented in Table 5.2. 
 
Table ‎5.2 Second order rate constants for the oxidation reaction of the α HbO2 by [Fe
III
(BpxxT)2]
+
  
and [Fe
III
(ApxxT)2]
+
  in comparison with [Fe
III
(DpxxT)2]
+
 under the conditions indicated in the 
experimental chapter. 
 
 
 
5.4 Biological significance 
 
The high affinity of thiosemicarbazone chelators to bind iron and the redox-activity of their 
iron complexes are essential in metHb formation as described previously.
124,
 
119, 256 
 This was 
supported by using the analog Dp2mT which is methylated at the N atom in the 2-position which 
normally bears a dissociable proton. As this ligand cannot be ionised it has a poor affinity for Fe 
and consequently cannot form a redox active Fe complex. The ligand Dp2mT does not promote 
metHb formation in red blood cells.
120
 In addition, administrations of DFO did not potentiate 
metHb generation despite its high ability to bind iron due to the redox inactive of its iron 
complex.
256
 This has been discussed in more detail in Chapter 4. As seen for the Fe
III
 complexes of 
Oxidant E[FeIII/II(L)2]
+/0/mV kf /M
–1
s
–1
 ks /M
–1
s
–1
 
[Fe
III
(DpT)2]
+
 +165 1.9(6) × 10
3
 9.2(4) × 10
2 
[Fe
III
(Dp4mT)2]
+
 +153 9.5(4) × 10
2 
3.7(1) × 10
2 
[Fe
III
(Dp4eT)2]
+
 +173 9.2(3) × 10
2 
3.2(1) × 10
2 
[Fe
III
(Dp44mT)2]
+
 +166 8.1(4) × 10
2 
4.1(1) × 10
2 
[Fe
III
(BpT)2]
+
 +120 1.8(5) × 10
3
 6.6(1) × 10
2 
[Fe
III
(Bp4mT)2]
+
 +108 1.0(2) × 10
2 
4.5(1) × 10
2 
[Fe
III
(Bp4eT)2]
+
 +99 1.1(3) × 10
3 
2.6(2) × 10
2 
[Fe
III
(Bp44mT)2]
+
 +119 9.2(6) × 10
2 
3.1(2) × 10
2 
[Fe
III
(ApT)2]
+
 +20 1.7(1) × 10
3
 3.9(1) × 10
2 
[Fe
III
(Ap4mT)2]
+
 -3 7.9(3) × 10
2 
1.9(1) × 10
2 
[Fe
III
(Ap44mT)2]
+
 +49 7.7(4) × 10
2 
1.3(1) × 10
2 
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the HDpxxT analogs in Chapter 4, an outer–sphere electron transfer mechanism in which electron 
transfer occurs between all iron complexes ([Fe
III
(BpxxT)2]
+  
or  [Fe
III
(ApxxT)2]
+
)
   
and exposed edge 
of the heme cofactor within the protein. An inner sphere mechanism can be ignored as firstly the 
Fe
III
 complexes bear no labile coordination sites at accommodate a bridging ligand and also their 
dimensions exceed a diameter of 10 Å which is too large to enter the heme pocket adjacent to the 
coordinated dioxygen ligand.
124,
 
119
 Curvature in the plot of kobs versus iron complex concentration 
was not observed as would be predicted by Equation 4.2 in Chapter 4.
271,
 
272
 However, only a 
relatively small concentration range of the Fe complexes was examined. It is likely that at very high 
Fe concentrations curvature would be seen towards a saturating value of kobs but this could not be 
tested as the strong absorbance of the Fe
III
 thiosemicarbazone complexes eventually obscured the 
spectrum of the heme protein entirely (see experimental chapter), as found with [Fe
III
(DpxxT)2]
+ 
. 
There was no correlation between the previously determined Fe
III/II
 redox potentials of the 
[Fe(BpxxT)2]
+
 or  [Fe
III
(ApxxT)2]
+ 
complexes  and  the differences in  the rate constants (both fast 
and slow). The Fe
III/II
 redox potentials of the three series of thiosemicarbazone complexes follow a 
clear pattern with  E
'
([Fe(DpxxT)2]
+/0
) >  E
'
([Fe(BpxxT)2]
+/0
) > E
'
([Fe(ApxxT)2]
+/0
) as shown in 
Table 5.2 reflecting the substituent effects of the non-coordinating pyridyl, phenyl and methyl 
groups respectively. However, despite the [Fe
III
(BpxxT)2]
+
 complexes being weaker oxidants than 
the [Fe
III
(DpxxT)2]
+
 analogs (and [Fe
III
(ApxxT)2]
+
 being less oxidising than [Fe(BpxxT)2]
+
)
 
there is 
no systematic decrease in HbO2 oxidising activity linked to redox potential as presented in Table 
5.2.
124,127
  Thus, there are other factors likely to differentiate these rate constants. 
Once again the N4-unsubstituted complexes [Fe
III
(BpT)2]
+ 
and  [Fe
III
(ApT)2]
+ 
 represent the 
most reactive oxidants in the conversion of HbO2 to metHb, similar to [Fe
III
(DpT)2]
+
 (Chapter 4) as 
shown in Table ‎5.2. Considering the structures of  HDpT (Chart 4.1), HBpT and HApT (Chart 5.1),  
all ligands lack substituents at the terminal amine (N4). This reduces steric bulk in the vicinity of 
N4 and also provides a pair of H-bond donors. Hence, this kind of structure provides two 
advantages; lowering steric effects and increasing H-bonding contact with the carboxylate external 
edge of the heme group which increases the outer sphere electron transfer rate constant between 
HbO2 and [Fe
III
(BpT)2]
+
 or [Fe
III
(ApT)2]
+
 by two-fold compared to other N4-substituted complexes 
in Table ‎5.2 which bear methyl (one or two) or ethyl groups at this terminal amine, thus hindering a 
close approach of the complex.  
The comparison between [Fe
III
(BpxxT)2]
+  
and [Fe
III
(ApxxT)2]
+ 
 and previously discussed 
  
 
[Fe
III
(DpxxT)2]
+ 
(Chapter 4) indicated that there are no significant differences in the rate constants 
of the fast reactions (kf). There are slight differences in the slower rate constants across the three 
series but they are barely significant (Table ‎5.2). 
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5.5 Summary 
The mechanism and kinetics of the oxidation of oxyhemoglobin  (HbO2) to methemoglobin 
(metHb) by biologically active iron(III) complexes of the 2-benzoylpyridine thiosemicarbazone 
series (HBpT) and 2-acetylpyridine thiosemicarbazone series (HApT) have been reported. The time 
resolved spectral changes are consistent with an intermediate semi-oxidised form that then is 
oxidised in a second slower reaction to the completely oxidised metHb, corresponding to separate 
oxidation of the  α - and β-chains in the protein. Interestingly, both [FeIII(BpT)2]
+ 
 and [Fe
III
(ApT)2]
+ 
complexes show a two-fold enhanced oxidation rate of -HbO2, when compared with the rest of 
the complexes with very similar redox Fe
III/II
 potentials but with substituents on the terminal N 
atom. This could be attributed to a combination of favourable steric and H-bonding effects that 
enable a closer and more efficient approach between the iron thiosemicarbazone complex and the 
heme co-factor, thus  the outer-sphere electron transfer becomes more rapid. 
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Chapter 6 Fluorescent Iron Chelators and their Complexes 
 
 
 
6.1 Overview 
 
Designing and developing chelation therapies for iron overload disorders has attracted much 
attention.
65-69
 These chelators ideally show high activity in mobilizing intracellular Fe by 
complexing labile (non-protein bound) and excrete it from the body as an intact Fe complex. 
However, the mechanism of how these chelators access Fe and their intracellular location are not 
well defined. Due to its high sensitivity and its high spatial resolution, fluorescence is a popular 
spectroscopic method for cellular imaging if a bifunctional fluorescent chelator can be made which 
is also capable of binding Fe. Therefore, the development of fluorescent probes for the efficient 
detection of iron in cells and also the mechanisms of iron trafficking have received considerable 
interest in recent years.
180,181
 The vast majority of reported fluorescent probes employed for imaging 
iron in living cells are based on a quenching of the fluorescence of a free ligand upon iron binding; 
so called ‗turn-off‘ sensors.180,181,189,190,196,273-278 Some examples include the commercially available 
reagents Calcein
187,188
 and Phen Green SK.
190, 189
 These sensors present technical difficulties 
because a positive signal due to Fe binding is difficult to quantify as it does not come from a ‗zero‘ 
background but instead from a decrease in fluorescence relative to a control where fluorescence is 
stronger. Designing ‗turn-on‘ fluorescent sensors, which only fluoresce when complexed with Fe, is 
more challenging as the usually paramagnetic ion often quenches fluorescence (Calcein and Phen 
Green SK). Other issues to be overcome include cell membrane permeability, selectivity for Fe over 
other metal ions and solubility.  
In this Chapter the Fe coordination chemistry of a range of new fluorescent chelators 
derived from heterocyclic hydrazone and hydrazine Fe chelators is presented. The fluorophores 
attached to the chelating group include rhodamine B and boron dipyrromethene (BODIPY) (Chart 
6.1). As mentioned above ideal turn-on probes are non-fluorescent in their uncomplexed form but 
become fluorescent in complex with iron. All free ligands and their 2:1 ligand:Fe complexes have 
been prepared and spectroscopically and electrochemically characterized. UV-Visible 
spectroelectrochemistry of some of these complexes have been examined to characterise their 
oxidation state (Fe(II) or Fe(III)) in solution. Kinetics and mechanisms of protonation and 
complexation reactions of fluorescent rhodamine B chelators have also been investigated. 
Protonation is often in competition with complexation and can often produce the same fluorescent 
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response from a turn-on probe so it is important to understand both protonation and complexation 
reactions separately. 
  
 
 
 
Chart 6.1 Fluorescent iron chelators investigated in this Chapter. 
 
 
6.2 Fluorescent iron chelators and their iron complexes characterization 
6.2.1 Synthesis of fluorescent ligands and their iron complexes 
 
Fluorescent iron probes of bearing a rhodamine B fluorophore, namely PCRBH and APRBH 
(Chart 6.1) were synthesized by condensation between rhodamine B hydrazide and 2-
pyridinecarboxaldehyde or 2-acetylpyridine in toluene, as demonstrated in Scheme 6.1. Good yields 
(80-90%) were obtained after chromatography on neutral alumina. This procedure is slightly 
different compared to the procedure recently published by Chereddy
279
 and co-workers using  
methanol and silica column chromatography. Similarly, the BODIPY-derived ligand of BODIPY 
(HPCBODIPYH (Chart 6.1)) was synthesized by condensation between BODIPY hydrazide 
(experimental Chapter) and 2-pyridinecarbaldehyde in ethanolic solution. These fluorescent probes 
can coordinate using a common NNO donor set similar to the 2-pyridinecarbaldehyde benzoyl 
hydrazone  (HPCBH) and benzoyl picolinoyl hydrazine (H2BPH)  series.
68, 65, 69
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The iron coordination chemistry of these fluorescent chelators is explored here. The only 
fluorescent iron complex from this family that has been investigated so far was isolated and 
characterized by Chartres et al., namely HBPRBH.
213
 Hence, the synthesis and characterization of 
other iron
 
complexes with the fluorescent probes in Chart 6.1 were the focus of this chapter. 
Reacting PCRBH or APRBH with ferrous perchlorate in ethanol afforded the complexes 
[Fe
III
(PCRBH)2]
3+
 and [Fe
III
(APRBH)2]
3+
 respectively. Coordination  of these ligands always 
occurs by binding Fe via the pyridyl N-atom, imine N-atom and amide O-atom affording a 
tridentate coordination mode similar to the structurally related complex derived from HBPRBH.
213
 
Specifically coordination of the O-atom causes the lactam ring to open and the spiro C-atom 
becomes conjugated with the tricyclic ring system. This change in electronic structure is associated 
with the appearance of an intense electronic absorption maximum around 550 nm from which 
fluorescence may be observed (see Section ‎6.2.5).  
[Fe
II
 (PCBODIPYH)2] was synthesized by reacting HPCBODIPYH with ferrous perchlorate 
in basic MeCN solution. Once again, each tridentate ligand coordinates Fe
II 
through the amide O-
atom, pyridyl N-atom and imine N-atom similar to the structurally related hydrazone ligands.
68
 In 
this case no structural change to the fluorophore occurs. Purification of the Fe complexes with 
fluorescent chelators was achieved by recrystallization.  
6.2.2 IR spectroscopy 
 
The IR spectra of the fluorescent ligands are different compared to their iron complexes. 
The relevant IR vibrations of the carbonyl functional group of the free ligands PCRBH, APRBH 
and HPCBODIPYH appear at 1721, 1692 and 1648 cm
-1
, respectively. Upon complexation of these 
ligands PCRBH, APRBH and HPCBODIPYH, the C=O IR bands shifted to lower frequency (ca. 
1330 cm
-1
), indicating the coordination of iron involved the carbonyl O-atom. A similar observation 
was found in the structurally related chelators from the hydrazines (HPCBH)
68
 and  HBPRBH 
(Chart 6.1).
213
 Furthermore, the IR spectra demonstrate  that the (C=N) bands of the free ligands 
PCRBH and APRBH at ca. 1615 cm
-1
 are shifted to lower frequency in the spectra of iron 
Scheme 6.1 
Scheme 6.1 
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complexes (ca. 1584 cm
-1
) highlighting coordination via the imine nitrogen atoms as previously 
reported for the hydrazone
68
 and hydrazine ligands.
213
 It is apparent that the IR spectra of these 
fluorescent probes and their iron complexes are quite complex, especially in the range 1200-1600 
cm
-1
 due to the overlapping C=N and C=C vibrations from the aromatic rings. In addition to that the 
existence of perchlorate counter ions are obvious from strong bands at ca. 1067 cm
-1
 and 620 cm
-1
 
(medium intensity) for the iron complexes of PCRBH, APRBH. This mirrored the results of the 
Fe
III
 complex of the hydrazine fluorescent ligand HBPRBH, [Fe
III
(HBPRBH)2](ClO4)3, reported by 
Chartres et al.
213
. In contrast, the absence of any perchlorate IR bands in the Fe complex of 
HPCBODIPYH provides evidence for this being a Fe
II
 complex where the two ligands bind as 
deprotonated monoanions. 
6.2.3 NMR spectroscopy 
 
The 
1
H NMR spectra of the fluorescent probes derived from rhodamine B (PCRBH and 
APRBH) exhibit typical chemical shifts of the xanthene skeleton (see the experimental chapter). 
Furthermore, the 
13
C NMR spectra of these chelators PCRBH and APRBH display a signal at 
around 66 ppm, which is characteristic of the sp
3
 hybridised spiro carbon atoms. This confirms the 
existence of the spirolactam form as reported in the literature for the structurally similar 
compounds.
 279, 213,
 
210, 214 
 In regards to the spectral differences between these chelators, the APRBH 
ligand shows resonances at 2.38 and 17.2 ppm in the 
1
H and 
13
C respectively assigned to the methyl 
group in N=CCH3 which is not observed in the PCRBH chelator where a proton is present instead 
as presented in the experimental Chapter 2. 
The 
1
H spectrum of HPCBODIPYH in DMSO-d6 reveals the NH (amide) signal at ca. 12 
ppm which is characteristic of the E isomer and is similar to the previously discussed HPCIH 
(hydrazone) series; these structural assignments were supported by X-ray crystallography. 
68
 The 
1
H 
NMR resonance of the alternative Z-isomer appears further downfield due to intramolecular H-
bonding as illustrated in Scheme 6.2. 
 
 
 
 
 
 
 
 
6 Fluorescent Iron Chelators and their Complexes 
118 
 
6.2.4 X-ray crystal structure analysis 
 
The crystal structure of APRBH has been determined and a view of the chelator is shown in 
Figure 6.1. The crystal refinement data and selected bond lengths (Å) and angles (
o
) are listed in 
Table 6.1. This crystal structure confirms the spirolactam ring configuration (spiro atom C14), as 
indicated in the NMR spectra of this ligand. The xanthene moiety is orthogonal to the chelating 
NNO group due to the spiro C-atom as observed previously in similar compounds.
 213,
 
214, 280-282
  The 
2-pyridyl N atom (N1) is anti with respect to the imine N atom (N2) (Figure 6.1) and the E-isomer 
is present. The O2-C7 and N2-C6 bonds have double bond character (1.224(4) and 1.292(3) Å 
respectively, Table 6.1), similar to those reported for the structurally related hydrazones.
68
 
Contrastingly, N3-C7 has intermediate bond order (1.379(4) Å) and is slightly longer than that for a 
hydrazone.
68,
 
66
     
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎6.1 ORTEP view of the free ligand APRBH (30% probability ellipsoids shown at 293 K). 
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Table ‎6.1 Crystallographic data for APRBH. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Crystal Data  
Formula C35H37N5O2 
Mol. Wt 559.70 
Crystal system Monoclinic 
a (Å) 11.376(2) 
b (Å) 13.530(2) 
c (Å) 19.981(2) 
 (°) 93.508(19) 
V (Å
3
) 3069.7 (9) 
Å) 1.5418 
T (K) 293 
Z 4 
Space group P21/n 

(mm
-1
) 
0.452 
Total refs 14336 
Indep. refs 
Rint 
4877 
0.0504 
R1 (obs. data) 0.0737 
wR2 (all data) 0.1063 
Selected Bond Lengths (Å)  
O2-C7 1.224(4) 
N2-N3 1.388(3) 
N3-C7 1.379(4) 
N3-C14 1.499(4) 
N2-C6 1.292(3) 
C6-C35 1.486(6) 
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6.2.5 Electronic spectra of fluorescent ligands and their iron complexes 
 
The electronic spectra of the chelators (PCRBH and APRBH) in MeCN solution were very 
similar and their solutions were colourless, exhibiting no electronic maxima in the visible region 
(Figure 6.2). However, their Fe
III 
complexes in the same solvent exhibited a very intense peak at 
about 558 nm, giving them a dark red colour, with a shoulder at ca. 520 nm. The intense band is due 
to the delocalized xanthene moiety of the ring-opened amide form of the complexes. Additionally, 
there were new peaks at ca. 353 and 254 nm that did not appear in the spectra of the ring closed free 
ligands as illustrated in Figure 6.2. The electronic properties of these probes and their Fe
III
 
complexes are similar to that of a related hydrazine
213 
fluorescent probe and its Fe
III
 complex. 
 
Figure ‎6.2 UV-vis spectra of PCRBH and APRBH and their Fe
III
 complexes in MeCN. (The 
concentration of all solutions was 1×10
-5
 M). 
 
On the other aspect, the chelator HPCBODIPYH displayed an intense peak at 502 nm (giving this 
ligand an orange colour), peaks at 364 and 308 nm in DMF solution (Figure ‎6.3, left). It is 
interesting to note that the Fe
II
 complex of this chelator exhibits the same peak at 502 nm but it was 
more intense (almost double) that of the free ligand, consistent with Fe
II
 binding two ligands.  
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Figure ‎6.3 UV-vis spectra of HPCBODIPYH and HPCBH and their Fe
II
 complexes in DMF. (The 
concentration of all solutions was 1×10
-5
M). 
 
Another distinct spectral feature for Fe
II
(PCBODIPYH)2  is the presence of a broad and 
asymmetric band at ca. 660 nm, which is typically found in related Fe
II
 complexes of pyridine 
containing hydrazone complexes giving them a characteristic green colour (Figure 6.3, left). The 
transition originates from a metal-to-ligand charge transfer transition (Fe
II
 (dπ)  L (pπ
*
)) as 
presented in Figure 6.3 (left). This is similar to Fe
II
 complexes of the hydrazone HPCIH series.
68
 As 
an example, HPCBH and its Fe
II
 complex which exhibited this electronic transition at 655 nm 
(Figure 6.3, right).   
 
6.2.6 Electrochemistry of iron complexes of fluorescent chelators 
 
Cyclic voltammetry of the Fe
III
 complexes of PCRBH and APRBH was performed in a 
mixture of MeCN and water (70:30) (v/v) due to insufficient solubility of these complexes in pure 
water.  In all cases, totally reversible Fe
III/II
 redox couples were identified with E' values +255 and 
+302 mV vs NHE for [Fe
III
(PCRBH)2]
3+
 and [Fe
III
(APRBH)2]
3+
 respectively as illustrated in Figure 
‎6.4 (left). The similar behaviour was observed (E' = 301 mV vs NHE) with the FeIII complex of the 
fluorescent probe derived from rhodamine B and hydrazine ([Fe
III
(HBPRBH)2]
3+
)  characterized in 
a previous investigation
213
 (Figure ‎6.4, left).  In comparison, FeIII complexes of the rhodamine B 
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derivative have a redox potential which is 200 mV  lower than that of  the hydrazone derivatives  
and about 600 mV higher than that of hydrazines.
68, 69
  
Electrochemistry of [Fe
III
(PCRBH)2]
3+
, [Fe
III
(APRBH)2]
3+
 and  [Fe
III
(HBPRBH)2]
3+
 in 
100% MeCN  was also investigated. These complexes [Fe
III
(PCRBH)2]
3+
, [Fe
III
(APRBH)2]
3+
) 
displayed totally reversible Fe
III/II
 redox couples with E' at ‒361 and ‒372 mV vs Fc+/0 (MeCN) 
respectively, which are more negative than that of [Fe
III
(HBPRBH)2]
3+
(‒266 mV vs Fc+/0(MeCN)), 
as showed in Figure 6.4 (right). 
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Figure ‎6.4 Cyclic voltammetry of the FeIII rhodamine B derivative complexes: sweep rate 100 mV, 
0.1 M Et4NClO4 supporting electrolyte, glassy carbon working electrode s
-1 
(a) MeCN: H2O 70:30 
(v/v) solvent (b) 100% MeCN solvent. 
 
 
The Fe
II
 complex of HPCBODIPYH displayed a totally irreversible anodic redox process at 
ca. 527 mV vs NHE in mixture of DMF and water (70:30) (v/v), essentially the same result as 
observed for the hydrazone anologues illustrated in Figure ‎6.5 (left). This irreversibility has been 
assigned to water adding to the C=N imine double bound upon oxidation to Fe
III
 which shifts the 
reduction wave to lower potential well away from the anodic peak potential.
68
 Electrochemistry of 
[Fe
II
(PCBODIPYH)2] in 100% DMF exhibited a totally reversible Fe
III
/Fe
II
 couple at ca. -142 mV 
vs Fc
+/0 
(DMF) which is only 54 mV higher than that of the related hydrazone complex 
[Fe
II
(PCBH)2] (-196 vs Fc
+/0
(DMF))  as illustrated in Figure ‎6.5 (right).68  
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Figure ‎6.5 Cyclic voltammetry of the [Fe
II
(PCBODIPYH)2] complex in comparison to 
[Fe
II
(PCBH)2] complex: sweep rate 100 mV s
-1
, 0.1 M Et4NClO4 supporting electrolyte, glassy 
carbon working electrode and (a) DMF: H2O 70:30 (v/v) solvent (b) DMF solvent. 
 
6.2.7 UV-visible Spectroelectrochemistry 
 
UV-visible Spectroelectrochemistry (SEC) of the iron complexes of the fluorescent probes 
was carried out in order to identity any oxidation dependent spectral changes. This was carried out 
with a thin-layer spectroelectrochemical cell (0.5 mm pathlength), a transparent gold grid working 
electrode, a Pt wire counter electrode and a nonaqueous reference electrode as indicated in the 
experimental Chapter. 
As an example, spectroelectrochemistry was carried out on a solution of [Fe
III
(APRBH)2]
3+
 
in MeCN in the potential range from –100 to –750 mV vs ferrocene/ferrocenium reference electrode 
and in the wavelength range 280-800 nm. At potentials above ca. -390 mV the intense rhodamine-
based transition is seen at about 558 nm and is assigned to the oxidised form (Fe
III
) of the complex.  
However, at lower potentials the [Fe
III
(APRBH)2]
3+
 complex is gradually converted to its Fe
II
 form 
and remarkably the intense rhodamine-centred visible maximum shifts to shorter wavelength (546 
nm) (Figure ‎6.6) which shows that there is strong electronic communication between the metal and 
the rhodamine chromophore. Also an increase in absorbance of the weaker maximum around 650 
nm is attributed to the metal-to-ligand charge-transfer origin MLCT (Fe
II  pyridine) as is also 
shown in Figure ‎6.3.  Furthermore, there is an increase in the intensity of the maximum around 353 
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nm and a decrease in absorbance at about 300 nm upon reduction of [Fe
III
(APRBH)2]
3+
 to [Fe
II
 
(APRBH)2]
2+
.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎6.6 UV-visible Spectroelectrochemistry spectra change of 2.73×10
-4 
M of iron complex of 
APRBH in MeCN, ([Fe(APRBH)2]
3+/2+
). 
 
 
 
Spectral changes were modelled by global analysis of the entire wavelength range using the 
program ReactLab Redox.
226
 The model was a simple one electron redox process and this enabled 
the spectra of the Fe
III
 and Fe
II
 complexes to be calculated. The redox potential of ‒374  mV vs 
Fc
+/0
(MeCN) was determined as shown in Figure ‎6.7, which is almost the same as measured by 
cyclic voltammetry in 100% MeCN (Section ‎6.2.6).    
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Figure ‎6.7 (a) Absorbances at 358 (squares) and 576 nm (diamonds) as a function of applied 
potential, solid lines are theoretical curves calculated with ReactLab Redox and (b) calculated 
spectra of the oxidized (A) and reduced (A
-
) forms of the of iron complex of APRBH in MeCN. 
 
6.2.8 Fluorescence spectra of the ligands and their Fe complexes 
 
The ligands PCRBH and APRBH are colourless and show no significant fluorescence 
emission, as shown in Figure ‎6.8. In contrast, the iron complexes of these chelators have a dark pink 
colour with orange emission; maxima at ca. 596λex=555 nm and 591λex=538 nm for [Fe
III
(PCRBH)2]
3+
 
and [Fe
III
(APRBH)2]
3+
, respectively (Figure ‎6.8). This is only observed when the ligands are forced 
into their ring-opened form and in this case complexation of these probes with iron leads to turn-on 
fluorescence. The fluorescence spectra of oxidized and reduced forms of the iron complex of 
APRBH was also investigated. This fluorescent measurement was performed in MeCN, employing 
(a) 
(b) 
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4-aminothiophenol as a reducing agent and ferrocenium hexafluorophosphate as an oxidizing agent. 
[Fe
III
(APRBH)2]
3+
exhibits fluorescence emission at ca. 598λex=559 nm while [Fe
II
(APRBH)2]
2+
  
exhibits this fluorescence emission at ca. 589λex=547 nm as illustrated in Figure 6.9.  
 
 
Figure ‎6.8 Fluorescence spectra of PCRBH and APRBH and their Fe
III
 complexes in MeCN. (The 
concentration of all solutions was 1×10
-5 
M.)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎6.9 Fluorescence spectra of the oxidized and the reduced forms of [Fe(APRBH)2]
3+/2+ 
in 
MeCN. (The concentration of all solutions was 5×10
-6 
M.) 
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 In regards to the fluorescence spectra of HPCBODIPYH and its Fe
II
 complex, 
HPCBODIPYH has a strong emission maximum at 526 nm when excited at 502 nm (Figure 6.10). 
However, complexation of this ligand with iron largely quenched the fluorescence which could be 
attributed to intermolecular Photoinduced Electron Transfer (PET) or Electronic Energy Transfer 
(EET) mechanisms.
184
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎6.10 Fluorescence spectra of HPCBODIPYH and its Fe
II
 complex in DMF (The 
concentration of all solutions was 1×10
-5 
M). 
 
 
6.3 Kinetic analysis  
6.3.1 Kinetic analysis of ring-opened fluorescent rhodamine B derivatives by protonation 
 
Apart from Fe-induced ring opening, it is also known that protons are capable of opening the 
rings of rhodamine lactams such as APRBH. In this sense it is important to study both processes 
independently to be able to understand which one may be occurring when both Fe and acid are 
present. With the eventual goal of finding a water soluble fluorescent sensor for Fe in cells, ring 
opening by protons in low pH regions of the cell could possibly give a false positive result. The 
kinetics of the ring-opening protonation reactions of the hydrazine HBPRBH
213
 as well as 
hydrazones APRBH and PCRBH by trifluoroacetic acid (TFA) was investigated here.  
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The reactions were followed by time-resolved UV-Vis spectrophotometry in the visible 
(400-800 nm) wavelength range using a stopped flow instrument. As indicated previously and based 
on the non-conjugated structure of these probes in their ring closed forms the neutral ligands do not 
absorb at all in the visible region of the spectrum. Upon introduction of TFA, a new band with a 
maximum around 559 nm emerges characteristic of the conjugated ring-opened rhodamine B 
chromophore as shown in Figure 6.11. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎6.11 Time resolved UV-Vis spectral changes of a TFA protonated solution of (a) APRBH 
(1×10
-5 
M) (total time 0.2 s), (b) PCRBH (4×10
-5 
M) (total time 10 s) and (c) HBPRBH (4×10
-5 
M) 
(total time 50 s). 
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The time-dependent spectral changes were modelled by global analysis with ReactLab 
Kinetics.
226
 Achieving a good agreement between the calculated and experimental data required a 
model involving a single exponential (pseudo-first order) process starting with the non-conjugated 
colourless form to generate the ring opened form. Pseudo-first order conditions were achieved by 
using at least a ten-fold higher concentration of TFA relative to the fluorescent ligands 
concentration.  
It is interesting to note that the spirolactam ring-opening reaction of the hydrazone APRBH 
is extremely fast (~0.07 s) compared to PCRBH and HBPRBH (Figure 6.12). The slowest reaction 
is observed for the hydrazine (HBPRBH) with a reaction time of ~ 2 minutes in contrast to the 
hydrazone PCRBH where its ring-opening reaction finishes within ~ 4 s as shown in Figure ‎6.13.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎6.12 (a) ReactLab Kinetics calculated time dependent concentrations of ring closed APRBH 
(black) and ring opened APRBH (red) and (b) calculated spectra for ring closed APRBH (black) 
and ring opened APRBH (red).  All spectra include a contribution of the 1×10
-5
 M of [TFA] and 
2.5×10
-7
 M of [APRBH] (pseudo-first order conditions).   
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Figure ‎6.13 ReactLab Kinetics calculated time dependent concentrations of (a) ring closed PCRBH 
(black) and ring opened PCRBH (red) and (b) ring closed HBPRBH (black) and ring opened 
HBPRBH (red) and  calculated spectra for (c) ring closed PCRBH (black) and ring opened PCRBH 
(red)  (total time 10 s) and (d) ring closed HBPRBH (black) and ring opened HBPRBH (red) (total 
time 50 s). All spectra include a contribution of the 4×10
-5 
M of [TFA] and 2.5×10
-7
 M of [PCRBH] 
or [HBPRBH] (pseudo-first order conditions).  
 
The values of the observed reaction rate kobs of APRBH are very large and practically too 
fast to be measured accurately (kobs > 10 s
-1
) while the values for PCRBH and HBPRBH are smaller 
and listed in Table ‎6.2. The plots of these observed rate constants versus TFA concentration 
generated curves that approached a saturating rate but with an inflection point at low acid 
concentration ( Figure 6.14). These data were fit to the model shown in Figure 6.14. The reason for 
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this unusual acid concentration dependence can be explained through the proposed mechanism of 
PCRBH, shown in Scheme 6.3.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The ring opening reaction requires a proton and does not proceed under either basic or 
neutral solutions. At low TFA concentrations, protonation of the pyridyl group provides the needed 
proton (protonation constant K1). Following this, a slow rearrangement breaks down this colourless 
intermediate, opening the ring and yielding a fully conjugated rhodamine B with the rate constant k1 
as indicated in Equation 6.1 and Scheme 6.3. 
 
 
 
 
 
 
 
 
 
 
 
 
(6.1) 
(Large K1 or high concentrations of protons) 
Scheme 6.3 
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However, at higher acid concentrations a second proton is introduced this time on the 
spirolactam carbonyl greatly accelerating the ring-opening reaction (k2), making the reaction 
pathway shown in the bottom of Scheme 6.3 operative. The final products from both pathways only 
differ in the presence of a proton on the remote pyridyl ring. Collectively, the kinetics of ring-
opening reaction involved two protonations (K1 and K2) that are expected to be diffusion controlled 
and too fast to measure
219,
 
220
 and two slower intramolecular rearrangements with rate constants k1 
and k2. The results for HBPRBH are fitted with the same equation and follow the same mechanism 
as PCRBH (Figure 6.14). Data in Table 6.2 were modelled with Equation 6.1 to give the parameters 
in Table 6.3.  All kinetic parameters are presented in Table ‎6.3.  
 
Table ‎6.2 Values of kobs obtained for the ring-opening induced by trifluoroacetic acid (TFA), T = 25 
ºC, [PCRBH] and [HBPRBH] = 2.5×10
–7
 M. 
 
[TFA] (M) kobs (s
–1
) (PCRBH) kobs (s
–1
) (HBPRBH) 
2.0×10
-6
 8.6×10
-2
 8.0×10
-3
 
4.0×10
-6
 1.6×10
-1
 6.0×10
-3
 
5.0×10
-6
 1.8×10
-1
 7.0×10
-3
 
7.5×10
-6
 2.1×10
-1
 6.0×10
-3
 
8.0×10
-6
 2.4×10
-1
 1.3×10
-2
 
9.0×10
-6
 2.5×10
-1
 1.2×10
-2
 
1.0×10
-5
 6. 5×10
-1
 2.6×10
-2
 
2.0×10
-5
 1.1 2.9×10
-2
 
3.0×10
-5
 1.3 3.2×10
-2
 
4.0×10
-5
 1.4 3.5×10
-2
 
5.0×10
-5
 1.6 3.4×10
-2
 
6.0×10
-5
 1.7 3.5×10
-2
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Figure ‎6.14 Plots of the observed first order rate constant (kobs) of PCRBH (circles) and kobs of 
HBPRBH (triangle) for the ring opening reaction as a function of [TFA] concentrations. (lines 
correspond to the fitting according to the Equation 6.1) 
 
Table ‎6.3 Kinetic parameters for ring-opening induced by trifluoroacetic acid (TFA). The values of 
K1 and K2 are not significant as their standard errors are similar to their values. 
 
 PCRBH Standard deviation HBPRBH Standard deviation 
K1 1.1×10
5
 
 
±6.8×10
4
 3.2×10
4
 
 
±6.1×10
4
 
 
K2 2.8×10
5
 
 
±7.8×10
5
 7.9×10
5
 
 
±1.8×10
5
 
 
k1 2.4×10
-1
  s
-1
 
 
±3.2 3.6×10
-1
   s
-1
 ±9.6×10
-1
    
k2 1.9  s
-1
 ±5.4×10
-1
 3.3×10
-2
    s
-1
 ±1.4×10
-2
     
 
 
6.3.2 Kinetic analysis of rhodamine B derivatives in complexation with iron 
6.3.2.1 Kinetic analysis of model ligands 
 
With the kinetics of trifluoroacetic acid-promoted ring opening understood, a comparable 
study was carried out with Fe as the Lewis acid in this case. As a starting point, the Fe 
complexation kinetics of known hydrazone ligands (HAPBH and HPCBH) with Fe
II 95, 68
 and 
hydrazine (H2BPH) ligands with Fe
III 69 
were carried. Given that the overall reaction of the 
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rhodamine substituted ligands with Fe involves ring opening and coordination as two distinct steps 
the study of ligands lacking the spirolactam ring but possessing the same NNO donor set enables the 
metal coordination reaction to be studied without complications from the ring opening process. This 
kinetic study was performed in the presence of Et3N in MeCN under pseudo-first order conditions 
using at least a tenfold higher concentration of ligand in a wide range (4×10
-5
 to 4×10
-3
 M). The 
addition of Et3N was necessary as a proton is released upon coordination of the hydrazine.  
Interesting, the hydrazones and Fe(ClO4)2 react within the mixing time of the instrument to give the 
regular spectra of either [Fe
II
(APBH)2] or [Fe
II
(PCBH)2] (data not shown) while the hydrazine 
H2BPH plus Fe(ClO4)3 reaction was much slower and could be resolved into two consecutive steps 
which are discussed below.  
The reaction of H2BPH with Fe(ClO4)3, yielding [Fe(BPH)2]
-
, was monitored by time-
resolved UV-Vis spectrophotometry in the 400-800 nm wavelength range using the stopped flow 
instrument. Changes were monitored over a timescale of 10 s. The increase in intensity of a broad 
maximum at ~ 600 nm indicated the formation of a complex as shown in Figure 6.15 and this is 
similar to the electronic spectra of isolated Fe
III
 complexes of H2BPH and other hydrazines.
69 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎6.15 Time resolved UV-Vis spectral changes of a solution 1.5×10
-3
 M of H2BPH, 3×10
-3
 M 
Et3N  and 4 × 10
-6
  M Fe (ClO4)3  (Total time 10 s, cycle time 50 ms). 
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The time-dependent spectral changes were modelled by global analysis of the entire 
wavelength range using ReactLab Kinetics.
226
 Achieving a good agreement between the calculated 
and experimental data required a model comprising two consecutive first order reactions steps 
(Figure 6.16). The first step is the formation of a weakly associated 1:1 outer sphere complex 
intermediate (Fe:L) which then yields a proper 1:1 FeL complex. The second step involves forming 
another outer sphere complex (FeL:L) as an intermediate which then results in the final fully 
coordinated FeL2 species (Equations 6.2 to 6.5). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎6.16 (a) ReactLab Kinetics calculated time dependent concentrations of uncomplexed Fe3+ 
(black), [Fe(BPH)]
+
 (red) and  [Fe(BPH)2]
- 
(blue) (b) calculated spectra for uncomplexed Fe
3+
  
(black),  [Fe(BPH)]
+
 (red) and  [Fe(BPH)2]
-
 (blue). All spectra include a background contribution of 
the excess H2BPH ligand.   
 
Considering the results in Table ‎6.4, the plot of kobs versus [H2BPH] is non-linear, indicating 
that outer sphere complexes are involved in both complexation reactions (Figure ‎6.17). Each data 
set was fit to Equation 6.6. All kinetic parameters are presented in Table ‎6.5. 
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Table ‎6.4 Values of kobs obtained for the complexation reaction between H2BPH and Fe (ClO4)3 T=   
25 ºC, [Fe(ClO4)3] = 4×10
–6
M. 
 
[H2BPH] / M kobs1 /  s
–1
  kobs2 / s
–1
 
4×10
-5
 1.7 9.8×10
-2
 
6×10
-5
 1.29 1.2×10
-1
 
8×10
-5
 1.25 9.7×10
-2
 
1×10
-4
 1.9 1.4×10
-1
 
5×10
-4
 2.2 1.8×10
-1
 
1×10
-3
 2.2 1.9×10
-1
 
1.5×10
-3
 2.7 2.2×10
-1
 
2×10
-3
 2.6 2×10
-1
 
2.5×10
-3
 2.9 2.2×10
-1
 
4×10
-3
 3.1 2.2×10
-1
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Figure ‎6.17 Plots of the values of observed first order rate kobs1 of the first step (circles) and kobs2 of 
the second step (triangle) for the complexation reaction as a function of [H2BPH] concentrations. 
(lines correspond to the fitting according to the Equation 6.6) 
 
(6.6) 
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Table ‎6.5 Kinetic parameters for the complexation reaction between H2BPH and Fe (ClO4)3 after 
fitting the data. 
 
 First or second step Standard deviation 
KOS1 7.6×10
2
 M
-1
 ± 5.9×10
2
 
KOS2             7.6×10
3
 M
-1
 ± 6.2×10
3
 
k1 2.1 s
-1
 ± 5.5×10
-1
 
k-1 1.5 s
-1
 ± 1.5×10
-1
 
k2 1.6×10
-1
 s
-1
 ± 3.6×10
-2
 
k-2 6.1×10
-2
  s
-1
 ± 4.1×10
-2
 
 
  
6.3.2.2 Kinetic analysis of APRBH complexation by FeII  
6.3.2.2.1 Kinetic analysis of ring opened of APRBH by reacting with FeII with ligand in excess  
 
The kinetics of the reaction of APRBH with Fe
II 
has been also been studied 
spectrophotometrically in MeCN both on the stopped flow timescale (~5 s) and with manual mixing 
over a relatively long timescale (2 hours). The reaction has been monitored under pseudo first order 
conditions (excess APRBH in the range 1×10
-5
 to 6×10
-5
 M). As discussed previously APRBH in its 
spirolactam ring closed form does not absorb in the visible region of the spectrum. Upon addition of 
Fe(ClO4)2, a new band with a maximum around 550 nm appears and shifts to shorter wavelength 
(546 nm, Figure ‎6.18). This band is attributed to the ring-opening of APRBH by complexation with 
Fe
II
 in contrast to ring opening by protonation (acid) which exhibits the corresponding band at 559 
nm as discussed previously. Interestingly, in a longer time scale experiment (~2 hours) the decrease 
in intensity of the characteristic [Fe
II
(APRBH)2]
2+
peaks at 546 nm occurs concomitantly with a 
decrease in a broad maximum at ~ 650 nm and a red shift of the rhodamine peak to 558 nm, which 
is attributed to the oxidation of [Fe
II
(APRBH)2]
2+ 
to [Fe
III
(APRBH)2]
3+
(Figure ‎6.18). These results 
are consistent with the data from UV-Vis spectroelectrochemistry of the [Fe
III
(APRBH)2]
3+/2+
 as 
discussed previously  Section ‎6.2.7. In this case oxygen is the cause of the oxidation reaction. 
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Figure ‎6.18 Time resolved UV-Vis spectral changes of a solution 3×10
-5 
M of APRBH with 1×10
-6
  
[Fe (ClO4)2]  (a) stopped flow (total time 5 s), (b) manual mixing  (total time 2 hours).  
 
 
 
Once again, time resolved electronic spectra were modelled by global analysis of spectra 
using ReactLab Kinetics.
226
 Over a short time scale (5 s) the reaction is resolved into two first-order 
steps to achieve a good agreement between the calculated and experimental data. As illustrated in 
Figure ‎6.19 (a,c) the initial spectrum is of a ring-opened form in this case presumably caused by 
coordination of Fe (perhaps monodentate O-bound) which is followed by rearrangement to the 
tridentate NNO bound form. This reaction is repeated by the entry of a second ligand and the 
putative [Fe
II
(APRBH)2]
2+
 complex is formed within 5 s. These two steps exhibit different observed 
rate constants (Figure ‎6.20) and (Table ‎6.6). The rate constants reach saturation as a function of 
ligand concentration very quickly and lower concentrations of ligand or Fe could not be employed 
(due to insufficient spectral absorbance changes) in an effort to better examine the expected non-
linear concentration dependence. 
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Figure ‎6.19 ReactLab Kinetics calculated time dependent concentrations of (a) ring-opening of 
APRBH with partial coordination of Fe
2+
 (black), [Fe
II
(APRBH)]
2+ 
(1:1complex) (red) and  
[Fe
II
(APRBH)2]
2+ 
(2:1complex) (blue) (5 s) (b) [Fe
II
(APRBH)2]
2+ 
(black), [Fe
III
(APRBH)2]
3+
 (red) 
and decomposition reaction (blue) (2 h) and calculated spectra for (c) ring-opening of APRBH with 
partial coordination of Fe (black), [Fe
II
(APRBH)]
2+ 
(1:1complex) (red) and [Fe
II
(APRBH)2]
2+
 
(2:1complex) (blue) and (d) [Fe
II
(APRBH)2]
2+ 
(black), [Fe
III
(APRBH)2]
3+
 (red) and decomposition 
reaction (blue). All spectra include a contribution of the 3×10
-5 
M of [APRBH] and 1×10
-6
 M of  
Fe(ClO4)2. 
 
On a long time scale (2 hours), there are another two much slower steps. The first step is the 
oxidation of [Fe
II
(APRBH)2]
2+ 
to [Fe
III
(APRBH)2]
3+
 (Figure 6.19 b, d) which is ligand 
concentration independent, as expected. The second step is a very slow reaction, perhaps a 
decomposition reaction which is only 25% complete by 2 h. Interestingly, the rate of this very slow 
reaction seems to decrease with an increase in the concentration of ligand (Figure ‎6.20) and (Table 
‎6.6) but the reasons for this are not obvious. It is possible that the unknown decomposition reaction 
involves dissociation of ligand from Fe
III
 and that this is opposed by higher ligand concentrations. 
Clearly, these results indicate that the ring-opening of APRBH by its complexation with Fe(ClO4)2 
involves many steps with the formation of [Fe
III
(APRBH)2]
3+
 as an intermediate which then appears 
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to undergo an even slower decomposition reaction (hours). The Fe
II
 complex is formed within a 
timescale of about 10 s with micromolar concentrations of reagents. Recall that reactions between 
the model ligands HAPBH or HPCBH and Fe
II
 were complete within the mixing time of the 
stopped flow instrument (~ 60 ms). 
 
Table ‎6.6 Values of kobs (f) (fast reaction, 5s) and  kobs (s) (slow reaction, 2 h) obtained for the 
complexation reaction between APRBH and Fe(ClO4)2, T = 25 ºC, [Fe (ClO4)2] = 1×10
–6 
M. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎6.20 Plots of the values of observed first order rate (a) kobs1(f) (circles)  kobs2(f) (triangle)  
(total time 5 s) of the fast reactions  (sequential ligand coordination) and (b) kobs1(s) (circles)  kobs2(s) 
(triangle)  (total time 2 h) of the slow reactions (oxidation then decomposition) as a function of 
[APRBH] concentrations. 
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6.3.2.2.2 The reaction of APRBH by reacting with FeII in excess 
 
The same reaction was investigated by mixing the free ligand with Fe
II
 in excess under 
stopped flow conditions (5 s). The reaction has been monitored under pseudo first order conditions 
that were achieved by using at least a ten-fold higher concentration of  Fe(ClO4)2 (in the range 
5×10
-6
 to 5×10
-5
 M) relative to the fluorescent ligand concentration. As mentioned previously 
APRBH in its ring closed form does not absorb at all in the visible region of the spectrum. After 
addition of Fe(ClO4)2, a new band with a maximum around 549 nm emerges and slightly shifts to 
552 nm, indicating ring-opening of APRBH by binding with Fe
II 
(Figure 6.21). Under these 
conditions (Fe:ligand > 10:1) only a 1:1 Fe:ligand complex is possible.  
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Figure ‎6.21 Time resolved UV-Vis spectral changes of a solution 2.5×10
-5
 M of Fe(ClO4)3 and 5 × 
10
-7
 M of APRBH (Total time 5 s). 
  
Time resolved electronic spectra were modelled by global analysis of the entire wavelength 
range (400-800 nm) using ReactLab Kinetics.
226
 A single exponential model, which involves the 
conversion from non-conjugated structure into the open ring structure of APRBH by binding with 
Fe
II
, was required to achieve good agreement between the calculated and experimental data. The 
initial observed spectrum is a partially ring opened form probably induced by coordination of Fe
2+
 
to the O atom (monodentate  O-bound). Following this, rearrangement to the tridentate NNO bound 
form occurs as illustrated in Figure ‎6.22 and Scheme 6.4. 
This is somewhat similar to the mechanism of protonation (Equation 6.1 and Scheme 6.3). 
At higher concentrations of Fe(ClO4)2 (remembering Fe is already in more than a 10-fold excess) 
another Fe
II
 coordinates, perhaps to the pyridyl with the association constant K2, accelerating the 
ring-opening reaction (rate constant k2). 
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Figure ‎6.22 (a) ReactLab Kinetics calculated time dependent concentrations of  the ring opened 
monodentate O-bound form (black) and  the ring opened tridentate NNO bound form (red)  (b) 
calculated spectra for the ring opened by Fe (monodentate O-bound) (black) and the  ring opened by 
Fe (tridentate NNO bound) (red) . All spectra include a contribution of the 2.5×10
-5
 M of Fe(ClO4)2 
and 5×10
-7 
M of APRBH. 
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The values of kobs obtained for the reaction between APRBH and Fe(ClO4)2 in excess are 
listed in Table 6.7. The plots of these observed rate constants versus Fe
II 
concentrations generated 
curves (Figure ‎6.23), similar to that of ring-opening reaction by protons (Section ‎6.3.1), fitting with 
the same Equation (6.1). All kinetic parameters are listed in Table 6.8. The fit is clearly not 
meaningful as there are too few data points to extract four independent parameters from Equation 
6.1.  
Collectively, Fe
II
 acts as a Lewis acid induced the ring opening of APRBH by forming 1:1 
complex as a final product in the time scale of about 10 s.  The results above are comparable with 
the data for the turn-on fluorescent chelator APRBH by binding with Fe
II
 with excess ligand 
(Section ‎6.3.2.2.1). In particular, the first step which is the formation of [FeII(APRBH)]2+  (1:1 
complex).  
 
 
Table ‎6.7 Values of kobs obtained for the complexation reaction between APRBH and Fe(ClO4)2 in 
excess, T = 25 ºC, [APRBH] = 5×10
–7
M. 
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Figure ‎6.23 Plots of the values of observed first order rate kobs of the complexation reaction of 
APRBH as a function of Fe
II
 concentrations. (lines correspond to the fitting according to the 
Equation 6.1) 
 
 
Table ‎6.8 Kinetic parameters for ring-opening induced by excess Fe(ClO4)2 after fitting the data. 
The uncertainties of the parameters K1 and K2 are very large and their values are not meaningful. 
 
 APRBH 
K1 2(140)×10
3
 
K2 3(200)×10
5
 
k1 10(80)  s
-1
 
k2 8(20)      s
-1
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6.3.2.3 Kinetic analysis of PCRBH complexation by FeII  
 
The complexation kinetics of the pro-fluorescent chelator PCRBH with Fe
II 
has been studied 
in a similar way to APRBH.  Stopped flow methods were used over a shorter timescale (100 s) and 
manual mixing instrument over a relatively long timescale (3 h). The reaction has been monitored 
under pseudo first order conditions (excess PCRBH in the range 2×10
-5
 to 6×10
-5
 M). Once again, 
PCRBH does not display any visible electronic maxima in its spirolactam ring closed form. The 
addition of  Fe(ClO4)2 generates a new band with a maximum around 550 nm which slightly shifts 
to around 557 nm  (Figure 6.24). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎6.24 Time resolved UV-Vis spectral changes of a solution 4×10
-5 
M of PCRBH with     
1×10
-6
 M Fe(ClO4)2 (a) total time 100 s and (b) total time 3 h. 
 
 Time resolved electronic spectra were modelled by global analysis of the wavelength range 
400-800 nm using ReactLab Kinetics.
226
 Over a short time scale of 100 s the overall reaction is 
resolved into two first-order steps to achieve a good agreement between the calculated and 
experimental data. The initial spectrum is a ring-closed form, which is followed by a ring-opened 
form by partial coordination of Fe that is likely to be monodentate O-bound (Figure ‎6.25 a, c). The 
observed first order rate constant of this reaction is dependent on the concentration of PCRBH 
(Table ‎6.9 and Figure ‎6.26 (a)). The second step of the fast reaction is rearrangement to the 
tridentate NNO bound form, forming [Fe
II
(PCRBH)]
2+
 (a 1:1 complex) as indicated in Figure ‎6.25 
(a, c) and this step is concentration independent (Table ‎6.9 and Figure ‎6.26(a)). To support this, the 
extinction coefficient of [Fe
II
(PCRBH)]
2+
 is too small to be due to two rhodamine chromophores 
(see Section ‎6.2.5). Within 2 hours (longer time scale), this reaction comprises different two steps. 
The first step is formation of a 1:2 Fe:ligand complex, which is complete in about 30 min and so not 
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observable in the stopped flow timescale. The extinction coefficient of the rhodamine absorption 
band of [Fe
II
(PCRBH)2]
2+
 is greater than that of the 1:1 complex observed in the short timescale 
experiment. The second step is possibly to be the oxidation of [Fe
II
(PCRBH)2]
2+
 to 
[Fe
III
(PCRBH)2]
3+
 (Figure 6.25 (b, d)). These two steps are concentration independent as presented 
in Table ‎6.9 and Figure ‎6.26(b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎6.25 ReactLab Kinetics calculated time dependent concentrations of (a) ring-closed of 
PCRBH (black), ring-opening by partially coordinated with Fe
II 
(red) and [Fe
II
(PCRBH)]
2+
 (1:1 
complex) (blue) (b) [Fe
II
(PCRBH)]
2+
 (1:1 complex) (black), [Fe
II
(PCRBH)2]
2+
(2:1 complex) (red) 
and [Fe
III
(PCRBH)2]
3+
(blue) and calculated spectra for (c) ring-closed of PCRBH (black), ring-
opening by partially coordinated with Fe
II
 (red) and [Fe
II
(PCRBH)]
2+ 
(1:1complex) (blue) and (d) 
[Fe
II
(PCRBH)]
2+
(1:1 complex) (black),[Fe
II
(PCRBH)2]
2+
(2:1complex) (red) and [Fe
III
(PCRBH)2]
3+ 
(blue). All spectra include a contribution of the 4×10
-5
 M  of PCRBH and 1×10
-6 
M of Fe(ClO4)2. 
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Table ‎6.9 Values of kobs obtained for the complexation reaction between PCRBH and Fe (ClO4)2, T 
= 25 ºC, [Fe
II
] = 1×10
–6 
M.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎6.26 Plots of the values of observed first order rate constants (a) kobs1(f) (circles)  kobs2(f) 
(triangle)  (total time 100 s) of the fast reaction and (b) kobs1(s) (circles)  kobs2(s) (triangle)  (total 
time 3 h) of the slow reaction for the complexation reaction as a function of PCRBH concentrations. 
 
As illustrated above, the plot of kobs1(f) versus [PCRBH] is likely to be nonlinear according 
to Equation (6.6) but there are not nearly enough data points to obtain a meaningful fit to this 
equation. Taken together, the results above suggest that the ring-opening of PCRBH by its 
complexation with Fe(ClO4)2 involves four steps with the formation of [Fe
III
(PCRBH)2]
3+
 as a final 
product similar to the complexation reaction of APRBH. However, what is most interesting is that 
the Fe complexation reaction of PCRBH is much slower than APRBH in spite of their similarity. 
The reasons for this are not clear but point to distinctly different conformations of ring-closed 
APRBH and PCRBH with the latter being trapped in a form that is less able to undergo ring 
opening. 
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6.3.2.4 Kinetic analysis of HBPRBH complexation by FeIII  
 
The kinetics of HBPRBH complexation with Fe
III
 has been followed in the same way on the 
stopped flow instrument (50 s). The reaction has been monitored under pseudo first order conditions 
that were achieved by using at least a ten-fold higher concentration of the fluorescent ligand  in the 
range (1.5×10
-5
 to 5×10
-5
 M) relative to Fe(ClO4)3 concentrations. HBPRBH in its ring closed form 
does not absorb in the visible region of the spectrum. Upon addition of Fe(ClO4)3, a new band 
characteristic of rhodamine with a maximum around 552 nm appears and shifts to a longer 
wavelength (559 nm, Figure 6.27), characteristic of ring-opening of HBPRBH driven by 
complexation with Fe
III
.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎6.27 Time resolved UV-Vis spectral changes of a solution 3×10
-5
 M of HBPRBH with 
1×10
-6
  of Fe(ClO4)3 (total time 50 s). 
 
The time-dependent spectral changes were modelled with ReactLab Kinetics.
226
 In the range 
of 1.5×10
-5
 to 3×10
-5
 M ligand concentration, the overall reaction is resolved into two first-order 
steps to achieve agreement between the calculated and experimental data over a period of 50 s. The 
initial spectrum is essentially of a ring-closed form which is followed by a ring-opened compound 
with an extinction coefficient consistent with Fe
III
 forming a 1:1 complex [Fe
III
(HBPRBH)]
3+
 
(Figure ‎6.28).  The second step of this reaction is due to entry of a second ligand yielding 
[Fe
III
(HBPRBH)2]
3+
. It is interesting to note that at slightly higher concentrations of ligand (4×10
-5
 
or 5×10
-5
), a single exponential fit could be employed to fit all the data over this period of time 
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([Fe
III
(HBPRBH)2]
3+ 
2:1 complex) without the interference from the first step, an example 
illustrated in Figure ‎6.29. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎6.28 (a) ReactLab Kinetics calculated time dependent concentrations of ring-closed of 
HBPRBH (black), [Fe
III
(HBPRBH)]
3+ 
(1:1 complex) (red), [Fe
III
(HBPRBH))2]
3+
 (2:1 complex) 
(blue) and (b) calculated spectra for ring-closed of HBPRBH (black), [Fe
III
(HBPRBH)]
3+
 (1:1 
complex) (red), [Fe
III
(HBPRBH)2]
3+
 (2:1 complex) (blue) at lower ligand concentrations (< 3×10
-5
 
M). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎6.29 (a) ReactLab Kinetics calculated time dependent concentrations of ring-closed of 
HBPRBH (black), [Fe
III
(HBPRBH)2]
3+ 
(2:1complex) (red) and (b) calculated spectra for ring-closed 
of HBPRBH (black), [Fe
III
(HBPRBH)2]
3+ 
(2:1 complex) (red) at higher ligand concentrations (> 
4×10
-5
 M). 
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The values of kobs1 and  kobs2 obtained for the reaction between HBPRBH and Fe(ClO4)3 are 
listed in Table ‎6.10. The values of kobs1(1:1 complex) show no obvious concentration dependence 
while the values of kobs2 (2:1 complex) are likely to be linearly dependent on the concentration of 
HBPRBH (Table 6.10 and Figure 6.30), perhaps the data point  does not reach saturation to be able 
to fit with Equation (6.6). 
 
Table ‎6.10 Values of kobs1 and kobs2 obtained for the complexation reaction between HBPRBH and 
Fe(ClO4)3, T = 25 ºC, [Fe
III
] = 1×10
–6
M (total time 50 s). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎6.30 Plots of the values of observed first order rate (a) kobs1 (b) kobs2 for the complexation 
reaction as a function of [HBPRBH] concentrations. 
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Collectively, the results above showed that HBPRBH in complexation with Fe(ClO4)3 
involves two steps with the formation of [Fe
III
(HBPRBH)2]
3+
 as the final product and this reaction 
is slower than that of  APRBH.  
6.4 Summary  
 
The iron coordination chemistry of a range of new fluorescent chelators derived from 
heterocyclic hydrazone and hydrazine Fe chelators that are attached to fluorophores including 
rhodamine B and boron dipyrromethene (BODIPY) have been presented and discussed. These 
chelators and their 2:1 ligand:Fe complexes have been isolated and spectroscopically and 
electrochemically characterized. The oxidation state (Fe(II) or Fe(III)) in solution of some of these 
complexes have been identified by UV-Visible spectroelectrochemistry. Kinetics and mechanisms 
of protonation reactions of fluorescent rhodamine B chelators induced by TFA have been reported 
and discussed. This protonation reaction involved a single exponential pseudo-first order reaction 
step which is the alteration from the non-conjugated structure ring close form to the conjugated one 
of rhodamine B chromophore. The spirolactam ring-opening reaction of the hydrazone APRBH is 
the fastest reaction compared to PCRBH and HBPRBH. The Fe complexation kinetics of known 
hydrazone ligands (HAPBH and HPCBH) with Fe
II 95, 68
 and hydrazine (H2BPH) ligands with Fe
III 
69 
were also investigated. The complexation reaction of hydrazones with Fe
II
  is very fast and 
finished within the mixing time of the instrument while that of hydrazine with Fe
III
 reaction was 
much slower and was resolved into two consecutive steps. The complexation kinetics of APRBH 
and PCRBH chelators with Fe
II
 (pseudo-first order reaction ligand in excess) has been studied and 
the reaction involves many steps. Surprisingly, the Fe complexation reaction of PCRBH is much 
slower than APRBH. The Fe complexation kinetics of APRBH with Fe
II
 in excess has also been 
investigated. This reaction resolved into one first-order step which formed a 1:1 complex. The 
kinetics of HBPRBH complexation with Fe
III
 has been studied and the overall reaction is resolved 
into two first-order steps. 
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Chapter 7   Conclusions 
 
 
 
Iron no doubt is crucial for life, yet it is toxic if present in excess. Excessive amounts of iron 
accumulated in the human body results in many diseases including Fe overload disorders. Hence, 
developing selective, non-toxic iron chelators for iron overload has gained much interest. Fe 
chelators have also been found to have another application as anticancer therapies. As discussed in 
the introduction Chapter, there have been enormous efforts for designing potent and selective 
anticancer iron chelators without adverse effects. Therefore, in this investigation iron coordination 
chemistry, redox properties and biological activity of a series of heterocyclic dithiocarbazate Schiff 
bases have been examined. These chelators are tridentate, utilizing the same NNS donor set as for 
the heterocyclic hydrazone
77,95
 and thiosemicarbazone
119,124
 analogues which have been studies 
previously, but with substitutions of mercaptomethyl or mercaptobenzyl groups, instead of an amine 
or aromatic ring. Low spin ferric and ferrous complexes of these dithiocarbazate Schiff bases were 
isolated, and structurally, spectroscopically and electrochemically characterized. An unusual 
hydroxylated ligand derivative has been identified, formed via an Fe-induced oxidation reaction. 
The cyclic voltammetry obtained exhibited totally reversible Fe
III/II
 couples in mixed aqueous 
solvent at potentials dependent on substituent effects inherent to their parent carbonyl compound (2-
acetylpyridine, di-2-pyridyl ketone or 2-pyridinecarbaldehyde). By comparison, these iron 
complexes of dithiocarbazate Schiff bases have slightly higher redox potentials compared to 
thiosemicarbazone iron complexes. Thus, in the presence of water and at physiological pH,   Fe
III 
complexes of these chelators immediately reduced to more stable Fe
II
 form, similar to the 
heterocyclic hydrazone analogues. The involvement of these Fe
III
 complexes in any oxidative 
processes such as the oxidation of oxy-hemoglobin (HbO2) to met-haemoglobin (Met-Hb) is 
unlikely, in contrast to the thiosemicarbazone series. The effectiveness of these dithiocarbazate 
chelators to mobilize intracellular iron and to prevent iron uptake from transferrin as well as their 
anti-proliferative activity have also been reported and discussed. All ligands under investigation 
were more effective in chelating intracellular iron than the clinically proven chelator 
desferrioxamine (DFO), with HPCSMC being the most active of the dithiocarbazate chelators and 
as effective as HDp44mT. The three S-benzyl dithiocarbazates (HAPSBC, HPCSBC and 
HPKSBC) were less effective at mobilising intracellular 
59
Fe and inhibiting cellular 
59
Fe uptake 
from 
59
Fe2-Tf compared to the S-methyl analogues (HAPSMC, HPCSMC and HPKSMC).  
 Interestingly, Schiff bases derived from aldehydes (bearing an H-atom at C6) displayed no 
toxicity against SK-N-MC neuroepithelioma cancer cells. Contrastingly, ketone-derived Schiff 
7 Conclusions 
 
153 
 
bases (bearing a methyl, pyridyl group at C6) demonstrated significant anti-proliferative activity. 
Taken together, iron chelators derived from the 2-pyridinecarboxaldehyde group are ideal drugs for 
iron overload, while those derived from ketones are undoubtedly suitable for the treatment of 
cancer. The similar observation was found in the related compounds HPCIH, HPKIH and HAPIH 
hydrazones
95
 but the reason for such behavior is not clear. This study will definitely contribute to 
design novel iron chelators for iron overload disease or cancer and preclinical assessment should be 
considered in the near future. 
  As mentioned in this thesis, there are some side effects associated with iron chelators as 
antitumour agents, including hypoxia and methemoglobinemia. For example, the Fe chelator 3-
amino-2-pyridinecarbaldehyde thiosemicarbazone (3-AP; Triapine), which has been examined in a 
number of Phase I and Phase II clinical trials for the treatment various cancers,
111-115,117,174
 exhibits 
such effects (metHb formation), limiting its effectiveness. However, the mechanism of these effects 
has not been investigated. Herein, the kinetics of methemoglobin formation by some members of 
structurally-related thiosemicarbazone chelators namely, HDpT, HBpT and HApT series have been 
reported. This investigation has been undertaken in vitro employing human hemoglobin. The results 
demonstrated that the oxidation of dimeric oxyhemoglobin (HbO2) to methemoglobin (MetHb) by 
Fe
III 
thiosemicarbazone complex proceeds with two distinct time-resolved steps corresponding to 
separate oxidations of the α- and β-chains in the protein. It was found that [FeIII(DpT)2]
+ 
, 
[Fe
III
(BpT)2]
+ 
 and [Fe
III
(ApT)2]
+ 
 demonstrate a two-fold enhanced oxidation rate of -HbO2, 
when compared with the rest of the complexes with very similar redox Fe
III/II
 potentials but with 
substituents on the terminal N atom. These variations in the rate attributed to desirable steric and H-
bonding effects that enable iron thiosemicarbazone complex to approach closer to the heme co-
factor, making outer-sphere electron transfer more rapid. In another case, there are no significant 
differences in the rate constants of the fast reactions (kf) across the three series. Nonetheless, the 
rate constants of the slow reaction (ks) are slightly different across these three series, especially for 
Fe
III
 complexes of the HApT series. The reasons for such observations are most likely to be due 
from the inductive effects, meaning the less electron-withdrawing functional group on the Fe
III
 
complexes, lowers the activity toward oxidation of HbO2 to metHb. The findings from this study 
will provide vital information for the development of thiosemicarbazone chelators as anti-cancer 
therapies with relatively no adverse effects. 
Despite the tremendous reports about iron chelators for iron overload disorders which have 
displayed high activity in mobilizing intracellular Fe,
65-69
 the mechanism of how these chelators 
access Fe and their intracellular location are not well defined. Hence, the Fe coordination chemistry 
of a range of new fluorescent chelators derived from rhodamine B and hydrazone and hydrazine 
ligands as well as ligands derived from BODIPY and hydrazone ligands for detection iron in the 
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cell has been presented. Ideal turn-on probes are non-fluorescent in their uncomplexed form but 
become fluorescent after binding iron and forming a complex. This behaviour was observed for 
rhodamine B derivatives probes in contrast to BODIPY derivative. The synthesis, spectroscopic and 
electrochemical characterizations of all free ligands and their 2:1 ligand:Fe complexes have been 
reported. UV-visible Spectroelectrochemistry of some of these complexes have been examined to 
characterise their oxidation state (Fe(II) or Fe(III)) in solution. Kinetics and mechanisms of 
protonation and complexation reactions of turn-on fluorescent rhodamine B chelators have also 
been demonstrated. There is a clear variation in the rates of ring opening reactions induced by 
protonation (TFA) or by binding with iron with the fastest fluorescence turn-on behavior observed 
for APRBH compared to PCRBH and HBPRBH. The findings from this study on the rate of turn-on 
rhodamine B probes are essential to differentiate whether fluorescence is induced by protons or by 
complex with iron. Further improvement to these fluorescent chelators presented here need to be 
considered in the future. In particular, their water solubility needs to be measured if they are to be 
utilized in the biological application for detection of iron pools. Also, sensitivity and selectivity d of 
these fluorescent chelators should be considered. 
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  Appendix    
 
 
 
A-I.    Free Ligand Crystallographic Data 
 
2-Acetylpyridine S-methyldithiocarbazate (HAPSMC) Crystallographic Data  
 
ORTEP view of the free ligand HAPSMC (30% probability ellipsoids shown). 
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Table 1.  Crystal data and structure refinement for HAPSMC 
Identification code  545mb1 
Empirical formula  C9 H11 N3 S2 
Formula weight  225.33 
Temperature  293(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P1 
Unit cell dimensions a = 5.8633(5) Å = 81.909(10)°. 
 b = 8.1483(10) Å = 79.334(9)°. 
 c = 11.7569(15) Å  = 84.497(8)°. 
Volume 545.09(11) Å3 
Z 2 
Density (calculated) 1.373 Mg/m3 
Absorption coefficient 0.452 mm-1 
F(000) 236 
Crystal size 0.4 x 0.1 x 0.07 mm3 
Theta range for data collection 2.90 to 24.99°. 
Index ranges -6<=h<=6, -9<=k<=9, -13<=l<=12 
Reflections collected 3488 
Independent reflections 1905 [R(int) = 0.0292] 
Completeness to theta = 24.99° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1 and 0.64771 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 1905 / 0 / 129 
Goodness-of-fit on F2 0.824 
Final R indices [I>2sigma(I)] R1 = 0.0431, wR2 = 0.0755 
R indices (all data) R1 = 0.0998, wR2 = 0.0829 
Largest diff. peak and hole 0.211 and -0.199 e.Å-3 
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Table 2.  Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2x 103) 
for HAPSMC.  U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________________ 
C(1) 3171(7) 2316(5) 6722(3) 81(1) 
C(2) 5087(8) 1372(5) 7025(3) 78(1) 
C(3) 6925(7) 1110(5) 6165(4) 73(1) 
C(4) 6787(6) 1747(4) 5039(3) 59(1) 
C(5) 4782(6) 2684(4) 4810(3) 42(1) 
C(6) 4525(5) 3374(4) 3598(3) 44(1) 
C(7) 2384(5) 4440(4) 3398(3) 62(1) 
C(8) 7911(5) 3050(4) 840(3) 40(1) 
C(9) 12220(5) 1460(4) 184(3) 62(1) 
N(1) 2990(5) 2955(4) 5641(3) 64(1) 
N(2) 6224(4) 2972(3) 2808(2) 45(1) 
N(3) 6159(4) 3514(3) 1653(2) 51(1) 
S(1) 7989(1) 3577(1) -569(1) 55(1) 
S(2) 10083(1) 1767(1) 1452(1) 52(1) 
________________________________________________________________________________
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Table 3.   Bond lengths [Å] and angles [°] for HAPSMC. 
_____________________________________________________ 
C(1)-N(1)  1.323(4) 
C(1)-C(2)  1.374(5) 
C(2)-C(3)  1.358(5) 
C(3)-C(4)  1.366(5) 
C(4)-C(5)  1.388(4) 
C(5)-N(1)  1.321(4) 
C(5)-C(6)  1.485(4) 
C(6)-N(2)  1.282(3) 
C(6)-C(7)  1.493(4) 
C(8)-N(3)  1.333(3) 
C(8)-S(1)  1.645(3) 
C(8)-S(2)  1.762(3) 
C(9)-S(2)  1.791(3) 
N(2)-N(3)  1.374(3) 
 
N(1)-C(1)-C(2) 124.0(4) 
C(3)-C(2)-C(1) 117.9(4) 
C(2)-C(3)-C(4) 119.5(4) 
C(3)-C(4)-C(5) 118.9(4) 
N(1)-C(5)-C(4) 122.1(4) 
N(1)-C(5)-C(6) 116.9(3) 
C(4)-C(5)-C(6) 120.9(3) 
N(2)-C(6)-C(5) 115.0(3) 
N(2)-C(6)-C(7) 126.0(3) 
C(5)-C(6)-C(7) 119.0(3) 
N(3)-C(8)-S(1) 123.7(2) 
N(3)-C(8)-S(2) 112.0(2) 
S(1)-C(8)-S(2) 124.28(18) 
C(5)-N(1)-C(1) 117.6(3) 
C(6)-N(2)-N(3) 120.1(3) 
C(8)-N(3)-N(2) 119.4(3) 
C(8)-S(2)-C(9) 101.65(15) 
_____________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
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Table 4.   Anisotropic displacement parameters (Å2x 103)for 545mb1.  The anisotropic 
displacement factor exponent takes the form: -22[ h2a*2U11 + ... + 2 h k a* b* U12 ] 
______________________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
______________________________________________________________________________ 
C(1) 75(3)  118(4) 36(3)  -1(2) 10(2)  10(3) 
C(2) 94(3)  92(3) 37(3)  9(2) -4(2)  1(3) 
C(3) 73(3)  80(3) 59(3)  6(2) -15(2)  16(2) 
C(4) 58(2)  73(3) 39(2)  -7(2) 3(2)  11(2) 
C(5) 46(2)  44(2) 36(2)  -7(2) -2(2)  -2(2) 
C(6) 50(2)  50(2) 31(2)  -10(2) 0(2)  -2(2) 
C(7) 55(2)  79(3) 45(2)  -11(2) 0(2)  17(2) 
C(8) 38(2)  41(2) 38(2)  -10(2) 1(2)  -3(2) 
C(9) 43(2)  78(3) 56(2)  -10(2) 1(2)  16(2) 
N(1) 59(2)  91(2) 31(2)  -3(2) 7(2)  13(2) 
N(2) 51(2)  54(2) 26(2)  -5(1) 1(1)  2(1) 
N(3) 49(2)  62(2) 36(2)  -4(2) 0(1)  12(1) 
S(1) 52(1)  72(1) 32(1)  -2(1) -1(1)  12(1) 
S(2) 51(1)  64(1) 36(1)  -4(1) -5(1)  12(1) 
______________________________________________________________________________ 
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3',6'-Bis(diethylamino)-2-((1-(pyridin-2-yl)ethylidene)amino)spiro[isoindoline-1,9'-xanthen]-
3-one (APRBH) Crystallographic Data 
 
ORTEP view of the free ligand APRBH (30% probability ellipsoids shown). 
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Table 1.  Crystal data and structure refinement for APRBH. 
Identification code  774mb10 
Empirical formula  C35 H37 N5 O2 
Formula weight  559.70 
Temperature  293(2) K 
Wavelength  1.54180 Å 
Crystal system  monoclinic 
Space group  P 21/n 
Unit cell dimensions a = 11.376(2) Å = 90°. 
 b = 13.530(2) Å = 93.508(19)°. 
 c = 19.981(4) Å  = 90°. 
Volume 3069.7(9) Å3 
Z 4 
Density (calculated) 1.211 Mg/m3 
Absorption coefficient 0.605 mm-1 
F(000) 1192 
Crystal size 0.2 x 0.2 x 0.2 mm3 
Theta range for data collection 3.95 to 63.15°. 
Index ranges -13<=h<=12, -15<=k<=10, -22<=l<=22 
Reflections collected 14336 
Independent reflections 4877 [R(int) = 0.0504] 
Completeness to theta = 63.15° 97.9 %  
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4877 / 0 / 379 
Goodness-of-fit on F2 0.966 
Final R indices [I>2sigma(I)] R1 = 0.0737, wR2 = 0.2138 
R indices (all data) R1 = 0.1063, wR2 = 0.2641 
Largest diff. peak and hole 0.358 and -0.435 e.Å-3 
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Table 2.  Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2x 103) 
for APRBH.  U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________________ 
O(001) 5762(2) 4284(2) 10649(1) 72(1) 
O(002) 6289(3) 675(2) 8685(1) 85(1) 
N(3) 5819(3) 1903(2) 9428(1) 64(1) 
N(2) 5081(3) 2490(2) 9017(1) 66(1) 
N(5) 3260(3) 2788(2) 12179(2) 80(1) 
C(20) 5256(3) 3421(2) 10854(2) 59(1) 
C(26) 6901(3) 3372(2) 9880(2) 60(1) 
C(21) 6595(3) 4244(2) 10176(2) 61(1) 
C(14) 6359(3) 2389(2) 10047(2) 59(1) 
C(15) 5472(3) 2518(2) 10568(2) 56(1) 
N(4) 8520(4) 6063(3) 9435(2) 92(1) 
C(16) 4883(3) 1714(2) 10827(2) 65(1) 
C(22) 7100(3) 5134(2) 10030(2) 67(1) 
C(17) 4151(3) 1786(2) 11338(2) 65(1) 
C(18) 3966(3) 2701(3) 11642(2) 64(1) 
C(6) 4175(3) 2076(3) 8713(2) 67(1) 
C(13) 7282(3) 1618(2) 10253(2) 68(1) 
C(19) 4520(3) 3521(2) 11378(2) 66(1) 
C(7) 6447(3) 1096(2) 9226(2) 68(1) 
C(8) 7310(3) 886(3) 9781(2) 72(1) 
C(1) 3451(3) 2746(3) 8276(2) 74(1) 
N(1) 2584(4) 2309(3) 7895(2) 104(1) 
C(12) 8014(4) 1595(3) 10830(2) 84(1) 
C(25) 7766(4) 3429(3) 9420(2) 74(1) 
C(23) 7980(4) 5192(3) 9569(2) 74(1) 
C(9) 8090(4) 84(3) 9870(3) 92(1) 
C(2) 3637(4) 3752(3) 8269(2) 85(1) 
C(24) 8291(4) 4303(3) 9262(2) 84(1) 
C(27) 3163(4) 3717(4) 12528(2) 93(1) 
C(10) 8812(4) 63(4) 10450(3) 100(2) 
C(35) 3800(4) 1035(3) 8804(3) 95(1) 
C(29) 2908(5) 1913(4) 12546(2) 105(2) 
C(11) 8773(4) 801(4) 10916(3) 101(2) 
C(31) 8196(4) 6981(3) 9733(3) 97(1) 
C(32) 8779(5) 7147(4) 10426(3) 111(2) 
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C(3) 2879(5) 4336(4) 7874(3) 112(2) 
C(34) 9498(13) 6126(6) 8592(8) 313(10) 
C(5) 1881(5) 2895(5) 7521(3) 127(2) 
C(4) 1976(5) 3893(6) 7504(3) 129(2) 
C(28) 4186(5) 3920(5) 13034(3) 125(2) 
C(33) 9950(8) 5986(5) 9139(3) 149(3) 
C(30) 1668(6) 1626(5) 12408(5) 170(3) 
________________________________________________________________________________
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Table 3.   Bond lengths [Å] and angles [°] for APRBH. 
_____________________________________________________ 
O(001)-C(20)  1.376(4) 
O(001)-C(21)  1.381(4) 
O(002)-C(7)  1.224(4) 
N(3)-N(2)  1.388(4) 
N(3)-C(7)  1.379(4) 
N(3)-C(14)  1.499(4) 
N(2)-C(6)  1.292(4) 
N(5)-C(18)  1.383(5) 
N(5)-C(27)  1.445(6) 
N(5)-C(29)  1.462(6) 
C(20)-C(15)  1.377(4) 
C(20)-C(19)  1.387(5) 
C(26)-C(21)  1.373(5) 
C(26)-C(25)  1.389(5) 
C(26)-C(14)  1.513(5) 
C(21)-C(22)  1.373(5) 
C(14)-C(15)  1.503(5) 
C(14)-C(13)  1.519(5) 
C(15)-C(16)  1.394(5) 
N(4)-C(23)  1.363(5) 
N(4)-C(31)  1.436(6) 
N(4)-C(33)  1.768(10) 
C(16)-C(17)  1.359(5) 
C(22)-C(23)  1.403(6) 
C(17)-C(18)  1.401(5) 
C(18)-C(19)  1.396(5) 
C(6)-C(1)  1.475(5) 
C(6)-C(35)  1.486(6) 
C(13)-C(8)  1.370(5) 
C(13)-C(12)  1.380(6) 
C(7)-C(8)  1.463(6) 
C(8)-C(9)  1.407(6) 
C(1)-N(1)  1.346(5) 
C(1)-C(2)  1.377(6) 
N(1)-C(5)  1.324(7) 
C(12)-C(11)  1.383(6) 
C(25)-C(24)  1.372(5) 
C(23)-C(24)  1.405(6) 
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C(9)-C(10)  1.378(7) 
C(2)-C(3)  1.382(6) 
C(27)-C(28)  1.519(7) 
C(10)-C(11)  1.369(8) 
C(29)-C(30)  1.472(9) 
C(31)-C(32)  1.515(7) 
C(3)-C(4)  1.367(8) 
C(34)-C(33)  1.194(11) 
C(5)-C(4)  1.355(9) 
C(20)-O(001)-C(21) 119.2(2) 
N(2)-N(3)-C(7) 125.8(3) 
N(2)-N(3)-C(14) 116.1(2) 
C(7)-N(3)-C(14) 113.3(3) 
C(6)-N(2)-N(3) 117.8(3) 
C(18)-N(5)-C(27) 120.9(3) 
C(18)-N(5)-C(29) 120.6(3) 
C(27)-N(5)-C(29) 115.6(3) 
O(001)-C(20)-C(15) 122.8(3) 
O(001)-C(20)-C(19) 115.1(3) 
C(15)-C(20)-C(19) 122.1(3) 
C(21)-C(26)-C(25) 116.5(3) 
C(21)-C(26)-C(14) 122.9(3) 
C(25)-C(26)-C(14) 120.6(3) 
C(22)-C(21)-C(26) 122.8(3) 
C(22)-C(21)-O(001) 115.1(3) 
C(26)-C(21)-O(001) 122.1(3) 
N(3)-C(14)-C(15) 111.4(3) 
N(3)-C(14)-C(26) 110.8(3) 
C(15)-C(14)-C(26) 110.6(3) 
N(3)-C(14)-C(13) 99.4(3) 
C(15)-C(14)-C(13) 112.0(3) 
C(26)-C(14)-C(13) 112.3(3) 
C(20)-C(15)-C(16) 115.9(3) 
C(20)-C(15)-C(14) 122.3(3) 
C(16)-C(15)-C(14) 121.7(3) 
C(23)-N(4)-C(31) 122.4(4) 
C(23)-N(4)-C(33) 116.7(4) 
C(31)-N(4)-C(33) 117.0(3) 
C(17)-C(16)-C(15) 123.6(3) 
C(21)-C(22)-C(23) 120.8(3) 
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C(16)-C(17)-C(18) 120.3(3) 
N(5)-C(18)-C(17) 121.5(3) 
N(5)-C(18)-C(19) 121.5(3) 
C(17)-C(18)-C(19) 117.0(3) 
N(2)-C(6)-C(1) 114.3(3) 
N(2)-C(6)-C(35) 125.4(4) 
C(1)-C(6)-C(35) 120.1(3) 
C(8)-C(13)-C(12) 121.4(4) 
C(8)-C(13)-C(14) 110.8(3) 
C(12)-C(13)-C(14) 127.8(3) 
C(20)-C(19)-C(18) 121.0(3) 
O(002)-C(7)-N(3) 125.2(4) 
O(002)-C(7)-C(8) 129.4(3) 
N(3)-C(7)-C(8) 105.5(3) 
C(13)-C(8)-C(9) 120.7(4) 
C(13)-C(8)-C(7) 109.9(3) 
C(9)-C(8)-C(7) 129.4(4) 
N(1)-C(1)-C(2) 122.5(4) 
N(1)-C(1)-C(6) 115.3(3) 
C(2)-C(1)-C(6) 122.2(3) 
C(5)-N(1)-C(1) 116.8(4) 
C(11)-C(12)-C(13) 117.5(5) 
C(24)-C(25)-C(26) 122.4(4) 
N(4)-C(23)-C(22) 121.7(4) 
N(4)-C(23)-C(24) 121.7(4) 
C(22)-C(23)-C(24) 116.6(3) 
C(10)-C(9)-C(8) 117.5(4) 
C(3)-C(2)-C(1) 118.7(4) 
C(25)-C(24)-C(23) 120.9(4) 
N(5)-C(27)-C(28) 113.6(4) 
C(11)-C(10)-C(9) 121.0(4) 
N(5)-C(29)-C(30) 114.2(5) 
C(10)-C(11)-C(12) 121.9(5) 
N(4)-C(31)-C(32) 113.5(4) 
C(2)-C(3)-C(4) 118.7(5) 
N(1)-C(5)-C(4) 124.4(5) 
C(5)-C(4)-C(3) 118.8(5) 
C(34)-C(33)-N(4) 86.8(11) 
_____________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
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 Table 4.   Anisotropic displacement parameters (Å2x 103)for APRBH.  The anisotropic 
displacement factor exponent takes the form: -22[ h2a*2U11 + ... + 2 h k a* b* U12 ] 
______________________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
______________________________________________________________________________ 
O(001) 76(2)  48(1) 92(2)  -5(1) 16(1)  -5(1) 
O(002) 103(2)  72(2) 84(2)  -17(1) 27(2)  -8(1) 
N(3) 76(2)  53(1) 62(2)  -5(1) 0(1)  0(1) 
N(2) 77(2)  59(2) 60(2)  -2(1) -6(1)  -6(1) 
N(5) 90(2)  79(2) 71(2)  -5(2) 14(2)  -5(2) 
C(20) 59(2)  54(2) 64(2)  -1(1) -3(1)  -2(1) 
C(26) 68(2)  54(2) 57(2)  1(1) -4(2)  -4(2) 
C(21) 65(2)  56(2) 61(2)  2(1) -2(2)  -2(2) 
C(14) 67(2)  55(2) 55(2)  -3(1) -3(1)  -1(2) 
C(15) 63(2)  49(2) 55(2)  -3(1) -3(1)  -1(1) 
N(4) 106(3)  74(2) 97(2)  9(2) 19(2)  -27(2) 
C(16) 77(2)  48(2) 69(2)  -2(1) -1(2)  -3(2) 
C(22) 72(2)  53(2) 75(2)  3(2) -4(2)  -1(2) 
C(17) 77(2)  59(2) 60(2)  2(2) 4(2)  -7(2) 
C(18) 66(2)  68(2) 57(2)  -4(2) -4(2)  -2(2) 
C(6) 73(2)  67(2) 62(2)  -6(2) 3(2)  -11(2) 
C(13) 71(2)  60(2) 74(2)  10(2) 9(2)  2(2) 
C(19) 69(2)  57(2) 72(2)  -9(2) 1(2)  -3(2) 
C(7) 80(2)  54(2) 73(2)  -6(2) 19(2)  -7(2) 
C(8) 72(2)  59(2) 86(2)  8(2) 20(2)  1(2) 
C(1) 80(2)  82(2) 60(2)  0(2) -5(2)  -11(2) 
N(1) 108(3)  110(3) 90(2)  6(2) -34(2)  -25(2) 
C(12) 76(2)  88(3) 86(3)  19(2) -6(2)  3(2) 
C(25) 90(3)  68(2) 66(2)  -7(2) 11(2)  -12(2) 
C(23) 87(2)  62(2) 70(2)  8(2) -5(2)  -13(2) 
C(9) 90(3)  69(2) 119(3)  10(2) 37(3)  13(2) 
C(2) 91(3)  81(2) 82(2)  7(2) -12(2)  -5(2) 
C(24) 99(3)  83(3) 72(2)  -4(2) 15(2)  -21(2) 
C(27) 93(3)  101(3) 86(3)  -26(2) 18(2)  -9(3) 
C(10) 78(3)  97(3) 127(4)  37(3) 19(3)  24(2) 
C(35) 91(3)  81(3) 113(3)  3(2) -2(2)  -27(2) 
C(29) 137(4)  103(3) 79(3)  10(2) 34(3)  4(3) 
C(11) 74(3)  113(4) 116(4)  40(3) -1(2)  7(3) 
C(31) 95(3)  63(2) 131(4)  21(2) -8(3)  -10(2) 
C(32) 100(3)  92(3) 139(4)  -23(3) 0(3)  -4(3) 
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C(3) 126(4)  102(3) 106(3)  24(3) -14(3)  0(3) 
C(34) 380(17)  126(6) 398(19)  97(9) -273(16)  -70(9) 
C(5) 122(4)  143(5) 109(4)  23(4) -47(3)  -22(4) 
C(4) 117(4)  150(6) 115(4)  37(4) -45(3)  4(4) 
C(28) 115(4)  158(5) 101(3)  -46(3) -5(3)  -15(4) 
C(33) 214(8)  99(4) 126(5)  9(3) -43(5)  -45(5) 
C(30) 133(5)  134(5) 245(9)  71(6) 17(6)  -43(4) 
______________________________________________________________________________ 
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A-II.   Fe
III 
Complexes Crystallographic Data 
 
[Fe
III
(APSMC)2](ClO4)  Crystallographic Data  
 
ORTEP view of the [Fe(APSMC)2]
+
 cation  (30% probability ellipsoids shown). 
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Table 5.  Crystal data and structure refinement for [Fe
III
(APSMC)2] (ClO4). 
Identification code  624mb5 
Empirical formula  C18 H20 Cl Fe N6 O4 S4 
Formula weight  603.94 
Temperature  293(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  C 1 2/m 1 
Unit cell dimensions a = 34.995(5) Å = 90°. 
 b = 10.9177(14) Å = 105.883(15)°. 
 c = 14.831(3) Å  = 90°. 
Volume 5450.0(14) Å3 
Z 8 
Density (calculated) 1.472 Mg/m3 
Absorption coefficient 0.993 mm-1 
F(000) 2472 
Crystal size 0.5 x 0.2 x 0.2 mm3 
Theta range for data collection 3.20 to 25.00°. 
Index ranges -22<=h<=41, -10<=k<=12, -17<=l<=9 
Reflections collected 5679 
Independent reflections 3846 [R(int) = 0.0416] 
Completeness to theta = 25.00° 80.2 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1 and 0.27629 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3846 / 30 / 335 
Goodness-of-fit on F2 1.046 
Final R indices [I>2sigma(I)] R1 = 0.0958, wR2 = 0.2317 
R indices (all data) R1 = 0.1557, wR2 = 0.2698 
Largest diff. peak and hole 0.859 and -0.658 e.Å-3 
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Table 6.  Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å 2x 103) 
for [Fe
III
(APSMC)2] (ClO4).  U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________________ 
C(1A) 9254(3) 5985(9) -1294(7) 63(3) 
C(1B) 9232(3) 8964(10) 295(9) 79(3) 
C(2A) 9525(3) 5053(10) -1142(9) 83(3) 
C(2B) 9498(4) 9908(13) 503(12) 106(4) 
C(3A) 9571(4) 4360(11) -359(10) 92(4) 
C(3B) 9542(5) 10602(13) -221(16) 122(6) 
C(4A) 9354(4) 4625(11) 268(9) 92(4) 
C(4B) 9322(4) 10374(12) -1135(13) 109(5) 
C(5A) 9083(3) 5557(9) 51(7) 66(3) 
C(5B) 9046(3) 9372(11) -1290(9) 80(3) 
C(6A) 8844(3) 5951(11) 669(7) 72(3) 
C(6B) 8816(4) 8973(12) -2184(9) 86(3) 
C(7A) 8875(4) 5430(15) 1605(8) 130(6) 
C(7B) 8828(5) 9515(15) -3105(10) 149(7) 
C(8A) 8129(3) 8204(14) 361(9) 88(4) 
C(8B) 8145(4) 6629(15) -2786(9) 101(5) 
C(9A) 7895(4) 8130(20) 1990(11) 210(11) 
C(9B) 7949(6) 6560(20) -4761(10) 223(12) 
Fe(1) 8588(1) 7439(1) -913(1) 53(1) 
N(1A) 9029(2) 6238(7) -727(5) 56(2) 
N(1B) 9001(2) 8709(7) -561(6) 61(2) 
N(2A) 8595(2) 6832(9) 305(6) 71(2) 
N(2B) 8585(3) 8041(9) -2134(5) 69(2) 
N(3A) 8344(3) 7313(11) 800(6) 85(3) 
N(3B) 8343(3) 7547(12) -2948(7) 96(4) 
S(1A) 8131(1) 8750(3) -721(2) 86(1) 
S(1B) 8164(1) 6019(3) -1689(2) 88(1) 
S(2A) 7791(1) 8872(6) 876(3) 155(2) 
S(2B) 7826(1) 5857(5) -3735(3) 154(2) 
Cl(1) 10000 2562(4) -2500 85(1) 
O(1A) 10000 1271(11) -2500 154(5) 
O(1B) 9612(7) 2925(18) -2440(40) 154(5) 
O(1C) 10286(10) 3082(18) -1790(20) 154(5) 
O(1D) 10027(16) 2954(18) -3396(16) 154(5) 
O(1E) 10358(5) 2003(17) -2370(20) 154(5) 
Appendix 
 
181 
 
O(1F) 10000 3813(11) -2500 154(5) 
O(1G) 9713(6) 1999(15) -2204(19) 154(5) 
O(1H) 9856(7) 3080(30) -3399(14) 154(5) 
Cl(2) 10000 7619(4) -2500 90(1) 
O(2A) 9617(4) 7469(15) -3094(13) 157(11) 
O(2B) 9956(7) 7919(17) -1588(10) 154(10) 
O(2C) 10200(5) 8578(16) -2786(13) 195(14) 
O(2D) 10212(6) 6527(15) -2412(15) 280(30) 
________________________________________________________________________________
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Table 7.   Bond lengths [Å] and angles [°] for [Fe
III
(APSMC)2] (ClO4). 
_____________________________________________________ 
C(1A)-N(1A)  1.330(11) 
C(1A)-C(2A)  1.366(13) 
C(1A)-H(1A)  0.9300 
C(1B)-N(1B)  1.334(12) 
C(1B)-C(2B)  1.368(15) 
C(1B)-H(1B)  0.9300 
C(2A)-C(3A)  1.358(15) 
C(2A)-H(2A)  0.9300 
C(2B)-C(3B)  1.357(19) 
C(2B)-H(2B)  0.9300 
C(3A)-C(4A)  1.383(18) 
C(3A)-H(3A)  0.9300 
C(3B)-C(4B)  1.386(19) 
C(3B)-H(3B)  0.9300 
C(4A)-C(5A)  1.367(15) 
C(4A)-H(4A)  0.9300 
C(4B)-C(5B)  1.437(17) 
C(4B)-H(4B)  0.9300 
C(5A)-N(1A)  1.341(12) 
C(5A)-C(6A)  1.466(14) 
C(5B)-N(1B)  1.346(12) 
C(5B)-C(6B)  1.417(16) 
C(6A)-N(2A)  1.310(13) 
C(6A)-C(7A)  1.475(14) 
C(6B)-N(2B)  1.315(14) 
C(6B)-C(7B)  1.500(15) 
C(7A)-H(7A)  0.9600 
C(7A)-H(7B)  0.9600 
C(7A)-H(7C)  0.9600 
C(7B)-H(7D)  0.9600 
C(7B)-H(7E)  0.9600 
C(7B)-H(7F)  0.9600 
C(8A)-N(3A)  1.293(15) 
C(8A)-S(1A)  1.714(14) 
C(8A)-S(2A)  1.734(11) 
C(8B)-N(3B)  1.278(16) 
C(8B)-S(1B)  1.742(16) 
C(8B)-S(2B)  1.755(13) 
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C(9A)-S(2A)  1.79(2) 
C(9A)-H(9A)  0.9600 
C(9A)-H(9B)  0.9600 
C(9A)-H(9C)  0.9600 
C(9B)-S(2B)  1.86(2) 
C(9B)-H(9D)  0.9600 
C(9B)-H(9E)  0.9600 
C(9B)-H(9F)  0.9600 
Fe(1)-N(2A)  1.918(8) 
Fe(1)-N(2B)  1.924(8) 
Fe(1)-N(1B)  1.967(8) 
Fe(1)-N(1A)  1.984(7) 
Fe(1)-S(1A)  2.223(3) 
Fe(1)-S(1B)  2.235(3) 
N(2A)-N(3A)  1.392(11) 
N(2B)-N(3B)  1.381(12) 
Cl(1)-O(1G)#1  1.348(11) 
Cl(1)-O(1G)  1.348(11) 
Cl(1)-O(1E)#1  1.359(11) 
Cl(1)-O(1E)  1.359(11) 
Cl(1)-O(1C)  1.365(11) 
Cl(1)-O(1C)#1  1.365(11) 
Cl(1)-O(1F)  1.366(11) 
Cl(1)-O(1A)  1.409(12) 
Cl(1)-O(1H)  1.410(11) 
Cl(1)-O(1H)#1  1.410(11) 
Cl(1)-O(1D)  1.423(11) 
Cl(1)-O(1D)#1  1.423(11) 
O(1B)-O(1C)#1  1.30(3) 
O(1B)-O(1D)#1  1.51(3) 
O(1C)-O(1D)#1  1.21(3) 
O(1C)-O(1B)#1  1.30(3) 
O(1D)-O(1C)#1  1.21(3) 
O(1D)-O(1B)#1  1.51(3) 
O(1E)-O(1G)#1  0.61(4) 
O(1F)-O(1H)  1.52(3) 
O(1F)-O(1H)#1  1.52(3) 
O(1G)-O(1E)#1  0.61(4) 
Cl(2)-O(2C)  1.389(11) 
Cl(2)-O(2C)#1  1.389(11) 
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Cl(2)-O(2D)#1  1.391(11) 
Cl(2)-O(2D)  1.391(11) 
Cl(2)-O(2A)  1.398(11) 
Cl(2)-O(2A)#1  1.398(11) 
Cl(2)-O(2B)#1  1.440(11) 
Cl(2)-O(2B)  1.440(11) 
O(2A)-O(2D)#1  1.32(3) 
O(2A)-O(2B)#1  1.76(2) 
O(2A)-O(2C)#1  1.77(3) 
O(2B)-O(2C)#1  1.18(3) 
O(2B)-O(2A)#1  1.76(2) 
O(2C)-O(2B)#1  1.18(3) 
O(2C)-O(2A)#1  1.77(3) 
O(2D)-O(2A)#1  1.32(3) 
O(2D)-O(2D)#1  1.43(4) 
N(1A)-C(1A)-C(2A) 123.7(10) 
N(1A)-C(1A)-H(1A) 118.1 
C(2A)-C(1A)-H(1A) 118.1 
N(1B)-C(1B)-C(2B) 124.8(12) 
N(1B)-C(1B)-H(1B) 117.6 
C(2B)-C(1B)-H(1B) 117.6 
C(3A)-C(2A)-C(1A) 118.0(11) 
C(3A)-C(2A)-H(2A) 121.0 
C(1A)-C(2A)-H(2A) 121.0 
C(3B)-C(2B)-C(1B) 117.3(15) 
C(3B)-C(2B)-H(2B) 121.3 
C(1B)-C(2B)-H(2B) 121.3 
C(2A)-C(3A)-C(4A) 120.0(12) 
C(2A)-C(3A)-H(3A) 120.0 
C(4A)-C(3A)-H(3A) 120.0 
C(2B)-C(3B)-C(4B) 121.4(14) 
C(2B)-C(3B)-H(3B) 119.3 
C(4B)-C(3B)-H(3B) 119.3 
C(5A)-C(4A)-C(3A) 118.0(12) 
C(5A)-C(4A)-H(4A) 121.0 
C(3A)-C(4A)-H(4A) 121.0 
C(3B)-C(4B)-C(5B) 117.5(13) 
C(3B)-C(4B)-H(4B) 121.2 
C(5B)-C(4B)-H(4B) 121.2 
N(1A)-C(5A)-C(4A) 122.8(11) 
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N(1A)-C(5A)-C(6A) 113.9(9) 
C(4A)-C(5A)-C(6A) 123.3(11) 
N(1B)-C(5B)-C(6B) 115.2(10) 
N(1B)-C(5B)-C(4B) 120.1(13) 
C(6B)-C(5B)-C(4B) 124.6(13) 
N(2A)-C(6A)-C(5A) 112.7(9) 
N(2A)-C(6A)-C(7A) 122.7(11) 
C(5A)-C(6A)-C(7A) 124.6(11) 
N(2B)-C(6B)-C(5B) 112.7(10) 
N(2B)-C(6B)-C(7B) 121.9(13) 
C(5B)-C(6B)-C(7B) 125.4(13) 
C(6A)-C(7A)-H(7A) 109.5 
C(6A)-C(7A)-H(7B) 109.5 
H(7A)-C(7A)-H(7B) 109.5 
C(6A)-C(7A)-H(7C) 109.5 
H(7A)-C(7A)-H(7C) 109.5 
H(7B)-C(7A)-H(7C) 109.5 
C(6B)-C(7B)-H(7D) 109.5 
C(6B)-C(7B)-H(7E) 109.5 
H(7D)-C(7B)-H(7E) 109.5 
C(6B)-C(7B)-H(7F) 109.5 
H(7D)-C(7B)-H(7F) 109.5 
H(7E)-C(7B)-H(7F) 109.5 
N(3A)-C(8A)-S(1A) 125.5(8) 
N(3A)-C(8A)-S(2A) 118.0(10) 
S(1A)-C(8A)-S(2A) 116.4(9) 
N(3B)-C(8B)-S(1B) 126.2(10) 
N(3B)-C(8B)-S(2B) 119.0(12) 
S(1B)-C(8B)-S(2B) 114.8(11) 
S(2A)-C(9A)-H(9A) 109.5 
S(2A)-C(9A)-H(9B) 109.5 
H(9A)-C(9A)-H(9B) 109.5 
S(2A)-C(9A)-H(9C) 109.5 
H(9A)-C(9A)-H(9C) 109.5 
H(9B)-C(9A)-H(9C) 109.5 
S(2B)-C(9B)-H(9D) 109.5 
S(2B)-C(9B)-H(9E) 109.5 
H(9D)-C(9B)-H(9E) 109.5 
S(2B)-C(9B)-H(9F) 109.5 
H(9D)-C(9B)-H(9F) 109.5 
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H(9E)-C(9B)-H(9F) 109.5 
N(2A)-Fe(1)-N(2B) 179.6(4) 
N(2A)-Fe(1)-N(1B) 100.0(3) 
N(2B)-Fe(1)-N(1B) 79.9(4) 
N(2A)-Fe(1)-N(1A) 80.3(4) 
N(2B)-Fe(1)-N(1A) 99.3(3) 
N(1B)-Fe(1)-N(1A) 86.7(3) 
N(2A)-Fe(1)-S(1A) 85.8(3) 
N(2B)-Fe(1)-S(1A) 94.7(2) 
N(1B)-Fe(1)-S(1A) 90.8(2) 
N(1A)-Fe(1)-S(1A) 165.2(2) 
N(2A)-Fe(1)-S(1B) 94.7(3) 
N(2B)-Fe(1)-S(1B) 85.4(3) 
N(1B)-Fe(1)-S(1B) 164.0(3) 
N(1A)-Fe(1)-S(1B) 89.7(2) 
S(1A)-Fe(1)-S(1B) 96.49(12) 
C(1A)-N(1A)-C(5A) 117.4(8) 
C(1A)-N(1A)-Fe(1) 128.5(7) 
C(5A)-N(1A)-Fe(1) 114.1(7) 
C(1B)-N(1B)-C(5B) 118.7(10) 
C(1B)-N(1B)-Fe(1) 127.5(7) 
C(5B)-N(1B)-Fe(1) 113.8(8) 
C(6A)-N(2A)-N(3A) 120.2(9) 
C(6A)-N(2A)-Fe(1) 118.5(7) 
N(3A)-N(2A)-Fe(1) 121.2(8) 
C(6B)-N(2B)-N(3B) 119.5(10) 
C(6B)-N(2B)-Fe(1) 118.2(8) 
N(3B)-N(2B)-Fe(1) 122.3(8) 
C(8A)-N(3A)-N(2A) 112.7(9) 
C(8B)-N(3B)-N(2B) 112.0(10) 
C(8A)-S(1A)-Fe(1) 94.8(4) 
C(8B)-S(1B)-Fe(1) 93.8(5) 
C(8A)-S(2A)-C(9A) 102.9(8) 
C(8B)-S(2B)-C(9B) 102.6(9) 
O(1G)#1-Cl(1)-O(1G) 125.7(17) 
O(1G)#1-Cl(1)-O(1E)#1 119.3(8) 
O(1G)-Cl(1)-O(1E)#1 25.9(16) 
O(1G)#1-Cl(1)-O(1E) 25.9(16) 
O(1G)-Cl(1)-O(1E) 119.3(8) 
O(1E)#1-Cl(1)-O(1E) 126.7(18) 
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O(1G)#1-Cl(1)-O(1C) 89(2) 
O(1G)-Cl(1)-O(1C) 113(2) 
O(1E)#1-Cl(1)-O(1C) 138(2) 
O(1E)-Cl(1)-O(1C) 68(2) 
O(1G)#1-Cl(1)-O(1C)#1 113(2) 
O(1G)-Cl(1)-O(1C)#1 89(2) 
O(1E)#1-Cl(1)-O(1C)#1 68(2) 
O(1E)-Cl(1)-O(1C)#1 138(2) 
O(1C)-Cl(1)-O(1C)#1 130.9(18) 
O(1G)#1-Cl(1)-O(1F) 117.1(8) 
O(1G)-Cl(1)-O(1F) 117.1(8) 
O(1E)#1-Cl(1)-O(1F) 116.7(9) 
O(1E)-Cl(1)-O(1F) 116.7(9) 
O(1C)-Cl(1)-O(1F) 65.4(9) 
O(1C)#1-Cl(1)-O(1F) 65.4(9) 
O(1G)#1-Cl(1)-O(1A) 62.9(8) 
O(1G)-Cl(1)-O(1A) 62.9(8) 
O(1E)#1-Cl(1)-O(1A) 63.3(9) 
O(1E)-Cl(1)-O(1A) 63.3(9) 
O(1C)-Cl(1)-O(1A) 114.6(9) 
O(1C)#1-Cl(1)-O(1A) 114.6(9) 
O(1F)-Cl(1)-O(1A) 180.000(3) 
O(1G)#1-Cl(1)-O(1H) 89.0(15) 
O(1G)-Cl(1)-O(1H) 112.8(10) 
O(1E)#1-Cl(1)-O(1H) 88.5(15) 
O(1E)-Cl(1)-O(1H) 112.9(10) 
O(1C)-Cl(1)-O(1H) 124(2) 
O(1C)#1-Cl(1)-O(1H) 26(2) 
O(1F)-Cl(1)-O(1H) 66.1(16) 
O(1A)-Cl(1)-O(1H) 113.9(16) 
O(1G)#1-Cl(1)-O(1H)#1 112.8(10) 
O(1G)-Cl(1)-O(1H)#1 89.0(15) 
O(1E)#1-Cl(1)-O(1H)#1 112.9(10) 
O(1E)-Cl(1)-O(1H)#1 88.5(15) 
O(1C)-Cl(1)-O(1H)#1 26(2) 
O(1C)#1-Cl(1)-O(1H)#1 124(2) 
O(1F)-Cl(1)-O(1H)#1 66.1(16) 
O(1A)-Cl(1)-O(1H)#1 113.9(16) 
O(1H)-Cl(1)-O(1H)#1 132(3) 
O(1G)#1-Cl(1)-O(1D) 66(2) 
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O(1G)-Cl(1)-O(1D) 133(2) 
O(1E)#1-Cl(1)-O(1D) 107(2) 
O(1E)-Cl(1)-O(1D) 88(2) 
O(1C)-Cl(1)-O(1D) 112.1(9) 
O(1C)#1-Cl(1)-O(1D) 51.3(12) 
O(1F)-Cl(1)-O(1D) 72.5(8) 
O(1A)-Cl(1)-O(1D) 107.5(8) 
O(1H)-Cl(1)-O(1D) 25(2) 
O(1H)#1-Cl(1)-O(1D) 131.5(19) 
O(1G)#1-Cl(1)-O(1D)#1 133(2) 
O(1G)-Cl(1)-O(1D)#1 66(2) 
O(1E)#1-Cl(1)-O(1D)#1 88(2) 
O(1E)-Cl(1)-O(1D)#1 107(2) 
O(1C)-Cl(1)-O(1D)#1 51.3(12) 
O(1C)#1-Cl(1)-O(1D)#1 112.1(9) 
O(1F)-Cl(1)-O(1D)#1 72.5(8) 
O(1A)-Cl(1)-O(1D)#1 107.5(8) 
O(1H)-Cl(1)-O(1D)#1 131.5(19) 
O(1H)#1-Cl(1)-O(1D)#1 25(2) 
O(1D)-Cl(1)-O(1D)#1 145.0(17) 
O(1C)#1-O(1B)-Cl(1) 59.6(8) 
O(1C)#1-O(1B)-O(1D)#1 110.6(18) 
Cl(1)-O(1B)-O(1D)#1 57.6(7) 
O(1D)#1-O(1C)-O(1B)#1 131.8(15) 
O(1D)#1-O(1C)-Cl(1) 66.8(8) 
O(1B)#1-O(1C)-Cl(1) 65.4(8) 
O(1C)#1-O(1D)-Cl(1) 61.9(8) 
O(1C)#1-O(1D)-O(1B)#1 115.1(18) 
Cl(1)-O(1D)-O(1B)#1 58.7(7) 
O(1G)#1-O(1E)-Cl(1) 76.1(15) 
Cl(1)-O(1F)-O(1H) 58.3(9) 
Cl(1)-O(1F)-O(1H)#1 58.3(9) 
O(1H)-O(1F)-O(1H)#1 116.7(17) 
O(1E)#1-O(1G)-Cl(1) 78.0(16) 
Cl(1)-O(1H)-O(1F) 55.5(9) 
O(2C)-Cl(2)-O(2C)#1 82.2(19) 
O(2C)-Cl(2)-O(2D)#1 156.6(12) 
O(2C)#1-Cl(2)-O(2D)#1 111.9(8) 
O(2C)-Cl(2)-O(2D) 111.9(8) 
O(2C)#1-Cl(2)-O(2D) 156.6(12) 
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O(2D)#1-Cl(2)-O(2D) 62.0(19) 
O(2C)-Cl(2)-O(2A) 111.9(8) 
O(2C)#1-Cl(2)-O(2A) 78.7(12) 
O(2D)#1-Cl(2)-O(2A) 56.4(14) 
O(2D)-Cl(2)-O(2A) 110.7(8) 
O(2C)-Cl(2)-O(2A)#1 78.7(12) 
O(2C)#1-Cl(2)-O(2A)#1 111.9(8) 
O(2D)#1-Cl(2)-O(2A)#1 110.7(8) 
O(2D)-Cl(2)-O(2A)#1 56.4(14) 
O(2A)-Cl(2)-O(2A)#1 166.6(14) 
O(2C)-Cl(2)-O(2B)#1 49.4(11) 
O(2C)#1-Cl(2)-O(2B)#1 108.0(7) 
O(2D)#1-Cl(2)-O(2B)#1 107.4(8) 
O(2D)-Cl(2)-O(2B)#1 95.2(13) 
O(2A)-Cl(2)-O(2B)#1 76.4(8) 
O(2A)#1-Cl(2)-O(2B)#1 106.7(8) 
O(2C)-Cl(2)-O(2B) 108.0(7) 
O(2C)#1-Cl(2)-O(2B) 49.4(11) 
O(2D)#1-Cl(2)-O(2B) 95.2(13) 
O(2D)-Cl(2)-O(2B) 107.4(8) 
O(2A)-Cl(2)-O(2B) 106.7(8) 
O(2A)#1-Cl(2)-O(2B) 76.4(8) 
O(2B)#1-Cl(2)-O(2B) 153.7(15) 
O(2D)#1-O(2A)-Cl(2) 61.6(9) 
O(2D)#1-O(2A)-O(2B)#1 94.8(13) 
Cl(2)-O(2A)-O(2B)#1 52.9(5) 
O(2D)#1-O(2A)-O(2C)#1 95.6(10) 
Cl(2)-O(2A)-O(2C)#1 50.4(7) 
O(2B)#1-O(2A)-O(2C)#1 81.0(9) 
O(2C)#1-O(2B)-Cl(2) 63.1(9) 
O(2C)#1-O(2B)-O(2A)#1 101.8(14) 
Cl(2)-O(2B)-O(2A)#1 50.7(5) 
O(2B)#1-O(2C)-Cl(2) 67.5(8) 
O(2B)#1-O(2C)-O(2A)#1 99.2(14) 
Cl(2)-O(2C)-O(2A)#1 50.9(7) 
O(2A)#1-O(2D)-Cl(2) 62.1(7) 
O(2A)#1-O(2D)-O(2D)#1 113.0(14) 
Cl(2)-O(2D)-O(2D)#1 59.0(10) 
_____________________________________________________________ 
Symmetry transformations used to generate equivalent atoms: #1 -x+2,y,-z-1/2  
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Table 8.   Anisotropic displacement parameters (Å 2x 103)for [Fe
III
(APSMC)2] (ClO4).  The anisotropic 
displacement factor exponent takes the form: -22[ h2a*2U11 + ... + 2 h k a* b* U12 ] 
______________________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
______________________________________________________________________________ 
C(1A) 64(6)  59(6) 64(6)  -2(5) 14(5)  11(5) 
C(1B) 68(7)  72(7) 108(9)  -21(7) 41(7)  -5(6) 
C(2A) 72(7)  79(8) 89(8)  -21(7) 7(6)  15(6) 
C(2B) 85(9)  73(8) 177(14)  -32(10) 63(9)  -13(7) 
C(3A) 81(9)  63(7) 120(11)  2(8) 5(8)  4(7) 
C(3B) 112(12)  56(8) 211(19)  -18(11) 65(13)  -18(8) 
C(4A) 89(9)  71(8) 99(9)  37(7) -6(8)  -4(7) 
C(4B) 113(11)  63(8) 182(15)  26(10) 92(11)  10(8) 
C(5A) 53(6)  59(6) 82(7)  4(6) 12(5)  -17(5) 
C(5B) 70(7)  78(8) 111(9)  18(7) 59(7)  14(6) 
C(6A) 61(7)  85(8) 64(6)  20(6) 8(5)  -21(6) 
C(6B) 96(9)  89(9) 87(9)  27(7) 51(7)  24(8) 
C(7A) 90(9)  212(16) 74(8)  61(9) 2(7)  -35(10) 
C(7B) 164(14)  165(14) 143(12)  98(12) 86(11)  38(13) 
C(8A) 40(6)  143(12) 90(8)  -44(8) 32(6)  -15(7) 
C(8B) 74(9)  144(13) 71(8)  -35(9) -1(7)  41(9) 
C(9A) 106(12)  410(30) 128(14)  -93(18) 65(10)  -31(17) 
C(9B) 199(19)  380(30) 62(9)  -16(14) -11(11)  90(20) 
Fe(1) 46(1)  62(1) 54(1)  -2(1) 18(1)  -1(1) 
N(1A) 54(5)  56(5) 53(4)  0(4) 8(4)  -3(4) 
N(1B) 51(5)  59(5) 82(6)  -1(5) 34(4)  6(4) 
N(2A) 56(5)  96(7) 65(5)  -7(5) 26(4)  -26(5) 
N(2B) 66(5)  90(6) 52(5)  0(5) 16(4)  26(5) 
N(3A) 56(6)  140(10) 69(6)  -15(6) 33(5)  -27(6) 
N(3B) 76(7)  148(11) 58(6)  11(7) 11(5)  35(7) 
S(1A) 60(2)  103(2) 102(2)  -16(2) 35(2)  13(2) 
S(1B) 59(2)  99(2) 100(2)  -24(2) 10(2)  -12(2) 
S(2A) 69(2)  281(6) 131(3)  -83(4) 54(2)  0(3) 
S(2B) 99(3)  207(5) 122(3)  -71(3) -25(2)  28(3) 
Cl(1) 84(3)  66(2) 118(3)  0 50(2)  0 
Cl(2) 99(3)  69(3) 91(3)  0 6(3)  0 
O(2A) 150(20)  150(20) 127(19)  -4(15) -27(16)  -92(18) 
O(2B) 200(30)  131(18) 130(19)  -69(16) 49(18)  -60(20) 
O(2C) 160(30)  190(20) 220(30)  20(20) 20(20)  -120(20) 
O(2D) 470(80)  240(30) 230(30)  140(40) 240(50)  280(40) 
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Fe
III
(PCSMC)2](ClO4)  Crystallographic Data  
 
ORTEP view of (a) the [Fe(PCSMC)2]
+
 cation  (30% probability ellipsoids shown). 
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Table 1.  Crystal data and structure refinement for [Fe
III
(PCSMC)2](ClO4). 
Identification code  717mb11 
Empirical formula  C16 H16 Cl Fe N6 O4 S4 
Formula weight  575.89 
Temperature  293(2) K 
Wavelength  0.71073 
Crystal system  Monoclinic 
Space group  C 1 2/c 1 
Unit cell dimensions a = 33.4374(17) Å = 90°. 
 b = 8.8580(4) Å = 90.851(5)°. 
 c = 14.8651(10) Å  = 90°. 
Volume 4402.4(4) Å
3
 
Z 8 
Density (calculated) 1.738 Mg/m3 
Absorption coefficient 1.224 mm-1 
F(000) 2344 
Crystal size 0.2 x 0.1 x 0.1 mm3 
Theta range for data collection 2.94 to 25.00°. 
Index ranges -39<=h<=39, -10<=k<=10, -13<=l<=17 
Reflections collected 14700 
Independent reflections 3881 [R(int) = 0.0425] 
Completeness to theta = 25.00° 99.8 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1 and 0.85174 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3881 / 0 / 289 
Goodness-of-fit on F2 1.087 
Final R indices [I>2sigma(I)] R1 = 0.0406, wR2 = 0.0855 
R indices (all data) R1 = 0.0540, wR2 = 0.0908 
Largest diff. peak and hole 0.303 and -0.305 e. Å
- ‎3  
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Table 2.  Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å ‎2 x 103) 
for [Fe
III
(PCSMC)2](ClO4) .  U(eq) is defined as one third of the trace of the orthogonalized U
ij tensor. 
________________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________________ 
C(1A) 6867(1) 1715(4) 4333(2) 41(1) 
C(1B) 6541(1) 3346(3) 6716(2) 40(1) 
C(2A) 7232(1) 2058(4) 3994(2) 48(1) 
C(2B) 6754(1) 3017(4) 7471(2) 50(1) 
C(3A) 7341(1) 3523(4) 3922(2) 47(1) 
C(3B) 6775(1) 1569(4) 7769(2) 47(1) 
C(4A) 7087(1) 4623(4) 4190(2) 40(1) 
C(4B) 6584(1) 478(4) 7285(2) 39(1) 
C(5A) 6721(1) 4214(3) 4485(2) 32(1) 
C(5B) 6387(1) 856(3) 6511(2) 30(1) 
C(6A) 6421(1) 5244(3) 4760(2) 35(1) 
C(6B) 6203(1) -188(3) 5906(2) 33(1) 
C(8A) 5530(1) 4793(3) 5725(2) 36(1) 
C(8B) 5769(1) 229(3) 3863(2) 35(1) 
C(9A) 5282(1) 7592(4) 6182(3) 65(1) 
C(9B) 5579(1) -2593(4) 3300(3) 64(1) 
N(1A) 6614(1) 2768(3) 4568(2) 32(1) 
N(1B) 6363(1) 2287(2) 6231(2) 31(1) 
N(2A) 6100(1) 4640(3) 5045(2) 32(1) 
N(2B) 6057(1) 409(3) 5192(2) 32(1) 
N(3A) 5812(1) 5572(3) 5379(2) 35(1) 
N(3B) 5888(1) -527(3) 4557(2) 36(1) 
O(1) 7274(1) 5974(3) 6107(3) 104(1) 
O(2) 6977(1) 8060(4) 5487(2) 85(1) 
O(3) 7311(1) 8243(3) 6843(2) 73(1) 
O(4) 6714(1) 6960(3) 6741(2) 77(1) 
S(1A) 5509(1) 2854(1) 5761(1) 40(1) 
S(1B) 5824(1) 2138(1) 3725(1) 41(1) 
S(2A) 5136(1) 5680(1) 6222(1) 50(1) 
S(2B) 5542(1) -679(1) 2976(1) 49(1) 
Cl(1) 7073(1) 7302(1) 6298(1) 53(1) 
Fe(1) 6078(1) 2520(1) 5080(1) 30(1) 
________________________________________________________________________________
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Table 3.   Bond lengths [Å] and angles [°] for [Fe
III
(PCSMC)2](ClO4).  
_____________________________________________________ 
C(1A)-N(1A)  1.312(4) 
C(1A)-C(2A)  1.361(4) 
C(1A)-H(1A)  0.9300 
C(1B)-N(1B)  1.319(4) 
C(1B)-C(2B)  1.352(5) 
C(1B)-H(1B)  0.9300 
C(2A)-C(3A)  1.352(5) 
C(2A)-H(2A)  0.9300 
C(2B)-C(3B)  1.359(5) 
C(2B)-H(2B)  0.9300 
C(3A)-C(4A)  1.356(4) 
C(3A)-H(3A)  0.9300 
C(3B)-C(4B)  1.357(4) 
C(3B)-H(3B)  0.9300 
C(4A)-C(5A)  1.356(4) 
C(4A)-H(4A)  0.9300 
C(4B)-C(5B)  1.359(4) 
C(4B)-H(4B)  0.9300 
C(5A)-N(1A)  1.336(4) 
C(5A)-C(6A)  1.421(4) 
C(5B)-N(1B)  1.336(3) 
C(5B)-C(6B)  1.423(4) 
C(6A)-N(2A)  1.277(3) 
C(6A)-H(6A)  0.9300 
C(6B)-N(2B)  1.276(4) 
C(6B)-H(6B)  0.9300 
C(8A)-N(3A)  1.282(4) 
C(8A)-S(2A)  1.710(3) 
C(8A)-S(1A)  1.720(3) 
C(8B)-N(3B)  1.288(4) 
C(8B)-S(2B)  1.713(3) 
C(8B)-S(1B)  1.713(3) 
C(9A)-S(2A)  1.764(3) 
C(9A)-H(9A1)  0.9600 
C(9A)-H(9A2)  0.9600 
C(9A)-H(9A3)  0.9600 
C(9B)-S(2B)  1.767(4) 
C(9B)-H(9B1)  0.9600 
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C(9B)-H(9B2)  0.9600 
C(9B)-H(9B3)  0.9600 
N(1A)-Fe(1)  1.968(2) 
N(1B)-Fe(1)  1.956(3) 
N(2A)-N(3A)  1.368(3) 
N(2A)-Fe(1)  1.880(2) 
N(2B)-N(3B)  1.371(3) 
N(2B)-Fe(1)  1.879(2) 
O(1)-Cl(1)  1.386(3) 
O(2)-Cl(1)  1.413(3) 
O(3)-Cl(1)  1.401(3) 
O(4)-Cl(1)  1.412(3) 
S(1A)-Fe(1)  2.1891(9) 
S(1B)-Fe(1)  2.2012(10) 
 
N(1A)-C(1A)-C(2A) 121.8(3) 
N(1A)-C(1A)-H(1A) 119.1 
C(2A)-C(1A)-H(1A) 119.1 
N(1B)-C(1B)-C(2B) 121.9(3) 
N(1B)-C(1B)-H(1B) 119.1 
C(2B)-C(1B)-H(1B) 119.1 
C(3A)-C(2A)-C(1A) 119.1(3) 
C(3A)-C(2A)-H(2A) 120.4 
C(1A)-C(2A)-H(2A) 120.4 
C(1B)-C(2B)-C(3B) 119.9(3) 
C(1B)-C(2B)-H(2B) 120.1 
C(3B)-C(2B)-H(2B) 120.1 
C(2A)-C(3A)-C(4A) 119.7(3) 
C(2A)-C(3A)-H(3A) 120.1 
C(4A)-C(3A)-H(3A) 120.1 
C(4B)-C(3B)-C(2B) 118.5(3) 
C(4B)-C(3B)-H(3B) 120.7 
C(2B)-C(3B)-H(3B) 120.7 
C(5A)-C(4A)-C(3A) 118.4(3) 
C(5A)-C(4A)-H(4A) 120.8 
C(3A)-C(4A)-H(4A) 120.8 
C(3B)-C(4B)-C(5B) 119.4(3) 
C(3B)-C(4B)-H(4B) 120.3 
C(5B)-C(4B)-H(4B) 120.3 
N(1A)-C(5A)-C(4A) 122.0(3) 
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N(1A)-C(5A)-C(6A) 113.4(2) 
C(4A)-C(5A)-C(6A) 124.5(3) 
N(1B)-C(5B)-C(4B) 121.6(3) 
N(1B)-C(5B)-C(6B) 113.3(3) 
C(4B)-C(5B)-C(6B) 125.1(3) 
N(2A)-C(6A)-C(5A) 115.3(3) 
N(2A)-C(6A)-H(6A) 122.4 
C(5A)-C(6A)-H(6A) 122.4 
N(2B)-C(6B)-C(5B) 114.4(3) 
N(2B)-C(6B)-H(6B) 122.8 
C(5B)-C(6B)-H(6B) 122.8 
N(3A)-C(8A)-S(2A) 120.1(2) 
N(3A)-C(8A)-S(1A) 125.4(2) 
S(2A)-C(8A)-S(1A) 114.45(18) 
N(3B)-C(8B)-S(2B) 120.0(2) 
N(3B)-C(8B)-S(1B) 125.3(2) 
S(2B)-C(8B)-S(1B) 114.70(19) 
S(2A)-C(9A)-H(9A1) 109.5 
S(2A)-C(9A)-H(9A2) 109.5 
H(9A1)-C(9A)-H(9A2) 109.5 
S(2A)-C(9A)-H(9A3) 109.5 
H(9A1)-C(9A)-H(9A3) 109.5 
H(9A2)-C(9A)-H(9A3) 109.5 
S(2B)-C(9B)-H(9B1) 109.5 
S(2B)-C(9B)-H(9B2) 109.5 
H(9B1)-C(9B)-H(9B2) 109.5 
S(2B)-C(9B)-H(9B3) 109.5 
H(9B1)-C(9B)-H(9B3) 109.5 
H(9B2)-C(9B)-H(9B3) 109.5 
C(1A)-N(1A)-C(5A) 118.8(3) 
C(1A)-N(1A)-Fe(1) 128.3(2) 
C(5A)-N(1A)-Fe(1) 112.92(18) 
C(1B)-N(1B)-C(5B) 118.6(3) 
C(1B)-N(1B)-Fe(1) 127.7(2) 
C(5B)-N(1B)-Fe(1) 113.55(19) 
C(6A)-N(2A)-N(3A) 117.9(2) 
C(6A)-N(2A)-Fe(1) 117.4(2) 
N(3A)-N(2A)-Fe(1) 124.40(18) 
C(6B)-N(2B)-N(3B) 118.1(2) 
C(6B)-N(2B)-Fe(1) 118.1(2) 
Appendix 
 
197 
 
N(3B)-N(2B)-Fe(1) 123.8(2) 
C(8A)-N(3A)-N(2A) 110.3(2) 
C(8B)-N(3B)-N(2B) 110.8(2) 
C(8A)-S(1A)-Fe(1) 94.85(11) 
C(8B)-S(1B)-Fe(1) 94.73(12) 
C(8A)-S(2A)-C(9A) 102.21(16) 
C(8B)-S(2B)-C(9B) 102.26(18) 
O(1)-Cl(1)-O(3) 110.6(2) 
O(1)-Cl(1)-O(4) 109.4(2) 
O(3)-Cl(1)-O(4) 109.69(18) 
O(1)-Cl(1)-O(2) 109.5(2) 
O(3)-Cl(1)-O(2) 109.3(2) 
O(4)-Cl(1)-O(2) 108.36(19) 
N(2B)-Fe(1)-N(2A) 176.51(11) 
N(2B)-Fe(1)-N(1B) 80.53(10) 
N(2A)-Fe(1)-N(1B) 96.40(10) 
N(2B)-Fe(1)-N(1A) 100.39(10) 
N(2A)-Fe(1)-N(1A) 80.93(10) 
N(1B)-Fe(1)-N(1A) 85.25(10) 
N(2B)-Fe(1)-S(1A) 93.42(7) 
N(2A)-Fe(1)-S(1A) 84.97(7) 
N(1B)-Fe(1)-S(1A) 91.42(7) 
N(1A)-Fe(1)-S(1A) 165.04(7) 
N(2B)-Fe(1)-S(1B) 85.03(8) 
N(2A)-Fe(1)-S(1B) 98.23(8) 
N(1B)-Fe(1)-S(1B) 163.80(7) 
N(1A)-Fe(1)-S(1B) 90.21(8) 
S(1A)-Fe(1)-S(1B) 96.75(4) 
_____________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
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Table 4.   Anisotropic displacement parameters (Å ‎2 x 103) for [Fe
III
(PCSMC)2](ClO4)  .  The anisotropic 
displacement factor exponent takes the form: -22[ h2a*2U11 + ... + 2 h k a* b* U12 ] 
______________________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
______________________________________________________________________________ 
C(1A) 45(2)  37(2) 40(2)  -3(1) -3(2)  6(2) 
C(1B) 50(2)  33(2) 38(2)  -1(1) -8(2)  -5(1) 
C(2A) 43(2)  55(2) 46(2)  -5(2) 1(2)  14(2) 
C(2B) 59(2)  48(2) 42(2)  -7(2) -14(2)  -11(2) 
C(3A) 35(2)  67(2) 40(2)  5(2) 4(2)  4(2) 
C(3B) 50(2)  55(2) 35(2)  4(2) -16(2)  2(2) 
C(4A) 37(2)  47(2) 35(2)  7(2) 2(2)  -1(1) 
C(4B) 39(2)  40(2) 37(2)  7(1) -5(2)  0(1) 
C(5A) 35(2)  35(2) 27(2)  4(1) -1(1)  4(1) 
C(5B) 29(2)  30(2) 31(2)  2(1) 0(1)  0(1) 
C(6A) 38(2)  28(2) 37(2)  6(1) 2(2)  -1(1) 
C(6B) 34(2)  28(2) 37(2)  7(1) -5(1)  -3(1) 
C(8A) 36(2)  38(2) 33(2)  0(1) -4(2)  5(1) 
C(8B) 28(2)  42(2) 34(2)  -3(1) -4(1)  -5(1) 
C(9A) 50(2)  52(2) 93(3)  -25(2) 14(2)  4(2) 
C(9B) 83(3)  56(2) 53(3)  -9(2) -5(2)  -25(2) 
N(1A) 34(1)  32(1) 31(2)  1(1) -2(1)  2(1) 
N(1B) 33(1)  30(1) 29(2)  1(1) -3(1)  -1(1) 
N(2A) 31(1)  32(1) 32(2)  5(1) -1(1)  4(1) 
N(2B) 31(1)  29(1) 36(2)  -1(1) -2(1)  -2(1) 
N(3A) 33(1)  34(1) 40(2)  2(1) 5(1)  7(1) 
N(3B) 38(2)  36(1) 35(2)  -3(1) -9(1)  -6(1) 
O(1) 111(3)  70(2) 131(3)  -23(2) -2(2)  48(2) 
O(2) 85(2)  92(2) 78(2)  24(2) -16(2)  5(2) 
O(3) 62(2)  83(2) 74(2)  -15(2) -2(2)  -27(1) 
O(4) 55(2)  53(2) 124(3)  6(2) 15(2)  -15(1) 
S(1A) 35(1)  39(1) 44(1)  6(1) 3(1)  -1(1) 
S(1B) 47(1)  42(1) 35(1)  5(1) -10(1)  -2(1) 
S(2A) 38(1)  51(1) 60(1)  -8(1) 11(1)  2(1) 
S(2B) 50(1)  57(1) 40(1)  -5(1) -13(1)  -10(1) 
Cl(1) 48(1)  41(1) 70(1)  -8(1) -4(1)  3(1) 
Fe(1) 31(1)  28(1) 31(1)  3(1) -3(1)  -1(1) 
______________________________________________________________________________
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Table 5.   Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å
 2
x 103) 
for [Fe
III
(PCSMC)2](ClO4).  
________________________________________________________________________________ 
 x  y  z  U(eq) 
________________________________________________________________________________ 
 
H(1A) 6796 707 4400 49 
H(1B) 6519 4347 6533 48 
H(2A) 7405 1294 3815 58 
H(2B) 6885 3781 7786 59 
H(3A) 7589 3775 3689 57 
H(3B) 6917 1330 8292 56 
H(4A) 7162 5633 4171 48 
H(4B) 6589 -518 7482 46 
H(6A) 6455 6284 4733 41 
H(6B) 6190 -1218 6022 39 
H(9A1) 5079 8207 6448 97 
H(9A2) 5317 7889 5567 97 
H(9A3) 5529 7720 6509 97 
H(9B1) 5459 -3218 2843 96 
H(9B2) 5443 -2740 3857 96 
H(9B3) 5856 -2861 3376 96 
________________________________________________________________________________
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[Fe
III
(PCSMC)(PSMC)]  Crystallographic Data  
 
ORTEP view of [Fe(PCSMC)(PSMC)] (30% probability ellipsoids shown). 
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Table 1.  Crystal data and structure refinement for [Fe
III
(PCSMC)(PSMC)]. 
Identification code  689mb8 
Empirical formula  C19 H21 Fe N6 O2 S4 
Formula weight  549.51 
Temperature  293(2) K 
Wavelength  0.71073 Å 
Crystal system  TRIGONAL 
Space group  R -3 
Unit cell dimensions a = 36.376(5) Å = 90°. 
 b = 36.376(5) Å = 90°. 
 c = 9.3420(7) Å  = 120°. 
Volume 10705(2) Å  3  
Z 18 
Density (calculated) 1.534 Mg/m3 
Absorption coefficient 1.014 mm-1 
F(000) 5094 
Crystal size 0.4184 x 0.1823 x 0.1251 mm3 
Theta range for data collection 2.96 to 24.99°. 
Index ranges -36<=h<=43, -43<=k<=13, -11<=l<=10 
Reflections collected 8404 
Independent reflections 4169 [R(int) = 0.0729] 
Completeness to theta = 24.99° 99.8 %  
Absorption correction Analytical 
Max. and min. transmission 0.994 and 0.987 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4169 / 0 / 253 
Goodness-of-fit on F2 0.949 
Final R indices [I>2sigma(I)] R1 = 0.0933, wR2 = 0.2160 
R indices (all data) R1 = 0.1707, wR2 = 0.2546 
Largest diff. peak and hole 0.858 and -0.452 e. Å‎-3 
Appendix 
 
202 
 
Table 2.  Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å  2 x 103) 
for [Fe
III
(PCSMC)(PSMC)]  .  U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________________ 
C(1A) 8821(3) 648(3) -2140(9) 60(3) 
C(1B) 7658(3) 382(4) -610(11) 72(3) 
C(2A) 8951(4) 765(4) -3534(11) 87(4) 
C(2B) 7513(4) 677(4) -449(14) 90(4) 
C(3A) 8722(4) 491(4) -4618(10) 97(4) 
C(3B) 7716(4) 1007(4) 465(13) 86(4) 
C(4A) 8369(3) 100(4) -4278(10) 73(3) 
C(4B) 8069(3) 1065(3) 1173(11) 73(3) 
C(5A) 8257(3) 12(3) -2879(8) 49(2) 
C(5B) 8209(3) 782(3) 970(9) 49(2) 
C(6A) 7885(3) -398(3) -2450(9) 57(3) 
C(6B) 8569(3) 809(3) 1643(8) 47(2) 
C(8A) 7503(3) -737(3) 981(10) 59(3) 
C(8B) 9045(3) 221(3) 1570(9) 47(2) 
C(9A) 7123(5) -1049(4) 3582(13) 147(7) 
C(9B) 9733(3) 608(4) 3328(10) 82(3) 
N(1A) 8482(2) 283(2) -1819(6) 46(2) 
N(1B) 8004(2) 443(2) 109(7) 51(2) 
N(2A) 7837(2) -405(2) -985(7) 47(2) 
N(2B) 8652(2) 516(2) 1350(6) 43(2) 
N(3A) 7517(2) -766(2) -391(8) 54(2) 
N(3B) 8994(2) 523(2) 1986(7) 46(2) 
O(1A) 7659(2) -683(2) -3305(6) 71(2) 
S(1A) 7857(1) -303(1) 1986(2) 56(1) 
S(1B) 8727(1) -163(1) 309(2) 57(1) 
S(2A) 7106(1) -1206(1) 1798(3) 105(1) 
S(2B) 9457(1) 154(1) 2217(3) 84(1) 
Fe(1) 8250(1) 62(1) 121(1) 44(1) 
________________________________________________________________________________
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Table 3.   Bond lengths [Å] and angles [°] for [Fe
III
(PCSMC)(PSMC)]. 
_____________________________________________________ 
C(1A)-N(1A)  1.316(10) 
C(1A)-C(2A)  1.379(12) 
C(1A)-H(1A)  0.9300 
C(1B)-N(1B)  1.343(11) 
C(1B)-C(2B)  1.421(15) 
C(1B)-H(1B)  0.9300 
C(2A)-C(3A)  1.372(14) 
C(2A)-H(2A)  0.9300 
C(2B)-C(3B)  1.352(16) 
C(2B)-H(2B)  0.9300 
C(3A)-C(4A)  1.395(15) 
C(3A)-H(3A)  0.9300 
C(3B)-C(4B)  1.363(15) 
C(3B)-H(3B)  0.9300 
C(4A)-C(5A)  1.359(12) 
C(4A)-H(4A)  0.9300 
C(4B)-C(5B)  1.372(12) 
C(4B)-H(4B)  0.9300 
C(5A)-N(1A)  1.348(10) 
C(5A)-C(6A)  1.482(13) 
C(5B)-N(1B)  1.344(11) 
C(5B)-C(6B)  1.409(12) 
C(6A)-O(1A)  1.239(10) 
C(6A)-N(2A)  1.379(10) 
C(6B)-N(2B)  1.273(10) 
C(6B)-H(6B)  0.9300 
C(8A)-N(3A)  1.289(10) 
C(8A)-S(1A)  1.732(10) 
C(8A)-S(2A)  1.765(9) 
C(8B)-N(3B)  1.261(10) 
C(8B)-S(2B)  1.740(9) 
C(8B)-S(1B)  1.751(9) 
C(9A)-S(2A)  1.753(13) 
C(9A)-H(9A)  0.9600 
C(9A)-H(9B)  0.9600 
C(9A)-H(9C)  0.9600 
C(9B)-S(2B)  1.776(10) 
C(9B)-H(9D)  0.9600 
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C(9B)-H(9E)  0.9600 
C(9B)-H(9F)  0.9600 
N(1A)-Fe(1)  1.992(6) 
N(1B)-Fe(1)  1.990(7) 
N(2A)-N(3A)  1.365(9) 
N(2A)-Fe(1)  1.911(7) 
N(2B)-N(3B)  1.369(9) 
N(2B)-Fe(1)  1.942(7) 
S(1A)-Fe(1)  2.223(2) 
S(1B)-Fe(1)  2.265(3) 
 
N(1A)-C(1A)-C(2A) 122.1(9) 
N(1A)-C(1A)-H(1A) 118.9 
C(2A)-C(1A)-H(1A) 118.9 
N(1B)-C(1B)-C(2B) 119.6(11) 
N(1B)-C(1B)-H(1B) 120.2 
C(2B)-C(1B)-H(1B) 120.2 
C(3A)-C(2A)-C(1A) 118.8(10) 
C(3A)-C(2A)-H(2A) 120.6 
C(1A)-C(2A)-H(2A) 120.6 
C(3B)-C(2B)-C(1B) 119.4(11) 
C(3B)-C(2B)-H(2B) 120.3 
C(1B)-C(2B)-H(2B) 120.3 
C(2A)-C(3A)-C(4A) 119.2(9) 
C(2A)-C(3A)-H(3A) 120.4 
C(4A)-C(3A)-H(3A) 120.4 
C(2B)-C(3B)-C(4B) 120.0(11) 
C(2B)-C(3B)-H(3B) 120.0 
C(4B)-C(3B)-H(3B) 120.0 
C(5A)-C(4A)-C(3A) 118.3(10) 
C(5A)-C(4A)-H(4A) 120.9 
C(3A)-C(4A)-H(4A) 120.9 
C(3B)-C(4B)-C(5B) 119.4(11) 
C(3B)-C(4B)-H(4B) 120.3 
C(5B)-C(4B)-H(4B) 120.3 
N(1A)-C(5A)-C(4A) 122.2(9) 
N(1A)-C(5A)-C(6A) 117.0(7) 
C(4A)-C(5A)-C(6A) 120.8(9) 
N(1B)-C(5B)-C(4B) 121.8(9) 
N(1B)-C(5B)-C(6B) 113.7(8) 
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C(4B)-C(5B)-C(6B) 124.5(9) 
O(1A)-C(6A)-N(2A) 126.9(9) 
O(1A)-C(6A)-C(5A) 123.9(8) 
N(2A)-C(6A)-C(5A) 109.2(8) 
N(2B)-C(6B)-C(5B) 116.6(8) 
N(2B)-C(6B)-H(6B) 121.7 
C(5B)-C(6B)-H(6B) 121.7 
N(3A)-C(8A)-S(1A) 124.9(7) 
N(3A)-C(8A)-S(2A) 113.4(7) 
S(1A)-C(8A)-S(2A) 121.6(5) 
N(3B)-C(8B)-S(2B) 121.7(7) 
N(3B)-C(8B)-S(1B) 125.1(7) 
S(2B)-C(8B)-S(1B) 113.2(5) 
S(2A)-C(9A)-H(9A) 109.5 
S(2A)-C(9A)-H(9B) 109.5 
H(9A)-C(9A)-H(9B) 109.5 
S(2A)-C(9A)-H(9C) 109.5 
H(9A)-C(9A)-H(9C) 109.5 
H(9B)-C(9A)-H(9C) 109.5 
S(2B)-C(9B)-H(9D) 109.5 
S(2B)-C(9B)-H(9E) 109.5 
H(9D)-C(9B)-H(9E) 109.5 
S(2B)-C(9B)-H(9F) 109.5 
H(9D)-C(9B)-H(9F) 109.5 
H(9E)-C(9B)-H(9F) 109.5 
C(1A)-N(1A)-C(5A) 119.4(7) 
C(1A)-N(1A)-Fe(1) 127.5(6) 
C(5A)-N(1A)-Fe(1) 113.1(6) 
C(1B)-N(1B)-C(5B) 119.7(8) 
C(1B)-N(1B)-Fe(1) 126.8(7) 
C(5B)-N(1B)-Fe(1) 113.4(6) 
N(3A)-N(2A)-C(6A) 117.3(7) 
N(3A)-N(2A)-Fe(1) 123.3(5) 
C(6A)-N(2A)-Fe(1) 119.0(6) 
C(6B)-N(2B)-N(3B) 119.1(7) 
C(6B)-N(2B)-Fe(1) 116.4(6) 
N(3B)-N(2B)-Fe(1) 124.3(5) 
C(8A)-N(3A)-N(2A) 112.0(7) 
C(8B)-N(3B)-N(2B) 112.2(7) 
C(8A)-S(1A)-Fe(1) 94.7(3) 
Appendix 
 
206 
 
C(8B)-S(1B)-Fe(1) 94.8(3) 
C(9A)-S(2A)-C(8A) 102.6(5) 
C(8B)-S(2B)-C(9B) 101.5(5) 
N(2A)-Fe(1)-N(2B) 176.5(3) 
N(2A)-Fe(1)-N(1B) 100.9(3) 
N(2B)-Fe(1)-N(1B) 79.7(3) 
N(2A)-Fe(1)-N(1A) 81.6(3) 
N(2B)-Fe(1)-N(1A) 102.0(3) 
N(1B)-Fe(1)-N(1A) 87.8(3) 
N(2A)-Fe(1)-S(1A) 84.8(2) 
N(2B)-Fe(1)-S(1A) 91.74(19) 
N(1B)-Fe(1)-S(1A) 92.4(2) 
N(1A)-Fe(1)-S(1A) 166.1(2) 
N(2A)-Fe(1)-S(1B) 97.1(2) 
N(2B)-Fe(1)-S(1B) 82.8(2) 
N(1B)-Fe(1)-S(1B) 160.8(2) 
N(1A)-Fe(1)-S(1B) 88.3(2) 
S(1A)-Fe(1)-S(1B) 95.93(10) 
_____________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
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Table 4.   Anisotropic displacement parameters (Å ‎2 x 103) for [Fe
III
(PCSMC)(PSMC)]  .  The anisotropic 
displacement factor exponent takes the form: -22[ h2a*2U11 + ... + 2 h k a* b* U12 ]. 
______________________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
______________________________________________________________________________ 
C(1A) 57(6)  56(6) 40(5)  6(4) 10(5)  8(5) 
C(1B) 56(7)  86(8) 80(7)  -7(6) -3(6)  40(6) 
C(2A) 76(8)  79(8) 73(8)  11(6) 35(6)  13(7) 
C(2B) 78(9)  103(10) 120(10)  17(9) -9(8)  68(8) 
C(3A) 122(11)  108(10) 30(5)  -14(6) 0(6)  33(9) 
C(3B) 96(10)  73(9) 109(10)  21(7) 31(8)  58(8) 
C(4A) 70(8)  79(8) 51(6)  -12(6) -2(5)  22(7) 
C(4B) 55(7)  75(8) 93(8)  10(6) 9(6)  36(6) 
C(5A) 67(6)  58(6) 27(4)  3(4) 1(4)  35(5) 
C(5B) 59(6)  42(6) 53(5)  3(4) 10(5)  31(5) 
C(6A) 56(6)  73(7) 34(5)  -7(5) -7(5)  27(6) 
C(6B) 58(6)  40(5) 37(5)  -5(4) 1(4)  20(5) 
C(8A) 60(7)  40(6) 56(6)  13(4) 16(5)  9(5) 
C(8B) 45(6)  38(5) 56(5)  14(4) 10(4)  18(5) 
C(9A) 145(13)  81(10) 118(11)  17(8) 76(10)  -17(9) 
C(9B) 68(7)  119(10) 63(6)  -7(6) -20(5)  49(7) 
N(1A) 53(5)  52(5) 26(4)  -3(3) 4(3)  22(4) 
N(1B) 49(5)  51(5) 50(4)  13(4) 5(4)  24(4) 
N(2A) 39(4)  48(5) 47(4)  -10(3) -1(3)  15(4) 
N(2B) 50(5)  39(4) 36(4)  1(3) 10(3)  20(4) 
N(3A) 40(5)  52(5) 55(5)  0(4) 5(4)  12(4) 
N(3B) 51(5)  44(5) 45(4)  1(3) 4(4)  25(4) 
O(1A) 71(5)  71(5) 55(4)  -17(4) -23(4)  25(4) 
S(1A) 69(2)  49(2) 39(1)  4(1) 10(1)  21(1) 
S(1B) 66(2)  54(2) 55(1)  -9(1) -3(1)  33(1) 
S(2A) 112(3)  64(2) 78(2)  7(2) 30(2)  -2(2) 
S(2B) 80(2)  94(2) 95(2)  5(2) -16(2)  55(2) 
Fe(1) 48(1)  42(1) 36(1)  -2(1) 3(1)  18(1) 
______________________________________________________________________________
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Table 5.   Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å 2x 103) 
for [Fe
III
(PCSMC)(PSMC)]. 
________________________________________________________________________________ 
 x  y  z  U(eq) 
________________________________________________________________________________ 
 
H(1A) 8977 831 -1403 72 
H(1B) 7514 149 -1209 86 
H(2A) 9191 1025 -3736 104 
H(2B) 7280 644 -968 108 
H(3A) 8800 566 -5568 117 
H(3B) 7616 1194 611 103 
H(4A) 8215 -96 -4991 88 
H(4B) 8214 1295 1788 87 
H(6B) 8736 1028 2269 56 
H(9A) 6913 -1284 4129 221 
H(9B) 7065 -819 3623 221 
H(9C) 7399 -958 3972 221 
H(9D) 9969 605 3768 123 
H(9E) 9545 604 4057 123 
H(9F) 9833 860 2761 123 
________________________________________________________________________________ 
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[Fe
III
(PKSMC)2](ClO4)   Crystallographic Data  
 
ORTEP view of the [Fe(PKSMC)2]
+
 and MPPT
+
 cations (30% probability ellipsoids). 
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Table 1.  Crystal data and structure refinement for [Fe
III
(PKSMC)2](ClO4). 
Identification code  614mb4 
Empirical formula  C39 H33 Cl2 Fe N12 O8 S5 
Formula weight  1084.82 
Temperature  293(2) K 
Wavelength  1.54184 Å 
Crystal system  Triclinic 
Space group  P -1 
Unit cell dimensions a = 7.9883(3) Å = 89.484(4)°. 
 b = 14.5465(7) Å = 82.777(4)°. 
 c = 20.3055(9) Å  = 84.060(4)°. 
Volume 2328.22(18) Å ‎3  
Z 2 
Density (calculated) 1.547 Mg/m3 
Absorption coefficient 6.302 mm-1 
F(000) 1110 
Crystal size 0.4 x 0.1 x 0.06 mm3 
Theta range for data collection 3.05 to 62.47°. 
Index ranges -7<=h<=9, -16<=k<=16, -23<=l<=23 
Reflections collected 21135 
Independent reflections 7365 [R(int) = 0.0398] 
Completeness to theta = 62.47° 99.2 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1 and 0.58346 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 7365 / 21 / 653 
Goodness-of-fit on F2 1.025 
Final R indices [I>2sigma(I)] R1 = 0.0424, wR2 = 0.1032 
R indices (all data) R1 = 0.0554, wR2 = 0.1120 
Largest diff. peak and hole 0.405 and -0.335 e. Å‎-3 
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Table 2.  Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å ‎2 x 103) 
for [Fe
III
(PKSMC)2](ClO4). U(eq) is defined as one third of the trace of the orthogonalized U
ij tensor. 
________________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________________ 
C(1A) 556(4) 1404(3) 5789(2) 62(1) 
C(1B) 1384(4) 2850(2) 7459(2) 54(1) 
C(2A) -688(5) 835(3) 5719(2) 75(1) 
C(2B) 389(5) 3592(3) 7761(2) 63(1) 
C(3A) -893(4) 95(3) 6130(2) 72(1) 
C(3B) 185(5) 4399(3) 7411(2) 66(1) 
C(4A) 174(4) -80(2) 6617(2) 60(1) 
C(4B) 951(4) 4449(2) 6768(2) 59(1) 
C(5A) 1428(4) 501(2) 6664(2) 46(1) 
C(5B) 1902(4) 3679(2) 6479(2) 48(1) 
C(6A) 2729(4) 370(2) 7113(2) 45(1) 
C(6B) 2716(4) 3599(2) 5789(2) 47(1) 
C(7A) 2817(4) -395(2) 7595(2) 51(1) 
C(7B) 2562(4) 4354(2) 5295(2) 51(1) 
C(8A) 6081(4) 1579(2) 7299(2) 47(1) 
C(8B) 5127(4) 1792(2) 4947(2) 52(1) 
C(9A) 7458(5) 760(3) 8363(2) 76(1) 
C(9B) 6005(6) 2467(3) 3687(2) 85(1) 
C(10A) 4294(5) -966(2) 7617(2) 65(1) 
C(10B) 2276(5) 4171(3) 4654(2) 63(1) 
C(11A) 4285(8) -1684(3) 8067(2) 90(1) 
C(11B) 2180(5) 4892(4) 4214(2) 83(1) 
C(12A) 2870(10) -1796(3) 8469(2) 105(2) 
C(12B) 2298(6) 5758(4) 4426(3) 90(1) 
C(13A) 1448(8) -1211(4) 8417(2) 101(2) 
C(13B) 2541(6) 5890(3) 5069(3) 90(1) 
N(1A) 1605(3) 1237(2) 6251(1) 49(1) 
N(1B) 2127(3) 2881(2) 6832(1) 46(1) 
N(2A) 3831(3) 980(2) 7024(1) 43(1) 
N(2B) 3537(3) 2784(2) 5653(1) 45(1) 
N(3A) 5101(3) 933(2) 7432(1) 48(1) 
N(3B) 4401(3) 2633(2) 5021(1) 52(1) 
N(4A) 1373(4) -499(2) 7980(2) 75(1) 
N(4B) 2690(4) 5200(2) 5514(2) 70(1) 
S(1A) 5906(1) 2404(1) 6681(1) 52(1) 
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S(1B) 5029(1) 938(1) 5550(1) 51(1) 
S(2A) 7717(1) 1678(1) 7775(1) 63(1) 
S(2B) 6331(1) 1468(1) 4200(1) 75(1) 
Fe(1) 3638(1) 1880(1) 6340(1) 42(1) 
Cl(1) 1169(1) 2729(1) 2965(1) 82(1) 
O(1A) 2273(6) 3410(3) 2819(2) 129(1) 
O(1B) 1444(17) 2257(7) 3532(4) 220(6) 
O(1C) 1538(13) 2083(6) 2442(4) 185(4) 
O(1D) -412(9) 3115(7) 2975(8) 285(9) 
O(1E) 2009(15) 1978(10) 3213(7) 80(5) 
O(1F) 80(20) 3141(10) 3560(7) 101(6) 
O(1G) 140(30) 2561(12) 2541(7) 119(7) 
Cl(2) -1957(1) 2771(1) 9701(1) 71(1) 
O(2A) -607(8) 2234(6) 9283(4) 179(4) 
O(2B) -2611(9) 3393(4) 9222(3) 123(2) 
O(2C) -1243(13) 3141(7) 10181(4) 149(4) 
O(2D) -3216(8) 2178(5) 9877(3) 124(3) 
O(2E) -1820(30) 1842(10) 9724(10) 83(6) 
O(2F) -3560(20) 3104(15) 10005(11) 93(7) 
O(2G) -1260(30) 3121(13) 9156(9) 97(7) 
O(2H) -900(30) 3010(20) 10287(13) 102(11) 
O(2I) -3120(20) 3279(13) 10244(10) 82(6) 
O(2J) -2960(40) 2670(30) 9239(14) 370(40) 
O(2K) -780(30) 3484(17) 9553(16) 152(11) 
O(2L) -1260(30) 2002(13) 9957(16) 138(11) 
C(1C) -7427(7) 5710(3) 8281(3) 94(1) 
C(2C) -6196(8) 5687(4) 7746(3) 107(2) 
C(3C) -5057(8) 4913(4) 7634(2) 105(2) 
C(4C) -5189(6) 4184(3) 8063(2) 80(1) 
C(5C) -6469(5) 4261(2) 8589(2) 61(1) 
C(6C) -6698(4) 3466(2) 9047(2) 55(1) 
C(7C) -7054(4) 3587(2) 9751(2) 56(1) 
C(8C) -7003(4) 1944(2) 9771(2) 56(1) 
C(9C) -7423(7) 143(3) 9601(3) 107(2) 
C(10C) -7221(6) 4427(3) 10085(2) 79(1) 
C(11C) -7494(7) 4454(3) 10761(2) 98(2) 
C(12C) -7619(7) 3645(3) 11116(2) 94(2) 
C(13C) -7471(5) 2832(3) 10794(2) 73(1) 
N(1C) -7589(5) 5009(2) 8706(2) 75(1) 
N(2C) -6492(4) 2656(2) 8759(1) 62(1) 
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N(3C) -6671(4) 1882(2) 9139(2) 63(1) 
N(4C) -7183(3) 2793(2) 10116(1) 55(1) 
S(2C) -7259(2) 955(1) 10246(1) 86(1) 
________________________________________________________________________________
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Table 3.   Bond lengths [Å] and angles [°] for [Fe
III
(PKSMC)2](ClO4). 
_____________________________________________________ 
C(1A)-N(1A)  1.338(4) 
C(1A)-C(2A)  1.379(5) 
C(1A)-H(1A)  0.9300 
C(1B)-N(1B)  1.337(4) 
C(1B)-C(2B)  1.373(5) 
C(1B)-H(1B)  0.9300 
C(2A)-C(3A)  1.366(6) 
C(2A)-H(2A)  0.9300 
C(2B)-C(3B)  1.374(5) 
C(2B)-H(2B)  0.9300 
C(3A)-C(4A)  1.391(5) 
C(3A)-H(3A)  0.9300 
C(3B)-C(4B)  1.374(5) 
C(3B)-H(3B)  0.9300 
C(4A)-C(5A)  1.388(4) 
C(4A)-H(4A)  0.9300 
C(4B)-C(5B)  1.378(4) 
C(4B)-H(4B)  0.9300 
C(5A)-N(1A)  1.362(4) 
C(5A)-C(6A)  1.464(4) 
C(5B)-N(1B)  1.367(4) 
C(5B)-C(6B)  1.468(4) 
C(6A)-N(2A)  1.308(4) 
C(6A)-C(7A)  1.478(4) 
C(6B)-N(2B)  1.309(4) 
C(6B)-C(7B)  1.488(4) 
C(7A)-N(4A)  1.330(4) 
C(7A)-C(10A)  1.375(5) 
C(7B)-N(4B)  1.329(4) 
C(7B)-C(10B)  1.383(5) 
C(8A)-N(3A)  1.291(4) 
C(8A)-S(1A)  1.735(3) 
C(8A)-S(2A)  1.738(3) 
C(8B)-N(3B)  1.301(4) 
C(8B)-S(2B)  1.733(3) 
C(8B)-S(1B)  1.735(3) 
C(9A)-S(2A)  1.794(4) 
C(9A)-H(9A)  0.9600 
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C(9A)-H(9B)  0.9600 
C(9A)-H(9C)  0.9600 
C(9B)-S(2B)  1.796(4) 
C(9B)-H(9D)  0.9600 
C(9B)-H(9E)  0.9600 
C(9B)-H(9F)  0.9600 
C(10A)-C(11A)  1.382(5) 
C(10A)-H(10A)  0.9300 
C(10B)-C(11B)  1.372(5) 
C(10B)-H(10B)  0.9300 
C(11A)-C(12A)  1.332(7) 
C(11A)-H(11A)  0.9300 
C(11B)-C(12B)  1.351(7) 
C(11B)-H(11B)  0.9300 
C(12A)-C(13A)  1.362(8) 
C(12A)-H(12A)  0.9300 
C(12B)-C(13B)  1.363(7) 
C(12B)-H(12B)  0.9300 
C(13A)-N(4A)  1.360(6) 
C(13A)-H(13A)  0.9300 
C(13B)-N(4B)  1.352(5) 
C(13B)-H(13B)  0.9300 
N(1A)-Fe(1)  1.984(3) 
N(1B)-Fe(1)  1.984(2) 
N(2A)-N(3A)  1.384(3) 
N(2A)-Fe(1)  1.910(2) 
N(2B)-N(3B)  1.385(3) 
N(2B)-Fe(1)  1.912(2) 
S(1A)-Fe(1)  2.2255(9) 
S(1B)-Fe(1)  2.2273(9) 
Cl(1)-O(1G)  1.301(14) 
Cl(1)-O(1D)  1.326(6) 
Cl(1)-O(1E)  1.350(13) 
Cl(1)-O(1B)  1.366(6) 
Cl(1)-O(1A)  1.398(3) 
Cl(1)-O(1C)  1.407(7) 
Cl(1)-O(1F)  1.489(12) 
Cl(2)-O(2G)  1.298(15) 
Cl(2)-O(2J)  1.32(2) 
Cl(2)-O(2L)  1.33(2) 
Appendix 
 
216 
 
Cl(2)-O(2C)  1.333(6) 
Cl(2)-O(2E)  1.346(15) 
Cl(2)-O(2F)  1.391(15) 
Cl(2)-O(2D)  1.402(5) 
Cl(2)-O(2B)  1.431(5) 
Cl(2)-O(2A)  1.450(6) 
Cl(2)-O(2K)  1.47(2) 
Cl(2)-O(2I)  1.498(16) 
Cl(2)-O(2H)  1.601(16) 
C(1C)-N(1C)  1.336(5) 
C(1C)-C(2C)  1.369(7) 
C(1C)-H(1C)  0.9300 
C(2C)-C(3C)  1.374(8) 
C(2C)-H(2C)  0.9300 
C(3C)-C(4C)  1.371(6) 
C(3C)-H(3C)  0.9300 
C(4C)-C(5C)  1.379(5) 
C(4C)-H(4C)  0.9300 
C(5C)-N(1C)  1.337(5) 
C(5C)-C(6C)  1.489(5) 
C(6C)-N(2C)  1.306(4) 
C(6C)-C(7C)  1.431(5) 
C(7C)-N(4C)  1.372(4) 
C(7C)-C(10C)  1.389(5) 
C(8C)-N(3C)  1.279(4) 
C(8C)-N(4C)  1.412(4) 
C(8C)-S(2C)  1.740(3) 
C(9C)-S(2C)  1.798(5) 
C(9C)-H(9G)  0.9600 
C(9C)-H(9H)  0.9600 
C(9C)-H(9I)  0.9600 
C(10C)-C(11C)  1.363(6) 
C(10C)-H(10C)  0.9300 
C(11C)-C(12C)  1.380(6) 
C(11C)-H(11C)  0.9300 
C(12C)-C(13C)  1.344(6) 
C(12C)-H(12C)  0.9300 
C(13C)-N(4C)  1.368(5) 
C(13C)-H(13C)  0.9300 
N(2C)-N(3C)  1.368(4) 
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N(1A)-C(1A)-C(2A) 121.0(4) 
N(1A)-C(1A)-H(1A) 119.5 
C(2A)-C(1A)-H(1A) 119.5 
N(1B)-C(1B)-C(2B) 122.3(3) 
N(1B)-C(1B)-H(1B) 118.9 
C(2B)-C(1B)-H(1B) 118.9 
C(3A)-C(2A)-C(1A) 120.4(4) 
C(3A)-C(2A)-H(2A) 119.8 
C(1A)-C(2A)-H(2A) 119.8 
C(1B)-C(2B)-C(3B) 118.6(3) 
C(1B)-C(2B)-H(2B) 120.7 
C(3B)-C(2B)-H(2B) 120.7 
C(2A)-C(3A)-C(4A) 119.2(3) 
C(2A)-C(3A)-H(3A) 120.4 
C(4A)-C(3A)-H(3A) 120.4 
C(2B)-C(3B)-C(4B) 120.0(3) 
C(2B)-C(3B)-H(3B) 120.0 
C(4B)-C(3B)-H(3B) 120.0 
C(5A)-C(4A)-C(3A) 118.5(3) 
C(5A)-C(4A)-H(4A) 120.7 
C(3A)-C(4A)-H(4A) 120.7 
C(3B)-C(4B)-C(5B) 119.3(3) 
C(3B)-C(4B)-H(4B) 120.3 
C(5B)-C(4B)-H(4B) 120.3 
N(1A)-C(5A)-C(4A) 121.3(3) 
N(1A)-C(5A)-C(6A) 113.4(3) 
C(4A)-C(5A)-C(6A) 125.2(3) 
N(1B)-C(5B)-C(4B) 120.5(3) 
N(1B)-C(5B)-C(6B) 113.2(3) 
C(4B)-C(5B)-C(6B) 126.2(3) 
N(2A)-C(6A)-C(5A) 112.8(3) 
N(2A)-C(6A)-C(7A) 124.0(3) 
C(5A)-C(6A)-C(7A) 123.1(3) 
N(2B)-C(6B)-C(5B) 112.7(3) 
N(2B)-C(6B)-C(7B) 123.9(3) 
C(5B)-C(6B)-C(7B) 123.4(3) 
N(4A)-C(7A)-C(10A) 123.8(3) 
N(4A)-C(7A)-C(6A) 115.2(3) 
C(10A)-C(7A)-C(6A) 120.9(3) 
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N(4B)-C(7B)-C(10B) 123.2(3) 
N(4B)-C(7B)-C(6B) 115.8(3) 
C(10B)-C(7B)-C(6B) 121.0(3) 
N(3A)-C(8A)-S(1A) 125.7(2) 
N(3A)-C(8A)-S(2A) 119.2(2) 
S(1A)-C(8A)-S(2A) 115.04(18) 
N(3B)-C(8B)-S(2B) 119.2(2) 
N(3B)-C(8B)-S(1B) 125.3(2) 
S(2B)-C(8B)-S(1B) 115.46(19) 
S(2A)-C(9A)-H(9A) 109.5 
S(2A)-C(9A)-H(9B) 109.5 
H(9A)-C(9A)-H(9B) 109.5 
S(2A)-C(9A)-H(9C) 109.5 
H(9A)-C(9A)-H(9C) 109.5 
H(9B)-C(9A)-H(9C) 109.5 
S(2B)-C(9B)-H(9D) 109.5 
S(2B)-C(9B)-H(9E) 109.5 
H(9D)-C(9B)-H(9E) 109.5 
S(2B)-C(9B)-H(9F) 109.5 
H(9D)-C(9B)-H(9F) 109.5 
H(9E)-C(9B)-H(9F) 109.5 
C(7A)-C(10A)-C(11A) 118.3(4) 
C(7A)-C(10A)-H(10A) 120.9 
C(11A)-C(10A)-H(10A) 120.9 
C(11B)-C(10B)-C(7B) 118.5(4) 
C(11B)-C(10B)-H(10B) 120.7 
C(7B)-C(10B)-H(10B) 120.7 
C(12A)-C(11A)-C(10A) 119.5(5) 
C(12A)-C(11A)-H(11A) 120.3 
C(10A)-C(11A)-H(11A) 120.3 
C(12B)-C(11B)-C(10B) 119.3(4) 
C(12B)-C(11B)-H(11B) 120.3 
C(10B)-C(11B)-H(11B) 120.3 
C(11A)-C(12A)-C(13A) 119.2(4) 
C(11A)-C(12A)-H(12A) 120.4 
C(13A)-C(12A)-H(12A) 120.4 
C(11B)-C(12B)-C(13B) 119.0(4) 
C(11B)-C(12B)-H(12B) 120.5 
C(13B)-C(12B)-H(12B) 120.5 
N(4A)-C(13A)-C(12A) 124.0(5) 
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N(4A)-C(13A)-H(13A) 118.0 
C(12A)-C(13A)-H(13A) 118.0 
N(4B)-C(13B)-C(12B) 123.8(4) 
N(4B)-C(13B)-H(13B) 118.1 
C(12B)-C(13B)-H(13B) 118.1 
C(1A)-N(1A)-C(5A) 119.5(3) 
C(1A)-N(1A)-Fe(1) 126.1(2) 
C(5A)-N(1A)-Fe(1) 114.0(2) 
C(1B)-N(1B)-C(5B) 119.2(3) 
C(1B)-N(1B)-Fe(1) 126.8(2) 
C(5B)-N(1B)-Fe(1) 114.1(2) 
C(6A)-N(2A)-N(3A) 117.8(2) 
C(6A)-N(2A)-Fe(1) 119.2(2) 
N(3A)-N(2A)-Fe(1) 123.02(19) 
C(6B)-N(2B)-N(3B) 118.1(2) 
C(6B)-N(2B)-Fe(1) 119.3(2) 
N(3B)-N(2B)-Fe(1) 122.43(19) 
C(8A)-N(3A)-N(2A) 111.5(2) 
C(8B)-N(3B)-N(2B) 111.8(3) 
C(7A)-N(4A)-C(13A) 115.2(4) 
C(7B)-N(4B)-C(13B) 116.1(4) 
C(8A)-S(1A)-Fe(1) 94.38(11) 
C(8B)-S(1B)-Fe(1) 94.31(11) 
C(8A)-S(2A)-C(9A) 102.39(17) 
C(8B)-S(2B)-C(9B) 103.23(19) 
N(2A)-Fe(1)-N(2B) 177.81(10) 
N(2A)-Fe(1)-N(1A) 80.41(10) 
N(2B)-Fe(1)-N(1A) 101.60(11) 
N(2A)-Fe(1)-N(1B) 100.65(10) 
N(2B)-Fe(1)-N(1B) 80.35(10) 
N(1A)-Fe(1)-N(1B) 88.50(10) 
N(2A)-Fe(1)-S(1A) 85.37(8) 
N(2B)-Fe(1)-S(1A) 92.67(8) 
N(1A)-Fe(1)-S(1A) 165.40(8) 
N(1B)-Fe(1)-S(1A) 90.88(8) 
N(2A)-Fe(1)-S(1B) 93.69(8) 
N(2B)-Fe(1)-S(1B) 85.56(8) 
N(1A)-Fe(1)-S(1B) 87.30(8) 
N(1B)-Fe(1)-S(1B) 164.17(8) 
S(1A)-Fe(1)-S(1B) 96.98(4) 
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O(1G)-Cl(1)-O(1D) 54.9(9) 
O(1G)-Cl(1)-O(1E) 115.6(9) 
O(1D)-Cl(1)-O(1E) 138.7(8) 
O(1G)-Cl(1)-O(1B) 127.8(9) 
O(1D)-Cl(1)-O(1B) 113.1(6) 
O(1E)-Cl(1)-O(1B) 35.3(7) 
O(1G)-Cl(1)-O(1A) 119.2(8) 
O(1D)-Cl(1)-O(1A) 108.7(5) 
O(1E)-Cl(1)-O(1A) 109.6(7) 
O(1B)-Cl(1)-O(1A) 112.6(4) 
O(1G)-Cl(1)-O(1C) 54.6(7) 
O(1D)-Cl(1)-O(1C) 109.4(7) 
O(1E)-Cl(1)-O(1C) 74.0(6) 
O(1B)-Cl(1)-O(1C) 106.5(6) 
O(1A)-Cl(1)-O(1C) 106.2(4) 
O(1G)-Cl(1)-O(1F) 106.2(9) 
O(1D)-Cl(1)-O(1F) 54.5(6) 
O(1E)-Cl(1)-O(1F) 102.9(7) 
O(1B)-Cl(1)-O(1F) 67.7(7) 
O(1A)-Cl(1)-O(1F) 100.8(6) 
O(1C)-Cl(1)-O(1F) 152.3(7) 
O(2G)-Cl(2)-O(2J) 72.7(18) 
O(2G)-Cl(2)-O(2L) 121.5(15) 
O(2J)-Cl(2)-O(2L) 116.6(15) 
O(2G)-Cl(2)-O(2C) 104.8(12) 
O(2J)-Cl(2)-O(2C) 161.4(18) 
O(2L)-Cl(2)-O(2C) 80.8(16) 
O(2G)-Cl(2)-O(2E) 115.5(10) 
O(2J)-Cl(2)-O(2E) 84.3(19) 
O(2L)-Cl(2)-O(2E) 32.3(14) 
O(2C)-Cl(2)-O(2E) 112.5(12) 
O(2G)-Cl(2)-O(2F) 122.4(10) 
O(2J)-Cl(2)-O(2F) 76.4(16) 
O(2L)-Cl(2)-O(2F) 115.6(15) 
O(2C)-Cl(2)-O(2F) 90.4(12) 
O(2E)-Cl(2)-O(2F) 108.2(10) 
O(2G)-Cl(2)-O(2D) 136.4(11) 
O(2J)-Cl(2)-O(2D) 65.4(19) 
O(2L)-Cl(2)-O(2D) 70.8(13) 
O(2C)-Cl(2)-O(2D) 118.7(5) 
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O(2E)-Cl(2)-O(2D) 50.5(9) 
O(2F)-Cl(2)-O(2D) 58.6(9) 
O(2G)-Cl(2)-O(2B) 47.2(9) 
O(2J)-Cl(2)-O(2B) 47.6(18) 
O(2L)-Cl(2)-O(2B) 159.7(14) 
O(2C)-Cl(2)-O(2B) 116.9(5) 
O(2E)-Cl(2)-O(2B) 130.3(10) 
O(2F)-Cl(2)-O(2B) 76.2(9) 
O(2D)-Cl(2)-O(2B) 105.6(4) 
O(2G)-Cl(2)-O(2A) 59.8(9) 
O(2J)-Cl(2)-O(2A) 88.1(15) 
O(2L)-Cl(2)-O(2A) 62.9(12) 
O(2C)-Cl(2)-O(2A) 106.8(6) 
O(2E)-Cl(2)-O(2A) 60.0(9) 
O(2F)-Cl(2)-O(2A) 161.7(11) 
O(2D)-Cl(2)-O(2A) 106.3(5) 
O(2B)-Cl(2)-O(2A) 100.5(4) 
O(2G)-Cl(2)-O(2K) 46.1(13) 
O(2J)-Cl(2)-O(2K) 114.7(15) 
O(2L)-Cl(2)-O(2K) 114.0(14) 
O(2C)-Cl(2)-O(2K) 58.9(14) 
O(2E)-Cl(2)-O(2K) 136.1(14) 
O(2F)-Cl(2)-O(2K) 114.5(13) 
O(2D)-Cl(2)-O(2K) 173.1(10) 
O(2B)-Cl(2)-O(2K) 71.6(13) 
O(2A)-Cl(2)-O(2K) 80.5(11) 
O(2G)-Cl(2)-O(2I) 126.7(12) 
O(2J)-Cl(2)-O(2I) 103.2(13) 
O(2L)-Cl(2)-O(2I) 107.9(13) 
O(2C)-Cl(2)-O(2I) 62.9(10) 
O(2E)-Cl(2)-O(2I) 116.9(12) 
O(2F)-Cl(2)-O(2I) 27.5(10) 
O(2D)-Cl(2)-O(2I) 75.9(9) 
O(2B)-Cl(2)-O(2I) 90.0(8) 
O(2A)-Cl(2)-O(2I) 168.1(10) 
O(2K)-Cl(2)-O(2I) 97.7(11) 
O(2G)-Cl(2)-O(2H) 108.1(12) 
O(2J)-Cl(2)-O(2H) 173.0(16) 
O(2L)-Cl(2)-O(2H) 69.3(17) 
O(2C)-Cl(2)-O(2H) 11.8(13) 
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O(2E)-Cl(2)-O(2H) 101.3(10) 
O(2F)-Cl(2)-O(2H) 97.7(9) 
O(2D)-Cl(2)-O(2H) 115.0(12) 
O(2B)-Cl(2)-O(2H) 127.7(12) 
O(2A)-Cl(2)-O(2H) 98.4(10) 
O(2K)-Cl(2)-O(2H) 64.1(17) 
O(2I)-Cl(2)-O(2H) 70.5(12) 
N(1C)-C(1C)-C(2C) 123.1(5) 
N(1C)-C(1C)-H(1C) 118.4 
C(2C)-C(1C)-H(1C) 118.4 
C(1C)-C(2C)-C(3C) 119.3(4) 
C(1C)-C(2C)-H(2C) 120.3 
C(3C)-C(2C)-H(2C) 120.3 
C(4C)-C(3C)-C(2C) 118.8(5) 
C(4C)-C(3C)-H(3C) 120.6 
C(2C)-C(3C)-H(3C) 120.6 
C(3C)-C(4C)-C(5C) 118.2(4) 
C(3C)-C(4C)-H(4C) 120.9 
C(5C)-C(4C)-H(4C) 120.9 
N(1C)-C(5C)-C(4C) 123.8(4) 
N(1C)-C(5C)-C(6C) 116.5(3) 
C(4C)-C(5C)-C(6C) 119.6(3) 
N(2C)-C(6C)-C(7C) 123.0(3) 
N(2C)-C(6C)-C(5C) 115.0(3) 
C(7C)-C(6C)-C(5C) 122.0(3) 
N(4C)-C(7C)-C(10C) 118.6(3) 
N(4C)-C(7C)-C(6C) 116.0(3) 
C(10C)-C(7C)-C(6C) 125.4(3) 
N(3C)-C(8C)-N(4C) 123.0(3) 
N(3C)-C(8C)-S(2C) 120.3(3) 
N(4C)-C(8C)-S(2C) 116.8(3) 
S(2C)-C(9C)-H(9G) 109.5 
S(2C)-C(9C)-H(9H) 109.5 
H(9G)-C(9C)-H(9H) 109.5 
S(2C)-C(9C)-H(9I) 109.5 
H(9G)-C(9C)-H(9I) 109.5 
H(9H)-C(9C)-H(9I) 109.5 
C(11C)-C(10C)-C(7C) 120.2(4) 
C(11C)-C(10C)-H(10C) 119.9 
C(7C)-C(10C)-H(10C) 119.9 
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C(10C)-C(11C)-C(12C) 120.0(4) 
C(10C)-C(11C)-H(11C) 120.0 
C(12C)-C(11C)-H(11C) 120.0 
C(13C)-C(12C)-C(11C) 119.9(4) 
C(13C)-C(12C)-H(12C) 120.0 
C(11C)-C(12C)-H(12C) 120.0 
C(12C)-C(13C)-N(4C) 120.8(4) 
C(12C)-C(13C)-H(13C) 119.6 
N(4C)-C(13C)-H(13C) 119.6 
C(1C)-N(1C)-C(5C) 116.7(4) 
C(6C)-N(2C)-N(3C) 119.3(3) 
C(8C)-N(3C)-N(2C) 120.8(3) 
C(13C)-N(4C)-C(7C) 120.5(3) 
C(13C)-N(4C)-C(8C) 121.5(3) 
C(7C)-N(4C)-C(8C) 118.0(3) 
C(8C)-S(2C)-C(9C) 99.7(2) 
_____________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
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Table 4.   Anisotropic displacement parameters (Å 2x 103)for [FeIII(PKSMC)2](ClO4).  The anisotropic 
displacement factor exponent takes the form: -22[ h2a*2U11 + ... + 2 h k a* b* U12 ] 
______________________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
______________________________________________________________________________ 
C(1A) 50(2)  71(2) 67(2)  0(2) -17(2)  0(2) 
C(1B) 61(2)  54(2) 45(2)  0(2) -2(2)  -9(2) 
C(2A) 55(2)  91(3) 84(3)  -4(2) -24(2)  -8(2) 
C(2B) 67(2)  71(2) 47(2)  -8(2) 8(2)  -6(2) 
C(3A) 45(2)  78(3) 95(3)  -16(2) -9(2)  -17(2) 
C(3B) 72(2)  61(2) 60(2)  -12(2) 3(2)  7(2) 
C(4A) 49(2)  58(2) 73(2)  -7(2) 0(2)  -13(2) 
C(4B) 69(2)  53(2) 54(2)  1(2) -6(2)  0(2) 
C(5A) 41(2)  44(2) 51(2)  -7(1) 2(1)  -4(1) 
C(5B) 50(2)  47(2) 46(2)  -3(1) -6(1)  -4(1) 
C(6A) 47(2)  42(2) 46(2)  -4(1) 4(1)  -6(1) 
C(6B) 53(2)  45(2) 44(2)  3(1) -8(1)  -8(1) 
C(7A) 65(2)  43(2) 46(2)  0(1) -3(2)  -14(2) 
C(7B) 50(2)  52(2) 51(2)  10(2) -4(1)  -8(1) 
C(8A) 47(2)  49(2) 44(2)  -7(1) -4(1)  -6(1) 
C(8B) 50(2)  63(2) 43(2)  -3(2) -2(1)  -8(2) 
C(9A) 74(3)  94(3) 63(2)  12(2) -22(2)  -3(2) 
C(9B) 117(4)  92(3) 45(2)  4(2) 3(2)  -19(3) 
C(10A) 81(3)  55(2) 59(2)  8(2) -11(2)  -7(2) 
C(10B) 65(2)  69(2) 55(2)  9(2) -11(2)  -2(2) 
C(11A) 146(5)  57(2) 72(3)  16(2) -38(3)  -11(3) 
C(11B) 76(3)  111(4) 62(3)  28(2) -14(2)  -3(3) 
C(12A) 195(6)  68(3) 59(3)  19(2) -23(4)  -48(4) 
C(12B) 90(3)  93(4) 91(3)  52(3) -19(3)  -25(3) 
C(13A) 143(5)  97(4) 65(3)  3(3) 22(3)  -63(4) 
C(13B) 102(3)  59(2) 116(4)  30(3) -29(3)  -32(2) 
N(1A) 45(1)  48(2) 53(2)  -3(1) -5(1)  -3(1) 
N(1B) 51(2)  45(1) 41(1)  1(1) -4(1)  -9(1) 
N(2A) 43(1)  44(1) 42(1)  0(1) -3(1)  -6(1) 
N(2B) 51(2)  46(1) 37(1)  0(1) -2(1)  -7(1) 
N(3A) 48(2)  49(2) 47(2)  2(1) -10(1)  -7(1) 
N(3B) 58(2)  57(2) 40(1)  3(1) 0(1)  -8(1) 
N(4A) 85(2)  70(2) 68(2)  1(2) 16(2)  -31(2) 
N(4B) 85(2)  55(2) 75(2)  16(2) -20(2)  -19(2) 
S(1A) 54(1)  52(1) 51(1)  6(1) -6(1)  -17(1) 
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S(1B) 54(1)  49(1) 49(1)  -4(1) -1(1)  -2(1) 
S(2A) 56(1)  73(1) 63(1)  -1(1) -17(1)  -14(1) 
S(2B) 87(1)  81(1) 49(1)  -6(1) 14(1)  4(1) 
Fe(1) 46(1)  41(1) 40(1)  1(1) -3(1)  -6(1) 
Cl(1) 80(1)  69(1) 98(1)  14(1) -15(1)  -17(1) 
O(1A) 165(4)  107(3) 126(3)  14(2) -10(3)  -72(3) 
O(1B) 392(15)  169(9) 128(7)  78(7) -74(9)  -122(10) 
O(1C) 203(9)  142(6) 213(9)  -70(5) 8(6)  -68(6) 
O(1D) 77(5)  258(11) 500(30)  48(14) -30(8)  47(5) 
Cl(2) 89(1)  60(1) 65(1)  9(1) -9(1)  -15(1) 
O(2A) 104(5)  228(9) 191(8)  -83(7) -11(5)  51(5) 
O(2B) 152(6)  103(4) 121(5)  52(3) -47(4)  -14(4) 
O(2C) 189(9)  173(8) 113(6)  -10(5) -74(6)  -79(6) 
O(2D) 103(4)  156(6) 127(5)  52(4) -24(3)  -72(4) 
C(1C) 136(4)  56(2) 93(4)  11(2) -21(3)  -16(3) 
C(2C) 165(5)  79(3) 82(3)  25(3) -15(4)  -41(4) 
C(3C) 138(5)  100(4) 73(3)  13(3) 20(3)  -41(3) 
C(4C) 103(3)  75(3) 61(2)  1(2) 7(2)  -18(2) 
C(5C) 80(2)  51(2) 52(2)  -2(2) -6(2)  -17(2) 
C(6C) 62(2)  50(2) 52(2)  -3(2) -4(2)  -8(2) 
C(7C) 62(2)  52(2) 52(2)  -2(2) -4(2)  -5(2) 
C(8C) 56(2)  48(2) 64(2)  2(2) -6(2)  -3(2) 
C(9C) 144(5)  56(3) 123(4)  2(3) -13(4)  -27(3) 
C(10C) 121(4)  56(2) 57(2)  -6(2) -4(2)  -8(2) 
C(11C) 158(5)  71(3) 61(3)  -19(2) -4(3)  -5(3) 
C(12C) 146(4)  87(3) 46(2)  -4(2) -3(2)  -3(3) 
C(13C) 93(3)  75(3) 51(2)  9(2) -6(2)  -10(2) 
N(1C) 104(3)  52(2) 69(2)  5(2) -9(2)  -10(2) 
N(2C) 78(2)  51(2) 56(2)  -4(1) -3(1)  -8(1) 
N(3C) 77(2)  46(2) 66(2)  -2(1) -4(2)  -7(1) 
N(4C) 57(2)  55(2) 52(2)  3(1) -3(1)  -5(1) 
S(2C) 112(1)  58(1) 86(1)  19(1) -9(1)  -11(1) 
______________________________________________________________________________
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Table 5.   Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å ‎2 x 103) 
for [Fe
III
(PKSMC)2](ClO4). 
________________________________________________________________________________ 
 x  y  z  U(eq) 
________________________________________________________________________________ 
H(1A) 668 1911 5511 75 
H(1B) 1548 2307 7698 64 
H(2A) -1393 956 5391 90 
H(2B) -136 3548 8194 76 
H(3A) -1736 -287 6084 86 
H(3B) -471 4913 7609 79 
H(4A) 51 -576 6906 72 
H(4B) 830 4996 6531 71 
H(9A) 6354 857 8615 114 
H(9B) 8311 752 8657 114 
H(9C) 7570 180 8131 114 
H(9D) 4845 2547 3600 128 
H(9E) 6738 2384 3275 128 
H(9F) 6258 3004 3911 128 
H(10A) 5272 -871 7336 78 
H(10B) 2151 3574 4523 76 
H(11A) 5260 -2086 8089 108 
H(11B) 2034 4785 3775 100 
H(12A) 2854 -2268 8781 125 
H(12B) 2216 6255 4137 108 
H(13A) 468 -1305 8697 121 
H(13B) 2608 6491 5210 108 
H(1C) -8187 6239 8353 113 
H(2C) -6132 6190 7462 128 
H(3C) -4212 4885 7273 125 
H(4C) -4437 3651 8001 96 
H(9G) -8250 397 9327 160 
H(9H) -7764 -422 9797 160 
H(9I) -6342 21 9336 160 
H(10C) -7146 4973 9846 95 
H(11C) -7597 5017 10983 117 
H(12C) -7804 3663 11577 113 
H(13C) -7566 2289 11036 88 
_________________________________________________________________________ 
